















































new	 depth	 to	 our	 understanding	 of	 clonal	 selection	 in	 cancer.	 In	 particular,	 high	
complexity	barcodes	are	used	to	identify	a	pre-existing	tamoxifen	resistant	population	
in	 the	MCF7	 cell	 line.	 This	 resistance	 phenotype	 is	 then	 linked	 to	 the	 induction	 of	
embryonic	 transcription	 factor	 OCT4.	 Finally,	 we	 use	 our	 molecular	 barcoding	
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pathologists	 began	 at	 the	 start	 of	 the	 19th	 century.	 At	 first,	 differences	 in	 cellular	




allowed	 stratification	 of	 patients	 based	 on	 the	 presence	 of	 oestrogen	 receptor	 alpha	
(ERα),	 which	 led	 to	 the	 successful	 targeting	 of	 tamoxifen	 for	 ERα	 positive	 (ERα+)	
patients	(6).	More	recent	work	has	enabled	comprehensive	stratification	of	breast	and	
other	cancers	(5,7).	For	example,	in	breast	cancer,	a	50	gene	signature	(PAM50)	can	be	
used	 to	 stratify	 patients	 into	 four	 intrinsic	 subtypes	 (luminal	 A,	 luminal	 B,	 HER2-
enriched	 &	 basal-like)	 with	 distinct	 clinical	 outcomes	 (8,9).	 Our	 lab	 has	 recently	
integrated	copy	number	(CN)	data	with	transcriptomics	to	improve	on	this	classification	
and	 uncover	 11	 distinct	 Integrative	 Clusters	 of	 breast	 cancer	 (7).	 Defined	 in	 2,000	





clearly	 associate	with	 discrete	 clinical	 outcomes,	 suggesting	 these	 clusters	 represent	
distinct	biological	entities.	Improving	the	taxonomy	of	cancer	is	the	initial	step	towards	
a	 better	 understanding	 of	 the	 drivers	 of	 tumour	 growth	 and	 consequently	 towards	




distinct	 cellular	 populations	within	 their	 bulk	 (1,12).	 For	 example	 Fidler	 and	Kripke	
reported	 in	 1977	 that	 clonal	 populations	derived	 from	mouse	metastatic	melanomas	
varied	extensively	 in	 their	 ability	 to	 seed	metastasis	 in	 syngeneic	hosts	 (13).	Of	note	
amongst	 the	 relatively	early	 research	 into	 tumour	heterogeneity,	were	 the	 important	
observations	using	human	patients,	although	highly	unethical	by	today’s	standards	these	
offered	unequivocal	 evidence	 for	 functional	heterogeneity	and	 fuelled	 five	decades	of	
subsequent	research.	For	example,	various	studies	around	the	late	1960s	showed	by	in	
vivo	 radiolabelling	 that	 the	 morphologically	 distinguishable	 populations	 of	 human	



























Although	 often	 considered	 disparate,	 the	 causes	 and	 consequences	 of	 intertumour	
heterogeneity	 (i.e.	 different	 sub-classifications	 of	 tumours	 from	 the	 same	 originating	
organ)	 and	 intratumour	 heterogeneity	 (i.e.	 different	 sub-clonal	 architectures)	 are	
inherently	 linked.	Moreover,	 compelling	models	 of	 tumour	 heterogeneity,	 linking	 the	
competing	theories	of	CSCs	and	somatic	evolution	have	recently	been	proposed	(24).	As	
computational	 and	 preclinical	 models	 improve,	 and	 as	 high-throughput	 single	 cell	
studies	become	mainstream,	we	will	begin	a	new	chapter	in	our	understanding	of	the	
causes	 and	 consequences	 of	 tumour	 heterogeneity.	 It	 is	 hoped	 that	 this	 new	 era	 of	
research	will	 lead	to	new	insights	 into	the	complex	ecosystem	that	 is	cancer	and	that	















Cancer	 is,	 first	 and	 foremost,	 a	 disease	 of	 the	 genome.	 Indeed,	 both	 inter-	 and	
intratumour	heterogeneity	 can	 be	 explained	 by	 the	 genomic	 instability	 inherent	 to	 a	










progeny.	 With	 time,	 this	 process	 generates	 a	 dominant	 clone	 that	 will	 expand	 and	
dominate	the	site	where	it	was	generated	through	Darwinian	selection	in	response	to	
spatial	 and	 temporal	 selective	 pressures	 (12).	 When	 clones	 arise	 with	 an	 increased	
fitness	 (or	 when	 selective	 pressures	 change),	 less	 advantaged	 clones	 will	 either	
disappear	or	will	be	maintained	as	sub-clones	alongside	the	dominant	clone,	acting	as	a	
reservoir	from	which	evolution	can	continue	(27).	This	compelling	theory	was	first	put	
forward	 by	 Peter	Nowell	 in	 1976	 (12)	 and	 supported	 by	 early	 evidence	 that	 genetic	
aberrations	 were	 the	 cause	 of	 a	 tumours	 phenotypic	 traits	 (21)	 and	 more	 recent	
genomics	research	(28,29).	It	is	now	accepted	that	tumours	harbour	various	layers	of	



























	Figure	1.1	 shows	an	overview	of	 tumour	heterogeneity.	 From	 left	 to	 right;	 intertumour	
heterogeneity	ensures	that	no	two	malignancies	are	the	same;	genomic	clonal	populations	
exist	 within	 a	 tumour	 (coloured)	 and	 functional	 heterogeneity	 (shape)	 exists	 within	
isogeneic	 populations.	 This	 non-genomic	 intratumour	 heterogeneity	 is	 due	 to	 intrinsic	
epigenetic	 differences	 (not	 shown),	 interaction	with	 the	 immune	 infiltrate	 (top	 panel),	
differences	 in	 tumour	metabolism	 (e.g.	 hypoxia;	middle	panel)	and	 interaction	with	 the	
extracellular	 matrix	 and	 stromal	 component	 (bottom	 panel).	 Each	 of	 the	 depicted	
environments	 could	 have	 different	 effects	 on	 cellular	 functions.	 Highlighting	 functional	
consequences	 of	 heterogeneity,	 in	 the	 lower	 half,	 two	 genomic	 clones	 are	 depicted	 as	
resistant	to	chemotherapy	and	able	to	repopulate	the	tumour	after	treatment.	Dead	cells	
are	 coloured	 black	 in	 the	 centre	 of	 the	 lower	 panel.	 These	 resistant	 clones	 could	 be	



























































and	 intertumoral	 heterogeneity	 (30,31).	 Throughout	 the	 process	 of	 tumour	
development,	cancer	cells	can	accrue	thousands	of	mutations,	some	of	which	can	even	
involve	the	gain	or	loss	of	entire	chromosome	arms	(32).	However,	there	is	evidence	that	





Solid	 tumours	 can	be	 classified	based	on	 the	dominance	of	single	nucleotide	variants	
(SNVs),	 i.e.	M-class	 tumours,	or	copy	number	aberrations	(CNAs),	 i.e.	C-class	 tumours	






























in	 the	genome	would	be	effectively	decayed	and	 the	 fidelity	of	genome	 	maintenance	
across	generations	would	be	severely	impacted	(34,48).	This	conceptual	framework	is	
supported	by	theoretical	models	and	evolutionary	experiments	(33–36,49),	applicable	
to	 unicellular	 organisms,	 multicellular	 organisms,	 and	 neoplastic	 cells	 (50,51).	
Mechanistically,	 it	 is	 though	 that	SNV	error	 rate	 limits	are	 supported	by	 ‘gatekeeper’	




are	 thought	 to	 confer	 substantial	 phenotypic	 plasticity,	 through	 gene	 duplication	 or	
deletion,	 and	have	been	described	as	 the	driving	 force	of	 genetic	diversification	 (19).	




2	 and	 15	 was	 used	 to	 define	 CNA	 driven	 genomic	 instability	 in	 ERα-	 breast	 cancer	
patients3.	The	authors	 found	that	cases	where	45%	of	 tumour	cells	had	chromosomal	









chromosomal	 abnormalities	 (60).	 Similarly,	 TNBCs	with	 a	 gene	 expression	 signature	
associated	with	high	chromosomal	instability	are	associated	with	increased	time	until	
relapse	 compared	 with	 those	 with	 low	 predicted	 instability	 (59).	 Limits	 on	 CNA	
abundance	could	be	explained	by	biophysical	constraints	(e.g.	chromosome	size	limiting	
alignment	 to	 the	 centre	of	 the	nucleus	and	 therefor	metaphase	efficiency)	 (61),	 gene	
dosage	(e.g.	amplification	of	neoantigens	or	tumour	suppressors	in	a	duplicated	region)	




heterogeneity	 may	 be	 associated	 with	 a	 poor	 prognosis,	 instability	 itself	 may	 be	




















initiation 4 .	 These	 events	 might	 be	 prognostic	 and	 predictive	 of	 drug	 responses,	
suggesting	they	can	be	used	to	classify	cancer	into	different	subtypes.	For	example,	ERα+	
tumours	(80%	of	breast	cancers)	tend	to	have	a	better	prognosis	and	are	treated	with	
oestrogen	 receptor	 antagonists	 (e.g.	 tamoxifen)	 or	 aromatase	 inhibitors	 (e.g.	
anastrozole),	 whereas	 HER2+	 tumours	 (20%	 of	 breast	 cancers)	 are	 generally	 faster	











mutations	 can	 have	 profound	 effects	 on	 intertumour	 heterogeneity	 and	 disease	
progression.	 For	 example,	 in	 Philadelphia	 chromosome	 negative	 myeloproliferative	
neoplasms	(MPNs),	recent	work	has	demonstrated	that	within	patients	harbouring	both	
a	Janus	kinase	2	(JAK2)	and	Tet	methylcytosine	dioxygenase	2	(TET2)	mutation,	those	who	
acquired	 the	 TET2	mutation	 first	 were	 less	 likely	 to	 present	 with	 the	 MPN	 subtype	

















clonal	 evolution	 that	 heavily	 influences	 intratumour	 heterogeneity.	 Taking	 the	 most	
extreme	example,	hypermethylation	or	mutation	of	MutL	homolog	1	(MLH1)	leads	to	a	
hypermutator	 phenotype	 in	 colorectal	 cancer	 (69).	 This	 microsatellite	 instability	













The	 acquisition	 and	 order	 of	 driver	 mutations	 can	 have	 profound	 implications	 for	
intertumour	heterogeneity.	However,	 tumours	are	characterised	by	continuous	clonal	
evolution	as	they	develop	(76).	Progeny	of	founder	clones	undergo	repeated	mutational	
events	 that	may	 confer	 a	 fitness	 advantage	with	 regards	 specific	 spatial	 or	 temporal	












evidence	 that	 clonal	 evolution	 occurs	 even	 in	 the	 earliest	 stages	 of	 a	 neoplasm’s	
development	(77).		
	
Numerous	 groups	 have	 been	 able	 to	 reconstruct	 the	 clonal	 hierarchy	 of	 individual	





to	 coexist	 and	 diversify	 alongside	 the	 dominant	 clone	 (28).	 This	model	 of	 branched	





Alongside	 this	 model	 of	 branched	 evolution,	 the	 survival	 of	 multiple	 sub-dominant	
clones	can	be	explained	by	the	spatial	segregation	of	clones	across	the	tumour	as	a	whole.	




learning7	to	 transition	 neural	networks	 trained	 on	 their	own	datasets	 to	 large	multi-
region	sequencing	datasets	from	lung,	breast,	renal,	and	colorectal	cancer,	in	each	case	
detecting	repeated	evolutionary	trajectories	in	subgroups	of	patient.	A	public	release	of	















































cell-of-origin	 specific	 chromatin	 accessibility	 and	 modification,	 that,	 together	 with	
replication	timing,	this	can	explain	up	to	86%	of	the	variance	in	mutation	rates	across	a	
cancer	 genome	 (85).	 Additionally,	 genomic	 heterogeneity	 itself	 cannot	 explain	 the	
complete	phenotypic	diversity	of	tumours:	even	genetically	homogenous	populations	of	
cancer	 cells	 show	 remarkable	 diversity	 in	 their	 response	 to	 therapeutic	 selective	
pressure	and	other	sources	of	environmental	stimuli	(83,86).	This	observation	suggests	






of	 genetic	 variation.	 As	 the	 vast	 majority	 of	 cells	 in	 an	 adult	 organ	 are	 genetically	
identical,	 cell	 type	heterogeneity	and	 the	 control	of	 cell	 fate	during	development,	 are	
attributed	 to	 epigenomic	 regulators	 (87).	 On	 the	 molecular	 level,	 mechanisms	 of	
developmental	control	are	 frequently	co-opted	by	tumours	during	their	development,	
these	 include:	 post-translational	 modification	 of	 histones;	 histone	 variants;	 DNA	






In	particular,	 two	classes	of	 epigenomic	 regulators,	DNA	methylation	and	histone	 tail	
modification,	 have	 been	 extensively	 studied	 as	 contributors	 to	 tumour	heterogeneity	





functional	 genomic	 boundaries	 between	 open	 (euchromatin)	 and	 tightly	 packed	
(heterochromatin)	 DNA	 (92).	 The	 blurring	 of	 euchromatin	 and	 heterochromatin	
boundaries	during	tumour	progression	is	thought	to	lead	to	more	global	restructuring	of	






More	 generally,	 epigenetic	 regulation	 is	 tightly	 associated	 to	 a	 cell’s	 transcriptional	
activity	(95)	and	consequently	may	influence	its	reaction	to	external	stimuli,	including	
cancer	therapies	(96–98).	Aside	from	transcriptional	control,	profound	heterogeneity	is	
seen	 in	 the	 post-transcriptional	 landscape	 in	 breast	 cancer	 (99–101).	 By	 integrating	
mRNA	and	microRNA	expression	data	from	1,302	breast	tumours,	our	group	was	able	to	
identify	 multiple	 prognostic	 microRNA	 expression	 signatures	 (99).	 These	 prognostic	
signatures	were	associated	with	immune	infiltrate	and	could	only	be	externally	validated	
in	CNA-devoid	breast	cancer	subtypes,	suggesting	a	particular	role	of	microRNAs	in	the	
progression	 of	 this	 breast	 cancer	 subtype	 (99).	 Interestingly	 expression	 of	 specific	





understanding	 of	 clonal	 evolution	 and	 therapy	 resistance.	 By	 understanding	












30	 frequently	 mutated	 genes8	known	 to	 play	 an	 active	 role	 in	 dysregulation	 of	 the	
epigenome	 (84,105).	 Those	 most	 frequently	 mutated	 include	 histones	 themselves;	
histone	 acetyltransferases;	 histone	 deacetylases;	 histone	 methyltransferases;	 histone	
demethylases;	 DNA	 methyltransferases	 and	 chromatin	 remodelling	 factors	 (84).	
Interestingly,	mutations	in	epigenetic	regulators	are	particularly	common	in	cancers	that	





Genomic	 mutations	 occur	 in	 noncoding	 regulatory	 regions	 of	 the	 genome	 at	 nearly	
double	 the	 frequency	 of	 protein	 coding	 regions	 (108).	 Such	 mutations	 have	 been	
identified	in	multiple	promoters	and	enhancer	elements	across	a	range	of	cancer	types	
and	 stages	 (109,110).	 For	 example,	 mutations	 in	 the	 promotor	 region	 of	 telomerase	
reverse	 transcriptase	 (TERT)	 are	 seen	 in	 more	 than	 70%	 of	 melanomas	 (111,112).	
Interestingly,	mutations	within	the	coding	region	of	TERT	are	uncommon,	but	those	in	
promotor	regions	are	thought	to	increase	TERT	expression	by	creating	a	de	novo	binding	
motif	 for	 E26	 transformation-specific	 (ETS)	 transcription	 factors.	 In	 breast	 cancer,	
however,	a	recent	study	found	TERT	promotor	mutations9	in	only	0.9%	of	the	319	cases	

















immune	 infiltrate,	 stromal	 compartment	 and	 extracellular	 matrix	 (ECM))	 vary	
significantly	 between	 tumours	 and	 contribute	 to	 spatial	 heterogeneity	 in	 individual	
neoplasms.	Moreover,	localised	signalling	from	stromal	and	immune	cells	could	lead	to	
phenotypic	plasticity	within	isogenic	populations.	For	these	reasons,	we	should	consider	






stromal	 compartment,	 tumour	vasculature	and	 immune	cells.	These	 tumour	extrinsic	




inter-	and	 intratumour	heterogeneity.	Perhaps	the	most	relevant	 facet	of	 the	TME	for	




patients	 (117).	 As	 such,	 stratification	of	 CRCs	based	 on	 immune	 infiltrate	 could	 both	









Natural	 Killer	 (NK)	 cells	 to	 define	 three	 breast	 cancer	 subtypes	 (118).	 Analysis	 of	






PD-L1	 expression	will	 aid	 in	 improving	 the	 efficacy	 of	 such	 agents	 (120).	Moreover,	
integration	 of	 immune	 and	 genomic-based	 classifications	 will	 further	 increase	 our	











the	 next	 (123).	 During	 tumour	 development,	 genomic	 instability,	 the	 acquisition	 of	
numerous	 passenger	 mutations,	 coupled	 with	 irregular	 activation	 of	 signalling	
pathways,	 contributes	 to	 instability	 in	 these	 epigenetic	 ‘attractor	 states’	 (124).	 Thus,	











with	a	blurring	of	 the	boundaries	between	stem	and	differentiated	cells,	 it	 is	possible	
that	 a	 loss	 of	 structured	 ECM	 is	 essential	 for	 the	 stability	 of	multiple	 sub-dominant	
cellular	 clones	within	a	 tumour	 (124).	A	 recent	 study	by	Wang	et	al.,	 provides	direct	
evidence	 that	 ECM	 dependent	 signalling	 confers	 dynamic	 switching	 between	
transforming	growth	factor	β	receptor	3	(TGFBR3)	and	 jun	D	proto-oncogene	(JUND)	





dependent	 heterogeneity,	 for	 example	 in	 cell	 adhesion	 and	 Wnt	 signalling 10 	(99).	
Moreover,	cells	may	be	able	to	enter	transient	drug-tolerant	states	based	on,	for	example,	
histone	 demethylase-mediated	 chromatin	 remodelling11	(86).	 In	 summary,	 cells	 exist	
not	in	isolation,	but	in	a	milieu	growth	factors,	cytokines,	morphogens,	and	biophysical	
cues.	Through	contact	guidance,	differential	ECM	features	are	able	 to	drive	the	 initial	

















The	 typical	 attrition	 rate	 of	 new	 investigational	 drugs	 submitted	 for	 clinical	 trials	 is	
around	88%	(128).	Consequently,	the	average	cost	of	bringing	a	new	therapeutic	agent	
through	 to	 regulatory	 approval,	 a	 process	 that	 can	 take	 a	 decade,	 is	 over	 $2.56B	
(128,129).	In	order	to	reduce	the	attrition	of	experimental	cancer	agents	and	improve	
the	outcome	of	patients	treated	with	approved	targeted	agents,	we	must	develop	a	more	





is	 that	 chemotherapy	 and	 targeted	 agents	 do	 not	 have	 uniform	 efficacy	 across	






more	 precise	 (131).	 Early	 genomic	 classifications	 based	 on	 single	 parameter12 	have	
evolved	 into	 complex	 integrative	 methodologies	 designed	 to	 capture	 heterogeneity	
across	multiple	levels,	such	as	the	11	Integrative	Clusters	defined	by	Curtis	et	al.,	(7),	see	



































































on	 response	 to	 therapy,	 the	 emergence	 of	 drug	 resistance	 and	 disease	 progression.	
Currently	our	ability	to	predict	the	emergence	of	drug	resistance	in	tumours	requires	a	
priori	 knowledge	 of	 resistance	 mechanisms	 and	 the	 identification	 of	 resistance-
associated	 clones	 within	 a	 tumour.	 However,	 there	 is	 some	 evidence	 that	 the	




Typically,	 resistance	 results	 from	 the	 outgrowth	 of	 specific	 pre-existing	 populations	














are	genetically	heterogeneous,	 they	 functionally	 converge	on	key	 signalling	pathways	
which	might	aid	the	identification	of	biomarkers	of	disease	progression	(138).	Similarly,	
numerous	 avenues	 to	 poly	 ADP	 ribose	 polymerase	 (PARP)-inhibitor	 resistance	 have	












and	 found	 that	 the	 total	 number	 of	 genomic	 clones	 had	 significant	 association	with	
overall	 survival	 (141).	 However,	 the	 authors	 note	 that	 high	 clone	 number	 was	 only	
indicative	of	survival	up	to	a	maximum	clonal	diversity	of	 four.	 Indeed,	a	diversity	of	






Although	 anti-cancer	 therapies	 introduce	 a	 strong	 selective	 pressure,	 they	 do	 not	
necessarily	 lead	 to	 a	 reduction	 in	 overall	 clonal	 diversity	 or	 tumour	 genomic	
heterogeneity	(92).	For	example,	in	a	study	of	47	breast	cancer	patients,	strong	changes	
in	cellular	phenotype	were	seen	before	and	after	chemotherapy,	with	no	corresponding	
changes	 in	 genetic	 diversity,	 implying	 that	 a	 shift	 in	 the	 epigenomic	 landscape	 had	























and	 a	 corresponding	 therapeutic	 strategy.	 Moreover,	 a	 greater	 understanding	 of	





Metastasis	 is	 the	 ultimate	 cause	 of	 90%	 of	 all	 cancer	 deaths	 (147).	 Aside	 from	 the	
development	of	resistance	and	recurrence	of	disease,	heterogeneity	among	cancer	cells	
widens	 the	 diversity	 available	 for	 the	 evolution	 of	metastatic	 populations.	 The	 long-
standing	 observation	 that	 some	 cells	 within	 a	 tumour	 were	 able	 to	 form	 secondary	
tumours	at	a	higher	 frequency	than	others	was	one	of	 the	key	arguments	 for	 the	CSC	
hypothesis	 (17).	 However,	multi-region	 sequencing	 studies	 have	 found	 that	multiple	
distinct	 genomic	 clones	 are	 able	 to	 form	 metastases	 in	 pancreatic	 cancer	 (148),	
suggesting	 that	 a	 single	 'CSC	 clone'	 is	 not	 necessary	 responsible	 for	 cancer	
dissemination.		
	
Metastasis	 is	 thought	 to	 be	 the	 end	 result	 of	 a	multistage	 process	 that	 includes	 local	
invasion	by	the	primary	tumour	cells,	intravasation	into	the	blood	or	lymphatic	system,	





extravasation,	 survival	 in	 a	 new	 environment,	 and	 metastatic	 colonization	
(125,149,150).	Each	of	these	steps	relies	on	specific	phenotypic	features	of	the	tumour	




in	 the	 metastatic	 process	 was	 likely	 possessed	 of	 some	 transcriptional	 plasticity.	









molecular	 time	 from	 the	 primary	 site	 and	 progresses	 through	 the	 independent	





patients	 with	 high-grade	 serous	 ovarian	 cancer	 (156).	 Through	 phylogenetic	 tree	
reconstruction	from	whole	genome	and	single	cell	sequencing,	the	authors	find	that	both	
unidirectional	monoclonal	seeding	and	polyclonal	spread	with	reseeding	contributed	to	
the	 formation	 of	 intraperitoneal	metastatic	 deposits.	 Importantly,	 only	 a	minority	 of	
patients	exhibited	extensive	migration	and	reseeding	of	polyclonal	mixtures	at	multiple	




















late	 stage	primary	 tumours.	Additionally,	new	research	 suggests	 that	metastatic	 sites	
must	be	‘primed’	before	disseminating	cells	can	form	distant	metastasis	(158,159).	It	is	
possible	 that	 clonal	 cooperation	 could	 contribute	 to	 this	 effect,	 with	 one	 cellular	
population	 releasing	 cytokines	 and	 the	 other	 disseminating	 into	 the	 circulation.	 In	
summary,	though	much	is	still	unknown,	by	studying	the	evolution	of	clonal	populations	























In	 breast	 cancer,	 early	 fluorescent	 cytometry	 studies	 showed	 that	 a	 CD44+/CD24-/low	
population	 could	 be	 isolated	 from	 bulk	 tumours	 and	 had	 enriched	 tumourigenic	
potential	 in	 limiting	 dilution	 transplantation	 assays	 (LDA)	 in	 immunocompromised	
murine	 models	 (161,162).	 This	 putative	 BC-TIC	 population	 maintained	 its	 tumour-
initiating	 advantage	 over	 multiple	 passage	 and	 could	 repeatedly	 reconstitute	
phenotypically	 heterogeneous	 tumours	 (161,162).	 More	 recent	 work	 has	 implicated	
further	 surface	 markers	 (Protein	 C	 Receptor	 (PROCR),	 alpha-6	 integrin	 (CD49f),	
Thy1+/CD24+	etc.	(163–165))	in	various	breast	cancer	models.	Cells	with	high	aldehyde	









patients	 were	 shown	 to	 be	 highly	 enriched	 in	 both	 sphere	 forming	 ability	 and	





with	 CD44+/CD24low/-	 populations.	 Similarly,	 in	 primary	 human	 breast	 cancers,	
CD44+/CD24low/-	expression	is	not	an	independent	predictor	of	survival	(170).	The	same	
study	 found	that	 in	4,125	patients	CSC	markers	tended	to	associate	with	ERα-	breast	
cancer	 and	 the	 BC-TIC	 markers	 ALDH1A1	 (for	 ALDH	 positivity)	 and	 CD49f	 were	 of	
independent	 prognostic	 value	 for	 ERα-	 patients	 (171).	 In	 general,	 BC-TIC	 associated	






in	 CD44high/CD24low	 subpopulations,	 have	 increased	 mammosphere	 forming	 efficacy	
(MFE)	and	increased	tumour	initiation	potential	by	LDA	(174–177).	BC-TICs	have	been	
hypothesised	 to	 be	 quiescent	 in	 nature,	 demonstrating	 this,	 isolated	 BC-TICs	 show	
increased	dye	retention	and	a	decrease	in	cell	cycle	related	expression	markers	(178–
181).	 This	 quiescent	 nature	may	 confer	 on	BC-TICs	 their	 demonstrated	 resistance	 to	
such	 drugs,	 since	 efficient	 induction	 of	 apoptosis	 by	 traditional	 cytotoxic	
chemotherapies	 requires	 cell	 division	 (175,182).	 Even	 in	 cell	 line	 models,	
CD44high/CD24low	 are	 slow	 cycling,	 enriched	 in	 MFE	 and	 are	 resistant	 to	 some	
chemotherapies.	Additionally,	side-population14	cells	isolated	from	the	MCF7	cell	line	are	
enriched	 for	 these	 BC-TIC	 features	 and	 for	 the	 expression	 of	 P-glycoprotein,	 a	 well	
characterised	 ATP-binding	 cassette	 (ABC)	 multidrug	 resistant	 transporter	 protein,	
potentially	hinting	at	a	more	complex	mechanism	of	drug	resistance	(181,183).		
	














Further	 demonstrating	 this	 plasticity,	 in	 transformed	 human	 mammary	 epithelial	





and	 the	 conversion	 of	 CD44+/CD24+	 luminal-like	 cells	 to	 CD44+/CD24-	
myoepithelial/basal-like	 cells	 is	 governed	 by	 Activin/Nodal	 initiated	 TGFb	 signalling	
(186,188).	 Several	 caveats	 in	 these	 studies	 exist,	 for	 example	 EMT	 transcriptional	
programs	have	yet	to	be	described	in	this	context	in	vivo	and	TGFb	signalling	is	known	
to	be	highly	context	dependent	in	its	action	(159).	For	example,	Bruna	et	al.,	studied	the	
effects	of	TGFb	 on	BC-TICs	and	EMT	 in	a	panel	of	breast	 cancer	 cell	 lines	 (159).	The	
authors	found	that	TGFb	increased	MFE	in	claudinlow	cell	lines	by	orchestrating	a	specific	
gene	signature	enriched	in	stem	cell	processes	and	predictive	of	worse	overall	clinical	
outcome	 in	 breast	 cancer	 patients.	 Similarly,	 the	 authors	 found	 that	 TGFβ	 induced	
progenitor	 activity	 in	 normal	 mammary	 epithelial	 cells	 only	 in	 the	 basal/stem	 cell	
compartment,	where	claudinlow	cancers	are	presumed	to	arise	(159).		
	
Recent	 research	 in	 the	 stem	 cell	 field	has	 identified	 various	 tissues	with	 dormant	 or	
quiescent	stem	cell	populations	with	the	ability	to	regenerate	tissues	on	damage	(189–
191).	These	cells	are	resistant	to	normal	genotoxic	stress	(of	the	type	used	in	chemo-	and	
radiotherapies)	 by	 virtue	 of	 their	 slow	 cycling	 nature.	 For	 these	 reasons	 and	 others,	
Kreso	and	Dick	have	recently	put	forth	a	unifying	model	of	CSCs	and	clonal	evolution	of	
genomic	 clones	 (24).	 The	 authors	 propose	 that	 certain	 cellular	 phenotypes	 within	







chemoresistance	 and	 later	 found	 to	 express	 the	 putative	 stem	 cell	marker	 polycomb	
group	RING	finger	protein	4	(BMI1)		(192).		
	
The	 realisation	 that	 oncogenic	 driver	 mutations	 can	 lead	 to	 reacquisition	 of	







a	 heterogeneous	mixture	 of	 cellular	 phenotypes.	 These	 cellular	 phenotypes	 could	 be	












































high	 self-renewal	 potential,	 where	 most	 cells	 are	 tumorigenic.	 B)	 Clonal	 structures,	























































































































































































Multiple	 groups	 have	 attempted	 to	 define	 clonal	 dynamics	 based	 on	 either	 lentiviral	
tagging	(cellular	clones)	or	mutational	clustering	(genomic	clones)	by	population	and	
single	cell	based	computational	approaches15	(195–197).	In	our	biobank	of	breast	cancer	









Several	 computational	 methods	 exist	 to	 group	 somatic	 mutations	 based	 on	 shared	
frequency.	 These	 techniques	 attempt	 to	 reflect	 true	 genomically	 distinct	 populations	
within	a	tumour.	For	example,	PyClone	is	a	Bayesian	clustering	method	for	grouping	sets	
of	somatic	mutations	into	putative	clonal	clusters.	PyClone	estimates	cellular	prevalence	
of	 clones	 and	 accounts	 for	 allelic	 imbalances	 introduced	 by	 segmental	 copy	 number	
changes	(199).	Eirew	et	al.,	were	able	to	reconstruct	the	genomic	clonal	dynamics	of	a	
panel	 of	 breast	 cancer	 PDX	 models	 using	 PyClone	 (195).	 In	 each	 of	 the	 15	 cases	
















of	 the	 patient’s	 metastatic	 lesion	 than	 primary	 tumour	 (153).	 Eirew	 et	 al.,	 further	
observed	variable	clonal	dynamics	between	PDXs	established	from	different	molecular	
subtypes,	underscoring	the	need	for	better	representation	of	tumour	molecular	subtypes	




change	 in	cellular	prevalence	between	passages.	 Interestingly,	only	4	of	 the	38	clonal	
clusters	 that	 changed	significantly	after	engraftment	or	during	passaging	 contained	a	
driver	mutation16.	These	data	suggest	that	proliferative	advantage	may	not	be	central	to	
clonal	dynamics	in	vivo	(198).	Together,	these	observations	suggest	that	deterministic,	






to	 link	 mother	 and	 daughter	 cells	 in	 lineage	 tracing	 experiments.	 Typically,	 such	
technologies	rely	on	viral	DNA	integration	in	the	host	cell,	however	detection	techniques	
can	 be	 varied.	 For	 example,	 Buczacki	 et	 al.,	 used	 pulse-chase	 labelling	 of	 transgenic	
Cyp1a1-H2B-YFP	mice	 to	 define	 quiescent	 label	 retaining	 cells	 in	 the	 intestinal	 crypt	
(189),	whereas	Davis	et	al.,	used	a	multicolour	lineage	tracing	approach,	coupled	with	
advanced	 3D	 imaging,	 to	uncover	 the	 unipotent	 nature	of	 adult	mammary	 stem	 cells	











in	 cell-line	 derived	 xenograft	 and	 PDX	 models	 of	 breast	 cancer	 (197).	 The	 authors	
focussed	on	 interrogating	 the	BC-TIC	phenomenon,	 finding	 that	 ‘clone-initiating’	 cells	
were	 present	 in	 the	 samples	 at	 frequencies	 of	 between	~1/10	 and	~1/10,000	 cells.	
Interestingly,	in	the	cell-line	xenograft	models,	clone-initiating	frequency	was	negatively	
affected	 in	transplants	of	more	than	20,000	cells,	suggesting	that	growth	competition	
negatively	 affects	 xenograft	 diversity.	 The	 authors	 describe	 up	 to	 five	 clonal	 growth	
patterns	 when	 studying	 PDX	 repopulation	 dynamics	 (unchanging,	 expanding,	
diminishing,	fluctuating	or	of	delayed	onset)	(83,197).		
	
Cell	 lines	 are	 often	 considered	 monoclonal,	 having	 lost	 diversity	 through	 numerous	
cycles	of	in	vitro	culture	(204).	Porter	et	al.,	utilised	cellular	barcoding	to	simultaneously	
track	 the	 clonal	dynamics	 in	 common	 cell	 lines	 including	HeLa,	 K562	 and	HEK293-T	
(204).	 Each	 cell	 line	 exhibited	 ongoing	 clonal	 dynamics,	 even	 in	 optimal	 culturing	
conditions.	Interestingly,	the	authors	found	that	re-deriving	K562	line	from	a	single	cell	
before	barcoding	and	clonal	tracking,	reduced	but	did	not	eradicate	clonal	dynamics	in	






library	 to	 trace	 the	 origins	 of	 resistance	 to	 EGFR	 inhibitors	 erlotinib,	 WZ4002	 and	
gefitinib	 (135,205).	 ClonTracer	 enables	 the	 labelling	 and	 tracking	 of	 >1	 million	
individual	cells	with	a	unique	30-nucleotide	long	semi-random	DNA	sequence	tag	(135).	
The	ClonTracer	library	was	designed	to	have	a	balanced	GC	content	to	ensure	uniform	









the	 non-small	 cell	 lung	 cancer	 (NSCLC)	 cell	 line	HCC827	 (135).	HCC827	harbours	 an	
activating	EGFR	mutation	that	confers	sensitivity	to	EGFR	inhibitors	and	has	been	widely	
used	 to	 study	 resistance	 to	 this	 class	of	 drug	 (206–208).	 The	 authors	 found,	 by	 next	
generation	 sequencing	 (NGS)	 of	 barcode	 amplicons,	 that	 0.05%	 of	 HCC827	 cells	
harboured	 a	 pre-existing	 resistance	 to	 erlotinib.	 Further	 analysis	 of	 this	 population	
found	MET	amplification,	and	treatment	with	the	c-Met	inhibitor	crizotinib	significantly	
reduced	the	diversity	of	resistant	populations.	A	small	proportion	of	cells	were	resistant	
to	 both	 inhibitors,	 and	 the	 authors	 noted	 that	 this	 sub-population	 tended	 to	 have	 a	




patient	 in	 blast	 crisis	 and	 harbours	 the	 BCR–ABL1	 translocation	 (210).	 The	 authors	
performed	 unsupervised	 hierarchical	 clustering	 on	 the	 100	most	 enriched	 barcodes	
from	 each	 replicate	 across	 each	 treatment	 group	 and	 found	 clustering	 of	 barcodes	
enriched	 in	nilotinib	and	imatinib	treatment	arms,	but	not	GNF-2.	These	data	suggest	
similar	 pre-existing	 clones	 drove	 resistance	 to	 imatinib	 and	 nilotinib	 (both	 catalytic	
subunit	 inhibitors),	 but	 that	 GNF-2	 (an	 allosteric	 inhibitor)	 resistance	was	 driven	 by	
separate	 cellular	 populations	 (211).	 Consistent	 with	 this	 notion,	 genomic	 analyses	












initially	 EGFRT790M-negative	 drug-tolerant	 cells.	 Interestingly,	 these	 distinct	 paths	 to	
drug	resistance	were	first	hinted	at	by	the	variable	time	required	to	develop	resistance	
in	two	PC9	sublines.	On	further	investigation,	the	authors	found	that	whilst	both	PC9-
GR2	 (6	 weeks	 to	 resistance)	 and	 PC9-GR3	 (24	 weeks	 to	 resistance)	 had	 diminished	
upregulation	of	Bcl-2-like	protein	11	(BIM),	a	key	mediator	of	apoptosis	in	EGFR-mutant	










fraction	 of	 drug-tolerant	 pools	 that	 were	 predicted	 to	 acquire	 mutations	 during	 16	
weeks	of	gefitinib	treatment.	Using	a	variable	set	of	parameters	 for	mutation	and	cell	

















Oestrogen	 and	 its	 primary	 receptor,	 ERα,	 play	 a	 major	 role	 in	 the	 initiation	 and	
progression	of	breast	cancer.	 Indeed,	70%	of	breast	cancer	patients	express	ERα,	PR,	
and/or	oestrogen-responsive	and	ERα-dependent	gene	products	(213).	ERα	status	was	




















with	 classical	models	 of	 tamoxifen	 (T)	 antagonism	 and	 possible	 biased	 agonism	 at	 the	
receptor.	mER	is	membrane	bound	ER,	CoR	is	coregulator	and	TF	is	transcription	factor.	
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a	 member	 of	 the	 48	 member	 nuclear	 receptor	 (NR)	 superfamily	 (215)	 of	 ligand-
regulated	transcription	factors.	NR	ligands,	including	oestrogen,	progesterone,	retinoic	
acid,	 oxysterols	 and	 thyroid	hormones,	 are	 generally	 lipophilic	 and	 cross	 the	 plasma	
membrane	to	directly	interact	with	NRs	inside	the	cell	(216).	NR	regulated	transcription	






the	 central	 DNA-binding	 domain	 (DBD),	 involved	 also	 in	 DNA	 recognition	 (218).	
Transcriptional	activation	is	dependent	on	two	distinct	activation	functions	(AFs),	AF-2	
resides	in	the	COOH-terminal	ligand-binding	domain	and	AF-1	(which	is	constitutively	
active)	 in	 the	 variable	 NH2	 terminus	 (219).	 On	 ligand	 activation,	 cell-specific	
transcriptional	 response	 to	 oestrogen	 is	 governed	 by	 a	 plethora	 of	 associated	
coregulatory	 proteins	 and	 pioneer	 factors,	 allowing	 context	 dependent	 effector	
functions	of	oestrogen	signalling	in	a	given	cell	or	tissue	(220).		Recruited	coregulators	
(CoRs)	 carry	 out	 all	 the	 reactions	 required	 for	 the	 entire	 transcriptional	 process;	
different	 receptors	 binding	 to	 the	 same	 genetic	 sequence	 can	 recruit	 different	
coactivators	and	thereby	provide	different	transcriptomic	response.	Similarly,	different	
ligands	occupying	 the	 same	 receptor	 at	 the	 same	 site	 can	 induce	 different	 structural	




(222).	 The	 Src	 family	 are	 the	 best	 characterised	 ERα	 coactivators.	 On	 primary	





coregulators	 such	 as	 p300	 (a	 histone	 acetyltransferase)	 and	 Coactivator	 Associated	
Arginine	Methyltransferase	1	(CARM1)	(a	histone	methyltransferase)	(223,224).	Src-1	
and	 Src-3	 also	 contain	 intrinsic	 acetyltransferase	 activity	 toward	 histones	 (225).	






In	 addition	 to	 coactivators,	 there	 are	 a	 group	 of	 transcription	 factors	 termed	








The	 adult	 mammary	 epithelium	 comprises	 two	 predominant	 lineages;	 luminal	 cells	
forming	 the	 ductal	 system	 and	 milk-secreting	 cells	 of	 the	 alveoli	 and	 myoepithelial	
(basal)	cells	lining	the	ducts	and	helping	in	milk	secretion	during	lactation	(231).	There	
is	a	great	deal	of	debate	currently	surrounding	the	maintenance	of	each	lineage	in	the	
adult	 gland.	 Whilst	 transplantation	 assays	 report	 bipotent	 progenitors	 in	 each	
compartment	 with	 complete	 regenerative	 potential,	 lineage	 tracing	 studies	
predominantly	 identify	 unipotent	 progenitors	 as	 responsible	 for	 maintenance	 of	 the	
gland	 in	 the	 absence	 of	 perturbation	 (200,231–233).	 It	 has	 been	 proposed	 that	
mammary	repopulating	cells	(identified	by	transplantation)	are	distinct	from	mammary	
stem	cells	under	physiological	conditions.	Functionally,	it	seems	likely	that,	as	identified	





capable	 of	 repopulating	 the	 entire	 gland	 in	 injury.	 Indeed,	 recent	 studies	 have	
demonstrated	 lineage	 restricted	 cell	 populations	 can	 regain	 multipotency	 by	 the	




dependent	 on	 oestrogen	 signalling	 for	 self-renewal	 and	 maintenance.	 Indeed,	
ovariectomised	 mice	 show	 markedly	 depleted	 mammary	 stem	 cell	 number	 and	
repopulation	potential	in	vivo	(234).	Whilst	cells	of	the	myoepithelial	compartment	are	
predominantly	 ERα-,	 those	 of	 the	 luminal	 epithelium	 may	 be	 either	 ERα+	 or	 ERα-.	
Interestingly,	 the	majority	 of	 luminal	 progenitors	 and	milk	 secretory	 cells	 are	 ERα-,	
suggesting	 a	 role	 for	 oestrogen	mediated	 paracrine	 signalling	 between	 cells	 of	 each	
compartment	(235).		
	
In	 general,	 organogenesis,	 development	 and	maintenance	 by	 stem	 cell	populations	 is	





pioneer	 factors	 can	 bring	 positive	 or	 negative	 effects	 on	 transcriptional	 programs	
depending	on	the	specific	cellular	context.		
	
Two	 ERα	 pioneer	 factors;	 GATA-binding	 protein	 3	 (GATA3)	 and	 Forkhead	 box	 A1	
(FOXA1)	are	thought	to	play	an	essential	role	in	mammary	gland	fate	determination	and	
in	ERα	cancer	specific	biology.	FOXA1	is	a	member	of	the	forkhead	transcription	factor	












of	 GATA3	 in	mammary	 stem	 cell	 enriched	 populations	 promotes	 differentiation	 into	






The	 first	 targeted	 antiestrogenic	 therapy	 for	 breast	 cancer,	 tamoxifen,	 has	 been	 a	
cornerstone	 of	 the	 clinical	 management	 of	 ERα+	 breast	 cancers	 for	 the	 past	 three	







limitation	of	 tamoxifen	 therapy	 is	 the	development	of	 endocrine	resistance	 in	a	 large	
proportion	of	patients,	including	almost	all	with	advanced	metastatic	disease	(238,242).	
	
Tamoxifen,	 and	 later	 derivatives	 such	 as	 raloxifene	 act	 by	 competing	 for	 oestrogen	
binding	at	ERα.	An	alternative	strategy	is	to	reduce	expression	of	ERα	directly	on	breast	








of	 aromatase	 inhibitors	 (AIs)	 in	 postmenopausal	women.	 AIs	work	 by	 inhibiting	 the	
action	 of	 aromatase,	 which	 converts	 androgens	 into	 oestrogens	 in	 a	 process	 called	
aromatization	 (245).	 In	 the	 adjuvant	 setting,	 AIs	 have	 proven	 more	 effective	 in	
prolonging	disease-free	survival	and	are	quickly	replacing	the	other	endocrine	therapies	
in	the	management	of	ERα+	breast	cancer.	Ten-year	analysis	of	the	ATAC	clinical	trial	
published	 in	 2010	 confirmed	 superior	 efficacy	 and	 safety	 of	 anastrozole	 (a	 third	











the	 development	 of	 resistance	 (213,238,248).	 Several	 mechanisms	 for	 acquired	 (de	
novo)	and	innate	resistance	to	endocrine	therapies	have	been	proposed.		
	
ERα	 expression	 is	 the	main	 predictor	 of	 response	 to	 endocrine	 therapy,	 and	 lack	 of	
expression	is	the	principle	mechanism	for	innate	resistance	to	hormonal	therapy	(249).	
Interestingly,	 several	 studies	 point	 to	 the	 possibility	 of	 reactivating	 silenced	 ERα	














Cross-talk	 between	 mitogenic	 growth	 factor	 and	 ERα-signalling	 pathways	 has	 been	
shown	 to	 play	 a	major	 role	 in	 acquired	 resistance	 to	 endocrine	 therapies	 (256).	 For	
example,	reporter	gene	constructs	in	tamoxifen	resistant	cell	lines	have	indicated	that	
the	 EGFR/	 mitogen	 activated	 protein	 kinase	 (MAPK)	 pathway	 can	 result	 in	
phosphorylation	of	ERα	AF-1	at	serines	118	and	167	(257).	Phosphorylation	of	AF-1	can	
lead	 to	 ligand	 independent	 ERα	 activation,	 coregulator	 recruitment	 and	 oestrogen	
regulated	gene	transcription	even	in	the	presence	of	tamoxifen-bound-ERα	(258–261).	
Similarly,	 in	 MCF-7/HER2-18	 cells	 manipulated	 to	 express	 HER2	 alongside	 ERα,	
tamoxifen	behaves	as	a	full	ERα	agonist	and	stimulates	cell	growth	through	oestrogen	
regulated	 gene	 transcription.	 In	 this	 model,	 gefetinib,	 a	 selective	 inhibitor	 of	 EGFR,	
restores	sensitivity	to	tamoxifen	(262).	Additionally,	the	HER2	tyrosine	kinase	inhibitor	
AG1478	 has	 efficacy	 in	 tamoxifen	 resistant	 MCF7s	 and	 the	 anti-HER2	 antibody	



















inhibitor)	 has	 some	 clinical	 benefit	 in	 terms	 of	 time	 to	 progression	 and	 disease-free	
survival	(266).		
	




programs.	 The	 ERα	 coactivator	 Src-3	 is	 amplified	 in	 10%	 of	 breast	 cancers	 and	 is	
associated	 with	 poor	 overall	 survival	 (227,268,269).	 Tamoxifen	 has	 been	 shown	 to	
induce	ERα-Src-3	interactions	in	HER2+	breast	cancers.	In	this	scenario,	tamoxifen	acts	
as	 a	 full	 ERα	 agonist	 and	 drives	molecular	 crosstalk	 with	 the	 HER2	 pathway	 (262).	
Tamoxifen	also	significantly	increases	the	expression	of	Src-1	and	Src-3,	both	of	which	
are	 associated	with	 the	 development	 of	 resistance	 (270,271).	 In	 addition,	 tamoxifen	
treatment	 increases	 co-localisation	 between	 Srcs	 and	 ERα	 in	 resistant	 cell	 lines	 and	






regulatory	 region	 in	 the	 ERBB2	 gene	 (272).	 When	 ERα	 recruited	 paired	 box	 gene	 2	
(Pax2),	 ERBB2	 expression	 was	 repressed	 but	 on	 the	 loss	 of	 PAX2,	 Src-3	 could	 turn	
expression	back	on	and	led	to	the	development	of	HER2	mediated	tamoxifen	resistance.	










cancers	were	 still	 able	 to	 recruit	 ERα	 to	 the	 chromatin	 (248).	 They	 found	 that	 those	
patients	who	would	go	on	 to	develop	 tamoxifen	 resistance	 had	 a	 unique	 set	 of	 ERα-




ERα-binding	 on	 a	 rapid	 timescale.	 Finally,	 in	 2015	 Mohammed	 and	 colleagues	
demonstrated	 that	 PR	 is	 capable	 of	modulating	 ERα	 behaviour	 and	 antagonising	 the	
proliferative	 effects	 of	 oestrogen	 in	 ERα+	 cell	 lines	 (273).	 The	 authors	 found	 that	
progesterone	treatment	synergised	with	the	effects	of	anti-oestrogen	treatment	in	cell	





























(276).	 The	 authors	 found	 that	 expression	 of	 three	 canonical	 master	 stem	 cell	
transcription	factors,	homeobox	transcription	factor	Nanog-delta	48	(NANOG),	octamer-
binding	transcription	 factor	4	 (OCT4)	and	sex	determining	region	Y	box	2	 (SOX2),	was	
higher	 in	 organoids	 than	 in	 differentiated	 cells	 from	 the	 same	 donor.	 Moreover,	
expression	 was	 reduced	 to	 a	 level	 more	 associated	 with	 differentiated	 cells	 by	 the	
addition	 of	 exogenous	 oestrogen.	 In	 MCF7	 mammospheres,	 the	 authors	 found	 that	
overexpression	 of	NANOG,	 POU5F1	or	 SOX2	 reduced	ESR1	 expression,	 the	 number	 of	
putative	BC-TICs	and	their	capacity	for	invasion.	Moreover,	tamoxifen	treatment	in	this	
model	 increased	 the	 number	 of	 mammospheres	 formed,	 and	 this	 corresponded	 to	
increased	NANOG,	POU5F1	or	SOX2	expression	(276).		
	





(2014	&	 2017),	 SOX2	was	 first	 found	 to	 play	an	 essential	 role	 in	 the	 self-renewal	 of	
melanoma	tumour	initiating	cells	and	hedgehog-induced	melanoma	cell	growth	(278),	
before	being	shown	by	CRISPR-Cas9	to	have	no	functional	role	in	melanoma	initiation,	








OCT4,	 encoded	 for	 by	 the	 POU5F1	 gene	 and	 another	 master	 transcription	 factor	 of	
embryonic	stem	cells	required	to	reprogram	differentiated	cells	 into	 iPSCs	(280),	has	







but	 not	 oestrogen,	 associated	 transcriptional	 sites	 (282).	 Further	 experiments	
uncovered	a	mechanism	by	which	Nkx3-1,	the	androgen	regulated	transcription	factor	
predominantly	 localised	 in	 the	 prostate	 epithelium	 (283),	 basally	 repressed	POU5F1	
expression	 in	MCF7	cells.	 	 Interestingly,	 the	authors	went	on	to	show	by	quantitative	
mass-spectrometry	 that	 tamoxifen	 treatment	 of	MCF7s	 elevated	 Nkx3-1	 degradation	
through	 a	 p38MAPK-dependent	 phosphorylation	 of	 the	 E3	 ligase,	 Skp2	 at	 serine-64	
(282).	
		
Interestingly,	 the	 third	 canonical	 transcription	 factor	 needed	 for	 derivation	 of	 iPSCs,	
kruppel-like	factor	4	(KLF4),	is	generally	associated	with	a	favourable	outcome	in	breast	
cancer	 (280,284).	 Jia	 et	 al.,	 found	 that	 higher	 expression	 of	 KLF4	 correlated	 with	
increased	 tamoxifen	 sensitivity	 in	 patients,	 and	 was	 positively	 correlated	 with	 ERα	
activity.	The	authors	went	on	to	knockdown	KLF4	 in	MCF7	and	BCAP37	cells,	 finding	














binding	 and	 consequently	 decreased	 gene	 expression	 of	 key	 oestrogen	 regulators.	 In	
another	 study	 by	 this	 group,	 promotor	 demethylation	 with	 5-Azacytidine	 (5-Aza),	
coupled	with	E2,	restored	ERα-regulated	gene	expression	in	TamR	lines	and	induced	a	
significant	anti-proliferative	effect	(97).	Cumulatively,	these	results	highlight	a	novel	role	
for	 ERα	 response	 element	 methylation	 in	 the	 induction	 of	 tamoxifen	 resistance.	
Interestingly,	embryonic	transcription	factors	OCT4,	SOX2	and	KLF4	each	have	roles	in	
regulating	 the	 methylome	 of	 stem	 and	 progenitor	 cells	 to	 control	 differentiation	





















As	 discussed	 in	 this	 Chapter,	 breast	 cancer	 is	 a	 collection	 of	 diseases	 with	 distinct	








Breast	cancer	cell	 lines	have	 found	extensive	use	 in	 the	 investigation	of	proliferation,	
apoptosis,	 migration	 and	 the	 BC-TIC	 phenomenon.	 The	 first	 breast	 cancer	 cell	 line	




line)	 and	MCF7	 account	 for	more	 than	 two	 thirds	 of	 all	 abstracts	mentioning	 breast	
cancer	cell	lines	(291).	Experiments	in	cell	lines	were	crucial	in	the	development	of	one	
of	 the	 first	 targeted	therapeutic	agents	 launched	 in	1998;	 the	anti-HER2	trastuzumab	
(Herceptin®),	a	humanized	antibody	that	binds	to	the	ectodomain	of	HER2	(292)	and	
has	demonstrated	 remarkable	 clinical	 impact	 in	ERBB2	amplified	breast	 cancers.	Cell	
lines	have	also	helped	to	elucidate	the	mechanisms	of	primary	and	acquired	resistance	















have	 also	 been	 used	 to	 unravel	 molecular	 mechanisms	 of	 signalling	 networks,	 for	
example	 those	 underlying	 the	 apparently	 paradoxical	 role	 of	 TGFb	 in	 breast	 cancer	
(159).	 Using	 these	 3D	mammosphere	 cultures,	 our	 group	 has	 identified	TGFb	 breast	











also	 characterised	 a	method	 of	using	 intraductal	 injections	 to	 introduce	 ERα+	breast	
cancer	cells	directly	into	the	mouse	mammary	duct.	Sflomos	et	al.,	found	this	method	was	
closer	physiologically	 to	 the	natural	environment	of	human	breast	cancer	cells	(477).	















cancers,	 genetically	 engineered	mouse	 (GEM)	models	 have	 been	 used	 extensively	 to	
investigate	 tumour	 initiation	 and	 progression.	 GEM	models	 generally	 fall	 into	 three	
distinct	histopathological	categories,	those	closely	resembling	non-GEM	tumours,	those	
with	 unique	 transgene-specific	 phenotypes	 and	 those	 that	 resemble	 human	





to	 characterize	 the	 effects	 of	 several	 now	 widely	 accepted	 oncogenes	 and	 tumour	
suppressors	in	breast	cancer	(including	tumour	suppressors	PTEN,	BRCA1,	TRP53	and	
oncogenes	 ERBB2,	MYC	 and	 CCND1)	 (298).	When	 combined	with	 advanced	 intravital	
imaging,	GEM	models	have	also	been	used	to	elucidate	the	precise	role	of	macrophages	
in	 breast	 cancer	metastasis.	 For	 example,	 the	 Pollard	 lab	 has	 relied	 heavily	 on	 these	
models	 to	 show	 that	 the	 purported	 metastasis-associated	 macrophages	 (MAMs)	 are	
active	promoters	of	the	metastatic	cascade	rather	than	bystanders	(299).	Like	syngeneic	
models	of	breast	cancer,	GEM	models	have	the	advantage	of	 including	native	stromal	
compartments	 of	 a	malignancy.	However,	 a	major	 limitation	 of	 early	GEM	models	 in	
particular	is	their	tendency	to	form	ERα	negative	tumours,	a	limitation	that	indicates	the	














mutational	 event.	 In	 each	 case,	 drug	 resistance	 occurred	 from	 the	 cancer	 cell	
autonomous	compartment	in	a	fashion	that	could	not	easily	be	predicted.	If	such	inter-
clonal	 cooperation	 exists	 in	 human	 breast	 cancer,	 this	would	 underline	 the	 need	 for	





A	major	 limitation	 of	 breast	 cancer	mouse	models	 has	historically	 been	 their	 lack	 of	
representation	 of	 ERα+	 disease,	 with	 GEM	 models	 typically	 generating	 ERα-	 breast	
cancers	(476,479).	Due	to	the	lack	of	sporadic	and	human-relevant	cases	of	ERα+	disease	
in	 mice,	 the	 earliest	 experimental	 models	 used	 the	 chemical	 carcinogen	 7,12-





Consequently,	 one	 of	 the	 best-known	 GEM	 for	 ERα+	 breast	 cancer	 is	 the	Trp53	 null	
mouse	(481).	Limitations	with	this	model18,	however,	have	 led	to	 the	development	of	






































and	 propagated	 in	 highly	 immunodeficient	 mice,	 typically	 NOD.Cg-Prkdcscid	
IL2rgtm1Wjl/SzJ	(NSG)	or	NOD.Cg-Rag1tm1Mom	 IL2rgtm1Wjl/SzJ	(NRG)	strains.	PDXs	reflect	
the	originating	sample’s	morphological	and	molecular	features	(306,307).	Genomically,	
they	 recapitulate	 most	 of	 the	 clonal	 architecture	 found	 in	 originating	 sample’s	 and	





iteration	 of	 these	 models	 do	 lack	 patient-matched	 stromal	 compartments	 and	 by	
necessity,	lack	a	functional	immune	system	(23).		
	










adult	 cancer	 types	was	 shown	 to	 capture	 the	genomic	and	 transcriptomic	 features	of	
tumours	seen	in	the	clinical	population	as	a	whole.	The	majority	of	PDXs	in	this	collection	
were	treated	with	a	variety	of	targeted	compounds	in	a	strategy	dubbed	‘1x1x1’	for	‘one	
animal	per	model	per	 treatment’.	This	approach	mimics	 the	 reality	of	human	clinical	
trials,	which	do	not	allow	for	technical	or	biological	replicates.	One	of	the	key	findings	of	
this	 study	 was	 that	 a	 population	 of	 PDXs	mimicked	 the	 spectrum	 of	 human	 clinical	
responses,	reinforcing	the	translatability	of	 these	models	 to	predict	population-based	
drug	 responses.	 Moreover,	 known	mechanisms	 of	 resistance	 were	 identified	 by	 this	
strategy;	for	example	three	PDXs	treated	with	encorafenib	developed	resistance	through	
















similar	 pattern	 of	 response	 across	 all	 samples	 tested.	 Recognising	 the	 importance	 of	
combination	 therapies	 in	 achieving	 long-lasting	 responses	 (312),	 we	 also	 tested	 and	
validated	 the	 PDX	 platform	 in	 a	 high	 throughput	 combinatorial	 drug	 screen	 with	
standard	of	 care	 chemotherapeutic	 agents	 (Cisplatin	and	Paclitaxel)	 and	 six	 clinically	
relevant	targeted	compounds.	Together	this	work	validates	the	use	of	PDX	models	as	an	
integral	part	of	the	breast	cancer	drug	discovery	and	development	pipeline.	Crucially,	as	














































PDTC	 pipeline	 was	 developed	 for	 high	 throughput	 studies	 on	 PDX	 models.	 D)	 High	
throughput	drug	screens	can	be	performed	on	PDTC	biobank.	E)	Multiple	analysis	processes	














































Diversity	 within	 a	 tumour	 has	 long	 been	 recognised.	 Indeed,	 as	 early	 as	 1958,	
evolutionary	biologist	Julian	Huxley	commented	on	‘‘genetic	inhomogeneity’’	in	cancer	
(313).	It	was	not	until	the	1970’s	that	theories	of	tumour	diversity	were	combined	with	
Darwinian	 evolution	 to	 explore	 the	 causes	 and	 consequences	 of	 tumour	 evolution.	





studies	 have	 uncovered	 the	 great	 diversity	 within	 tumours	 of	 the	 same	 organ,	 for	
example	 our	 own	work	 in	 delineating	 the	 11	 distinct	 diseases	 typically	 classified	 as	










dynamics	 and	 engraftment	 biases	 (83,195,198).	 Our	 own	work	 has	 shown	 that	 such	
models	 reflect	 most	 of	 the	 clonal	 structures	 of	 their	 originating	 samples	 and	 are	













oestrogen	 receptor	 antagonists	 (e.g.	 tamoxifen)	 or	 aromatase	 inhibitors	 (e.g.	
anastrozole).	However,	50%	of	metastatic	ERα+	tumours	will	have	innate	resistance	to	
such	 endocrine	 therapies	 and	 nearly	 40%	 of	 initially	 responsive	 early-stage	 breast	
cancers	 will	 relapse	 with	 endocrine	 therapy	 resistant	 disease	 (317).	 Historically,	
tamoxifen	was	the	most	widely	prescribed	therapy	for	ERα+	breast	cancer,	its	continued	
clinical	 use	 means	 it	 remains	 as	 on	 the	 World	 Health	 Organisation’s	 2018	 list	 of	
“Essential	Medicines”	(318).	The	development	of	tamoxifen	resistance	has	been	widely	
studied,	 but	 unlike	 many	 cases	 of	 resistance	 to	 targeted	 agents,	 its	 origins	 remain	
controversial	 (213,255,272,319,320).	Crucially,	 the	 interplay	between	epigenetic	 (97)	




























native	 microenvironment.	 Reciprocal	 signalling	 pathways	 between	 tumour	 cells	 and	
tumour	 associated	 macrophages	 (TAMs)	 and	 CAFs	 are	 highlighted.	 ECM	 is	 shown	 as	
collagen	 fibres	 with	 associated	 fibroblasts	 and	 macrophage/dendritic	 cells	 with	 T/B	







their	 human	 counterparts	 (323).	 C)	 A	 PDX	 tumour	 in	 its	 native	 microenvironment.	
Questions	over	whether	pro-	and	antitumor	CAF/TAM	signalling	pathways	are	present	to	
the	same	extent	in	PDX	models	as	in	the	primary	tumour	are	highlighted.	Stromal	and	tissue	

























































and	 the	 European	Union	Directive	 EU	86/609	 and	 underwent	 local	 ethical	 review	 at	
Cambridge	 University.	 Human	 tissues	 for	 PDX	 implantation	 were	 collected	 from	
consenting	patients	with	appropriate	approval	by	the	National	Research	Ethics	Service,	
Cambridgeshire	2	REC	(REC	reference	number:	08/H0308/178).	Some	PDX	models	were	
obtained	 from	 our	 network	 of	 collaborators,	 with	 appropriate	 Institutional	 Review	
Board	 agreement	 and	 under	 Materials	 Transfer	 Agreements.	 NOD.Cg-Prkdcscid	
IL2rgtm1Wjl/SzJ	 (NSG)	mice	were	 obtained	 from	Charles	River.	NSG,	 PDX	 and	 cell	 line	










collaborating	 hospitals	 in	 Europe	 (Institute	 Curie,	 Paris	 and	 VHIO,	 Barcelona),	 US	
(Huntsman	 Cancer	 Institute,	 Salt	 Lake	 City,	 Utah)	 and	 Canada	 (UBC,	 Vancouver).	
Surgically	resected	primary	breast	cancer	tissue,	biopsies	from	brain,	skin,	liver,	bone,	
axilla	and	lymph	node	metastasis,	and	pleural	effusions	or	ascites	samples	were	obtained	













mouse.	 Genotyping	 of	 all	 samples	 was	 performed	 to	 confirm	 matching	 with	 the	





















































































































(EDTA)	 (0.5%	 Sigma)	 for	 5	minutes.	 Samples	were	washed	 and	 incubated	with	 2ml	
prewarmed	5mg/ml	Dispase	and	500μl	of	1mg/ml	DNase	I.	Samples	were	then	washed	






























femoral	 artery	 severed,	 as	 per	 local	 procedures	 and	 best	 practises.	 In	 some	 cases,	
euthanised	 mice	 were	 inspected	 in	 the	 Xenogen	 small	 animal	 imaging	 system	 for	
suspected	metastatic	sites.	Euthanised	mice	were	placed	in	dorsal	recumbency	on	a	clean	
dissection	board	and	an	 incision	made	across	the	 full	 length	of	 the	ventrum	(anus	 to	
chin),	 reflecting	 the	 skin	 and	 incising	 the	 abdominal	 wall,	 exposing	 the	 abdominal	
viscera,	 salivary	and	preputial/clitoral	 glands,	and	cervical	 and	axillary	 lymph	nodes.	
Skin	was	pinned	back	to	expose	the	PDX	tumour	site	(left	or	right	flank).	Tumour	was	
identified,	excised	and	stored	as	appropriate	(neutral	buffered	 formalin	 for	histology,	
serum	with	10%	DMSO	 for	 cryogenic	preservation	and	DMEM	+10%	FBS	 for	 further	
study,	 PDTC	 dissociation,	 dissection	 or	 reimplantation).	 Continuing	 with	 the	 post	









animal	 imaging	 system.	 We	 next	 checked	 the	 mesentery	 for	 enlarged	 lymph	 nodes	













by	 trypsinisation	 (0.25%	 trypsin	 EDTA;	 Life	 Technologies)	 every	 7	 days	 or	 at	 80%	
confluence.	 TamRs	 were	 cultured	 under	 the	 same	 conditions,	 though	 with	 charcoal	
striped	 FBS	 (Life	 Technologies)	 and	 DMEM:	 F12	 without	 phenol	 red	 to	 minimise	
oestrogens	and	pseudo-oestrogens.	Prior	to	cell	based	assays,	cells	were	briefly	serum	
starved	(media	+	0.1%	FBS)	for	24hrs	to	synchronise	cell	cycles.	Assay	media	containing	
1%	 FBS	 was	 used	 in	 all	 2D	 cellular	 assays.	 Viability	 was	 calculated	 by	 Trypan	 Blue	
























manufacturers	 recommended	 protocols).	 Second	 generation	 spheres	 were	 then	





















24hrs.	Monolayers	were	washed	with	phosphate	buffered	 saline	 (PBS)	and	 scratched	
using	 a	 24	 or	 96	 well	 wound	 maker	 as	 per	 manufacturer’s	 instructions	 (Essen	
Biosciences).	If	using	24-well	wound	maker,	pipette	tips	were	changed	after	each	plate.	
Monolayers	were	again	washed	(gently	in	PBS)	to	remove	dead	cells	and	assay	media	






acquired	 every	 2-4hrs.	 We	 aimed	 to	 avoid	 proliferation	 at	 the	 wound	 site	 to	 assay	
migration	independent	of	proliferation.	Thus,	the	assay	was	limited	by	visual	inspection	











via	 another	 primary	 metabolite	 N-desmethyltamoxifen	 (NDMTAM)	 to	 a	 biologically	
active	secondary	metabolite	endoxifen	through	a	cytochrome	P450	2D6	variant	system	
(CYP2D6)	 primarily	 expressed	 by	 the	 liver	 and	 certain	 areas	 of	 the	 central	 nervous	
system	 (e.g.	 substantia	 nigra)	 (326).	 Hence,	 direct	 use	 of	 4-OHT	 over	 the	 tamoxifen	
prodrug	was	 chosen.	 Plating	was	 such	 that	 possible	 sources	 of	 variance	 due	 to	well	
location	was	minimised	 by	 pseudo-randomisation.	Where	 possible,	 outer	wells	were	
filled	with	PBS	to	 further	reduce	variability.	After	 the	treatment	period	(typically	24-
48hrs),	media	was	aspirated,	and	cell	viability	quantified	by	CellTiter-Glo	Luminescent	
Cell	 Viability	 Assay	 (Promega)	 as	 per	 manufacturer’s	 instructions.	 Quantification	 of	
fluorescent	signal	intensity	was	performed	using	PHERAstar	FSX	Multimode	Microplate	
Reader	and	inbuilt	CellTiter-Glo	assay	protocol.	In	cases	where	multiple	dose	response	






















Adherent	 cell	 lines	 or	 PDTCs	 were	 passaged	 as	 normal	 and	 resuspended	 at	 1	 x104	
cells/ml	 in	 appropriate	 media	 (supplemented	 with	 0.1%	 FBS	 and	 2%	 growth	 factor	
reduced	 (GFR)	 Matrigel,	 BD	 Biosciences).	 Cells	 were	 plated	 onto	 BD	 Falcon	 8-well	
CultureSlides	 (BD	Biosciences)	pre-coated	with	 60µl	 collagen:	Matrigel	mix	 (collagen	
used	was	type	IV	from	rat	tail,	Sigma)	and	incubated	for	up	to	2	weeks	at	37°C	5%	CO2,	
changing	media	every	four	days.	Protocol	was	adapted	from	the	Brugge	lab	at	Harvard	
Medical	 School	 (327),	 available	 at	 http://brugge.med.harvard.edu/.	 Spheres	 were	
visualized	 by	 phase	 contrast	microscopy	 or	 by	 4’,6-diamidino-2-phenylindole	 (DAPI)	
counterstain	 (DAPI	 dilactate,	 Invitrogen)	 and	 fluorescent	 microscopy.	 For	 3D	 acinar	
growth	assays,	cells	were	trypsinised	as	normal	and	dissociated	into	single	cells.	1	x105	
cells	 were	 resuspended	 in	 75%	Matrigel24 	(25%	 DMEM:	 F12)	 and	 plated	 as	 a	 50μl	













cells	 were	 harvested	 as	 normal	 by	 trypsinisation	 and	 resuspended	 1	 x106	 cells/ml.	






wells	 of	 1	 cells/well.	 Plates	were	 topped	 up	with	 growth	media	 as	 appropriate	 and	
cultured	for	3	weeks	at	5%	CO2	37°C.	After	3	weeks,	plates	were	scored	for	spheroid	


























Figure	 2.3.0	 A-C.	 Packaging	 plasmids	 for	 production	 of	 lentiviral	 vectors	 were:	
pMDLg/pRRE	 (Plasmid	 #12251)	 containing	 gag	 and	 pol	 genes,	 pRSV-Rev	 (Plasmid	
#12253)	 containing	 rev	 gene	 (both	were	 generous	 gifts	 of	 the	 Trono	 lab	 (330))	 and	








ice.	 Heat-shock	 was	 performed	 as	 per	 manufacturer’s	 instructions	 at	 42°C	 for	 30	





































































Figure	 2.3.0	 shows	 plasmid	 maps	 for	 plasmids	 obtained	 through	 Addgene.	 A)	 pHIV-
ZsGreen1	 (pHIV-ZSG),	 a	generous	gift	 from	 the	Werb	 lab	 (328).	B)	 pLM-vexGFP-Oct4,	a	
generous	 gift	 from	 the	 Sadelain	 lab	 (329).	C)	 ClonTracer	 Library	 (pRSI9-U6-(sh)-UbiC-
TagRFP-2A-Puro),	 a	 generous	 gift	 from	 the	 Stegmeier	 Lab	 (135).	 D)	 pMDLg/pRRE	









































Lentiviral	 plasmids	were	 packaged	 into	 virions	 in	 HEK293-Ts	 of	 low	 (<20)	 passage,	
cultured	in	10cm	tissue	culture	dishes.	Briefly,	HEK293-Ts	were	culture	in	DMEM:	F12	
10%	FBS	with	PenStrep	as	normal,	trypsinised	and	plated	at	2	x106	/15	cm	dish.	Cells	
were	 cultured	 undisturbed	 overnight,	 aiming	 for	 80%	 confluence.	 1hr	 prior	 to	




40μl	 JetPEI	 (Polyplus)	 in	250μl	NaCl	 (150mM).	Mixture	was	 incubated	 for	30mins	at	





30ml	Konical	 tubes	 (Beckman	Coulter)	with	 an	 underlay	 of	 4ml	 sterile	 20%	 sucrose	
solution	25.	Up	to	four	sequential	spins	could	be	carried	out	in	the	same	Konical	tube	to	
concentrate	the	virus	(332).	Viral	pellets	were	resuspended	in	phospho-buffered	saline	

















































Figure	 2.3.2	 shows	 the	 viral	 production	 scale	 up	 for	 preparing	 ClonTracer	 lentiviral	




















virions	 in	 a	 preparation	 as	 the	 measurement	will	 include	 defective	 particles	 and/or	






































































line	 with	 values	 found	 in	 the	 literature	 (43),	 and	 so	 used	 2,000ng/ml	 for	 48hrs	 in	




































filtered	 through	 a	 4μm	 cell	 strainer.	 For	 ALDH	 activity	 assays,	 the	 ALDEFLUOR	 Kit	
(Stemcell	Technologies)	was	used	as	per	manufacturer’s	 instructions.	For	 cell	sorting	
experiments,	cells	were	transferred	to	FACs	tubes	and	stained	with	pan	mouse	MHC-
I/MHC-II	 (H-2kb/H2-Db)	 conjugated	 fluorescein	 isothiocyanate	 (FITC)	 (Biolegend,	






(for	MacOS).	Cells	were	gated	and	sorted	 if	required	using	standard	protocols	 for	 the	
FACSAria.	 After	 flow	 sorting,	 cells	 were	 collected	 in	 MEGM	with	 20%	 PenStrep	 and	
washed	three	times	in	MEGM	supplemented	with	20%	PenStrep	(Life	Technologies)	to	
minimise	the	possibility	of	contamination	from	the	flow	cytometer.	For	mouse	studies,	
around	 1	 x105	 cells	 were	 resuspended	 in	 100μl	 and	 100μl	 Matrigel	 was	 added	
immediately	 prior	 to	 injection	 into	 the	 flank	 of	 21-day-old	 NSG	 mice27 .	 Cells	 were	
analysed	and	sorted	using	the	BD	FACSAria	or	the	BD	Influx	FACS	machine	with	data	files	

























was	 added	 to	 each	well	 containing	 siRNA	+	 lipofectamine	 (final	 siRNA	 concentration	
10nM)	and	wells	plated	rocked	gently	for	5	minutes	at	ambient	temperature.	Cells	were	


























protocol).	 Genomic	DNA	was	 removed	 from	RNA	 samples	 prior	 to	RT-PCR	using	 the	







Fast	 Universal	 PCR	master	mix	 (2x)	 (Applied	 Biosystems)	 in	 an	 Applied	 Biosystems	
7900HT	 thermocycler	 (fast	 364-well	 protocol) 28 .	 A	 melting	 curve	 analysis	 was	
performed	from	70°C	to	95°C	in	0.3°C	intervals	to	demonstrate	the	specificity	of	each	






















14,000	 rpm	 (4°C).	 Fresh	 tissue	 was	 washed	 in	 PBS,	 homogenised	 using	 the	 Tissue	
Homogenising	Kit	(CK28-R,	Precellys)	and	trypsinised	to	make	a	single	cell	mixture.	Each	
preparation	was	treated	with	between	50-150μl	complete	lysis	buffer	29	(depending	on	
size	 of	 pellet),	mixed	 thoroughly	 by	 pipetting	 and	 incubated	 for	 30	minutes	 at	 37°C.	
Pierce	 BSA	 protein	 quantification	 assay	 was	 carried	 out	 as	 per	 manufacturer’s	
																																																								
29	5ml	1M	Tris-HCL	pH	7.5	(=50mM),	1ml	0.5M	EDTA	(=5mM),	10ml	1.5M	NaCl	(=150mM),	1ml	TritonX-








instructions	 (Thermo	 Scientific)	 with	 an	 EnVision	 plate	 reader	 (PerkinElmer)	 and	
standard	curve	prepared	in	GraphPad	Prism	5	(for	MacOS).	5μl	loading	buffer	(Laemmli	
2x	 concentrate	 (Sigma	 Aldrich)	 was	 added	 to	 20μg	 protein	 from	 each	 sample	 and	
mixture	boiled.	Laemmli	buffer	contains	sodium	dodecyl	sulphate	(SDS)	to	negatively	
charge	 proteins	 and	 2-mercaptoethanol	 to	 reduce	 disulphide	 bridges.	 Samples	 were	
loaded	 and	 separated	 by	 gel	 electrophoresis 30 .	 Protein	 were	 transferred	 to	 a	
nitrocellulose	 membrane	 using	 an	 iBlot	 transfer	 device	 and	 iBlot	 transfer	 stacks	
(Invitrogen).	Membrane	was	blocked	overnight	(LI-COR	Odyssey	blocking	buffer)	and	
stained	with	primary	(Anti-SOX2	antibody	(Abcam,	ab97959),	Anti-Oct4	antibody	-	ChIP	

































Paraffin-embedded	 tissue	 blocks	 were	 sectioned,	 and	 sections	 dewaxed	 by	 2x	 10	
minutes	 immersions	 in	xylene	 (Fischer	Scientific).	Rehydration	was	achieved	by	2x	5	
minutes	immersions	in	100%	ethanol	(EtOH)	followed	by	a	5	minute	emersion	in	70%	
EtOH	 (Fischer	Scientific).	Dewaxing	and	hydration	were	 conducted	on	 the	automated	
Leica	ST5020	multistainer	system	(Leica	Microsystems).	Heat-induced	antigen	retrieval	
(with	sodium	citrate)	was	performed	at	100°C	and	protease-induced	antigen	retrieval	
(with	 Bond	 enzyme	 concentrate	 (Leica	 Microsystems))	 at	 37°C.	 IHC	 was	 performed	
using	the	Leica	BOND-MAX	autostainer	(Leica	Microsystems).	Bound	primary	antibodies	
were	 detected	 using	 a	 horseradish	 peroxidase	 (HRP)	 polymer-conjugated	 secondary	
antibody	 or	 a	 biotinylated	 secondary	 antibody	 (both	 from	 Bond	 Polymer	 Refine	
Detection	Kit;	Leica	Microsystems).	In	the	first	case,	primary	antibodies	raised	in	mouse	
or	rabbit	are	detected	by	a	secondary	linker	anti-mouse	antibody	raised	in	rabbit	(or	vice	
versa),	 followed	 by	 detection	 of	 the	 linker	 antibody	 by	 the	 HRP	 polymer-conjugated	
secondary	antibody.	Binding	of	the	secondary	is	visualised	using	3,3-diaminobenzidine	
tetrahydrochloride	 (DAB),	 which	 is	 a	 substrate	 for	 the	 HRP	 enzyme.	 Staining	 was	



























































































































Table	 shows	primers	used	 for	 cell	 lines	and	PDX	models	 in	ClonTracer	 studies.	 Forward	










the	 FastX	 toolkit	 (adapter	 trimming	 function)	 allowing	 for	 up	 to	 one	 mismatch	
(http://hannonlab.cshl.edu/fastx_toolkit/).	 All	 further	 analysis	 was	 undertaken	 in	
python	using	the	ClonTracer	Analysis	package	(Algorithms	for	Deconvoluting	NGS	data	
V1.2)	 (https://bit.ly/2Lv5UVs)	 (135).	Reads	were	 then	 filtered	 to	keep	 those	 that	 (a)	
showed	 the	WS	×	15	 pattern;	 (b)	matched	 the	 expected	 sequence	 after	 the	WS	×	 15	
barcode	for	sequence	libraries	with	lengths	of	≥37	bp;	and	(c)	had	an	estimated	Phred	
quality	score	of	at	least	10	for	all	base	pairs	in	the	read,	with	an	average	Phred	quality	













































relative	 barcode	 abundance	 (RBA)	 equivalent	 of	 which,	 varied	 slightly	 between	 test	





















of	 PCR	 amplification	 were	 again	 normalized	 to	 15nM	 and	 pooled	 for	 high-coverage	
paired-end	exome	sequencing.	The	sequencing	was	performed	using	125bp	paired-end	




variants	 (SNVs),	 a	minimum	genotyping	 quality	 of	 20,	 at	 least	 5	 reads	 at	 the	 variant	
position,	 a	 strand	 bias	 Phred-scale	 p	 value	 smaller	 than	 40	 and	 no	 presence	 of	






















clusters	 mutations	 that	 shift	 together	 across	 the	 samples,	 predicting	 the	 cellular	
frequency	 for	 each	 cluster	 in	 each	 sample	 accounting	 for	 copy	 number	 changes	 and	
normal	cell	contamination.	PyClone	was	run	in	Python	using	recommended	settings	for	











































Mann–Whitney	 U-tests	 and	 more	 than	 two	 groups	 by	 one-way	 ANOVA	 or	 Kruskal–
Wallis,	multiple	 comparisons	were	 corrected	 for	 by	 the	 Bonferroni	method.	 Kaplan–
Meier	disease	free	survival	graphs	were	constructed	in	GraphPad	Prism	6	and	presented	




































Despite	 remarkable	 advances	 in	 our	 understanding	 of	 the	 progression	 of	 human	
malignancies	and	the	molecular	events	 that	underpin	tumour	survival,	new	therapies	
often	 fail	 to	show	significant	efficacy	 in	clinical	 trials.	Even	with	patient	stratification,	
clinical	 responses	 can	 be	 fleeting,	 often	 adding	 only	 6-12	 months	 before	 disease	
progression	(339).	As	discussed,	tumours	have	long	been	known	to	be	heterogeneous	in	
nature	 and	 composed	 of	 multiple	 cellular	 phenotypes	 (340).	 This	 intratumour	
heterogeneity	 is	 governed	 by	 both	 cell-autonomous	 (e.g.	 genomic	 and	 epigenomic	
heterogeneity)	and	non-cell-autonomous	(e.g.	stromal	heterogeneity)	factors	(124)	and	










(255).	 Despite	 significant	 benefit	 to	 the	 majority	 of	 ERα+	 patients,	 both	 innate	 and	
acquired	 resistance	 to	 tamoxifen	 are	 common	 clinical	 outcomes	 (255).	 Tamoxifen	
resistance	 in	 ERα+	 tumours	 is	 generally	 associated	 with	 differential	 ERα-binding	
programmes	 mediated	 by	 FOXA1,	 increased	 AIB-1	 expression	 and	 loss	 of	 ERBB2,	
repression	 by	 the	 ERα-PAX2	 complex	 (248,272,273).	 	 Along	 with	 large	 scale	
transcription	factor	binding	studies	in	patient	samples,	the	breast	cancer	cell	line	MCF7	






The	 emergence	 of	 tamoxifen	 resistance	 in	 the	 ERα	 and	 progesterone	 receptor	 (PR)	
positive	(HER2	negative),	luminal	epithelial	cell	line	MCF7	is	a	well-documented	process	








are	 further	 characterised	 by	 the	 acquisition	 of	 PAX2	 expression	 and	 loss	 of	 active	
phospho-HER2	(345).	 Interestingly,	 there	 is	evidence	 for	 the	role	of	 the	transcription	
factor	 SOX2	 in	 MCF7s	 selected	 for	 tamoxifen	 resistance	 (‘TamR’	 cell	 lines),	 through	
supporting	a	stem/progenitor	cell	population		(342,346).	SOX2	is	best	known	for	its	role	










able	 to	 repopulate	 the	 tumour	 bulk	 after	 treatment	with	 chemotherapy	 (196).	These	
quiescent	 cell	 populations	 were	 genetically	 similar	 to	 their	 highly	 proliferative	
counterparts,	and	were	later	linked	to	the	BMI1	positive	population,	thought	to	act	as	
reserve	stem	cells	of	the	intestinal	and	colonic	crypts	(192).	Recently,	high-complexity	













parental	 line.	 We	 utilise	 the	 ClonTracer	 barcode	 library,	 featuring	 a	 30-nucleotide	
degenerate-sequence	and	theoretical	complexity	of	~72	x106	(334),	in	order	to	track	the	
contribution	of	phenotypically	distinct	cellular	clones	to	the	development	of	resistance.	
We	 reasoned	 that	 having	 multiple	 replicates	 with	 comparable	 starting	 barcode	
representations	provides	 a	means	 to	distinguish	 pre-existing	 from	de	 novo	 acquired-
resistance	 clones.	 If	 resistance	 were	 mostly	 driven	 by	 de	 novo	 alterations,	 distinct	
barcoded	populations	would	emerge	in	independent	replicates;	if,	rather	resistance	was	














3.2	 Characterisation	 of	 an	 Established	 Oestrogen-
Insensitive	Cell	Line	Derived	from	MCF7s	
	
In	 order	 to	 establish	 a	 baseline	 for	 our	 studies,	 we	 sought	 to	 profile	 a	 previously	













cells	were	 found	 to	 be	 viable	 (Inhibitory	 Concentration	 50%	 (IC50))	 by	 trypan	 blue	
exclusion	 (348)	was	0.24µM	 for	 the	parental	MCF7	cell	 line	and	2.8µM	 for	 the	TamR	
derivative	(p<0.01;	extra	sum-of-squares	F	test).	Previous	studies	have	placed	the	IC50	




























versus	 TamR	 (One-way	 ANOVA	 with	 Bonferroni	 correction).	 Interestingly,	 ESR1	
expression	was	significantly,	though	not	markedly,	lower	in	TamR	cells	than	MCF7s,	at	
baseline	 (p=0.0047).	Whereas	 E2	 appeared	 to	 have	 relatively	 little	 effect	 on	 baseline	
expression	of	ESR1	in	either	cell	line,	4-OHT	markedly	reduced	its	expression	in	MCF7	
cells	only.	A	combination	of	E2	&	4-OHT	similarly	reduced	expression	of	ESR1	in	MCF7s,	


















exogenous	E2	 slightly	 increased	 their	proliferation	 (p>0.05).	Together,	 these	 findings	
suggest	the	presence	of	a	functionally	different	ERα	signalling	pathway	in	TamRs	versus	

















and	PGR	 (ERα	 target)	 in	MCF7s	 and	TamRs	 treated	with	 10nM	E2,	100nM	4-OHT	or	 a	

































































100nM	4-OHT.	A)	 Shows	E2	 induced	growth	and	4-OHT	 inhibition	of	growth	 in	MCF7s.	
Inhibition	by	4-OHT	was	statistically	different	from	NS	(control)	and	10nM	E2	(p<0.001;	
non-linear	mixed	effects	model,	E2	increases	in	proliferation	were	not	significant.	B)	shows	

















































lot	(356).	 In	order	to	mimic	more	closely	 the	physiological	development	of	 tamoxifen	
resistance	 in	 a	 breast	 cancer	 patient,	 we	 opted	 to	 include	 4-OHT	 in	 our	 long-term	
resistance	 cultures.	 It	 was	 reasoned	 that	 even	 if	 c/s	 serum	 contained	 residual	
oestrogens,	this	would	mimic	the	situation	in	vivo33.	4-OHT	was	kept	at	a	sub-IC50	dose	
and	removed	from	the	media	24hrs	before	any	experiments	to	ensure	residual	drug	did	
not	 to	 affect	 ERα	 binding	 experiments.	 Figure	 3.3.1	 shows	 the	 culture	 protocol	 (A)	
alongside	 representative	 phase	 contrast	 images	 from	 defined	 time-points,	 and	
corresponding	dose	response	graphs	(B).	 In	practice,	cells	were	passaged	after	phase	
contrast	 images	were	 taken,	 and	 re-plated	 to	 include	experimental	24-well	plates	 for	















serum	&	 EtOH,	 as	 the	 4-OHT	 carrier).	 At	 60	 days	 culture	 (Figure	 3.3.1A/B	 ii)	 4-OHT	
treated	 MCF7s	 showed	 increased	 cell	 growth,	 by	 qualitative	 analysis,	 and	 a	 slight	
increase	 in	 4-OHT	 IC50	 (0.269µM	 to	 0.397µM).	Whilst	 far	 below	 the	 aforementioned	
IC50	of	TamR	cell	lines	(2.8µM),	this	was	an	early	indication	of	resistance,	which	at	day	















OHT	reduced	expression	of	both	genes,	both	on	 its	own	and	 in	 combination	with	E2.	
Whilst	this	was	only	seen	in	TamRs	for	PGR,	there	was	a	trend	for	decreased	expression	



































resistance	 by	 continuous	 culture.	 Scale	 bar	 is	 100µm.	 Time	 points	 are	 labelled	 i-iv,	
corresponding	 to	 dose-responses.	 IC50	 values	 are	 molar	 concentration.	B)	 Shows	 dose	
response	 curves	 for	 parental	 and	 continuously	 cultured	 sublines	 in	 response	 to	 4-OHT	
treatment.	Shows	gradual	induction	of	tamoxifen	resistance.	iii	and	iv	(corresponding	to	




















































































A)	 Proliferation	 study	with	MCF7-R1,	 data	 derived	 from	 the	 IncuCyte	 live	 cell	 imaging	
system.	No	supplement	(NS):	i.e.	EtOH	carrier	only.	E2	dose	was	10nM	and	4-OHT	100nM,	
as	before.	No	curves	were	statistically	different	by	non-linear	mixed	effects	model.	B)	qPCR	












































Although	 targeted	 cancer	 therapies	 often	 yield	 impressive	 initial	 responses,	 tumours	
frequently	develop	resistance	(357–359),	this	is	no	more	obvious	than	in	ERα+	breast	
cancer,	where	the	development	of	resistance	to	tamoxifen	is	common	place	(213,272).	






Tamoxifen	 resistant	 tumours	 are	 characterised	 by	 differential	 ERα-binding	 patterns	
with	prognostic	 capacity	exclusively	 in	ERα+	patients	 (248).	Differential	ERα-binding	
and	the	emergence	of	tamoxifen	resistance	in	patients	is	not	thought	to	be	associated	
with	the	selection	of	a	rare	subpopulation	of	cells	but	rather	rapid	reprogramming	of	
FOXA1	 binding	 events	 (238).	 FOXA1	 acts	 as	 a	 pioneer	 factor,	 recruiting	 ERα	 to	 the	
chromatin.	However,	what	directs	differential	FOXA1	binding	remains	to	be	established	
(248).	MCF7s	have	been	observed	to	give	rise	to	multiple	distinct	resistance	phenotypes	
when	 cultured	 for	 prolonged	 periods	with	 4-OHT,	 supporting	 the	 idea	 that	multiple	
tamoxifen	 resistant	 subpopulations	 exist	 within	 the	 parental	 cell	 line	 (345).	
Interestingly,	 MCF7s	 have	 an	 ‘intermediate’	 ERα	 binding	 profile	 between	 ‘good	
prognosis’	and	 ‘bad	prognosis’	profiles	characterised	by	Ross-Innes	et	al.,	 (248)	which	
could	reconcile	this	supposed	contradiction.	Whether	clonal	outgrowth	or	the	initiation	
of	 de	 novo	 resistance	 pathways,	 the	 development	 of	 drug	 resistance	 has	 profound	
implications	for	patients	and	warrants	further	study.		
	
In	 this	 section,	 we	 utilise	 the	 ClonTracer	 barcode	 library	 to	 individually	 label	 a	
population	of	MCF7s	(Figure	3.4.1B	&	C).	In	order	to	have	enough	starting	material	for	






complexity.	 24	 individual	 colonies	were	 picked	 from	 across	 the	 amplification	 plates,	
plasmids	purified	and	analysed	by	qPCR.	Figure	3.4.2	A	shows	similar	CT	values	for	each	
preparation,	suggesting	no	significant	bias	 in	PCR	amplification	efficiency.	To	test	 the	
complexity	 of	 our	 amplified	 ClonTracer	 library,	 we	 serially	 diluted	 the	 pool	 to	 a	
theoretical	concentration	of	100	plasmid	molecules.	In	the	most	dilute	sample,	83	unique	
barcodes	were	found	out	of	a	theoretical	100,	in	the	most	concentrated,	100,836	out	of	






optimised	 infection	 conditions	 in	 MCF7s.	 Lentiviral	 infection	 is	 thought	 to	 follow	 a	
Poisson	distribution,	in	our	studies,	a	MOI	of	0.1	was	targeted	to	ensure	that	most	cells	
with	an	integration	event	(~10%)	had	a	single	integration	event	(360).	Various	methods	

























clones	 the	 population	 originated	 from,	 and	 the	 counts	 per	 unique	 barcode	 offered	 a	





debris,	 followed	 by	 a	 dead	 cell	 exclusion	 assay	 using	 propidium	 iodine,	 and	 doublet	
exclusion	 by	 both	 forward	 and	 side	 scatter	 discrimination.	 Figure	 3.4.4	B	 shows	 the	
proportion	of	RFP	positive	(RFP+)	cells	with	an	escalating	dose	of	ClonTracer	viral	prep.	
This	analysis	found	10.1%	of	cells	were	RFP+	with	a	viral	load	of	2	x106	TU,	showing	
reasonable	 concordance	with	 the	7.6%	of	 cells	 resistant	 to	puromycin	with	the	 same	
viral	 load.	 Differences	 could	 be	 due	 to	 relative	 insensitivity	 of	 puromycin	 titration	
compared	to	flow	cytometry.	However,	in	giving	the	more	conservative	estimate	of	MOI,	
and	 thus	 less	 likely	 to	 suffer	 from	 false	 positive	 infections,	 puromycin	 selection	was	
chosen	for	future	studies	34.		
	
Our	 optimised	 infection	 protocol	 was	 used	 to	 infect	 10	 x	 15cm	 dishes.	 Cells	 were	
puromycin	 selected	 for	 48hrs	 and	 dead	 cells	 removed,	 around	 20	 million	 viral	




























































































































all	 24	 barcodes	 suggesting	 that	 the	 distinct	 barcode	 sequence	 did	 not	 introduce	 any	
significant	bias	in	their	PCR	amplification	efficiency.	B)	Plasmid	stock	was	serially	diluted	

































































A)	 Shows	 puromycin	 toxicity	 for	 optimising	 infected	 MCF7	 selection.	 The	 ClonTracer	
plasmid	contains	a	puromycin	resistance	cassette	to	aid	in	both	bacterial	and	mammalian	
cell	 selection.	 At	 2000ng/ml	 <99%	 of	 MCF7s	 survived	 48hrs	 of	 culture,	 as	 assessed	 by	













































































































































































the	 cancer	 cell	population,	 similar	 to	 the	experimental	plan	designed	by	Bhang	et	al.,	
(334).	We	reasoned	that	having	multiple	replicates	with	comparable	starting	barcode	
representations	 would	 provide	 a	 means	 to	 distinguish	 pre-existing	 from	 de	 novo	
acquired-resistance	 clones.	 If	 resistance	 were	 mostly	 driven	 by	 de	 novo	 alterations,	
distinct	barcoded	populations	would	emerge	in	independent	replicates.	By	contrast,	if	
pre-existing	clones	were	the	major	source	of	resistance,	one	could	expect	the	selective	
enrichment	 of	 the	 same	 sets	 of	 barcodes	 (labelling	 the	 same	 pre-existing	
subpopulations)	in	replicate	experiments.		
	
To	explore	 this,	pooled	barcoded	MCF7s	 (MCF7-CT)	were	expanded	and	plated	 in	10	
replicates	with	10-fold	library	representation	each	(i.e.	10	x107	cells	each)	to	minimize	
stochastic	 loss	of	barcodes	during	plating	and	to	ensure	comparable	starting	barcode	




























all	 statistical	 analysis	 by	 extra	 sum-of-squares	 F-test).	 Interestingly,	 the	 Hill	 Slope	
followed	the	same	pattern	as	seen	in	Figure	3.3.1	(increased	slope	/potential	cooperative	
binding	in	resistant	lines),	with	the	exception	of	MCF7-CT	res1,	which	also	had	the	lowest	
calculated	 IC50.	 These	 results	 are	 likely	 the	 result	 of	 less	 than	 perfect	 curve	 fitting,	
though	 could	 represent	 heterogeneity	 amongst	 resistance	 lines.	 Next,	 three	
representative	 resistance	 lines	 were	 grown	 to	 confluence	 in	 the	 Incucyte	 live	 cell	

























correction).	 In	 Figure	 3.5.4	 C,	 we	 see	 that	 resistant	 line	 MCF7-CT	 res4	 has	 lost	
proliferative	response	to	E2	and	4-OHT	in	culture,	and	these	were	retained	by	control	




Reports	 in	 the	 literature	have	shown	that	derived	tamoxifen	resistant	 lines	can	differ	
markedly	 in	 sensitivity	 to	 rapamycin	 and	 activation	 of	 mTORC1/2.	 Moreover,	
Everolimus	(rapamycin)	is	used	clinically	to	tackle	tamoxifen	resistant	breast	cancers.	
Slight	 differences	 in	 resistant	 line	 phenotypes	observed	 in	Figure	 3.5.3.2	 (IC50s	 of	 4-
OHT)	and	Figure	3.5.4	A	(proliferation)	led	us	to	question	whether	the	phenotypes	of	our	
five	 derived	 resistant	 cell	 lines	 were	 identical.	 Figure	 3.5.5	 shows	 rapamycin	 dose	
response	curves	 for	4-OHT	resistant	cell	 lines.	Large	differences	exist	between	 IC50s,	


























Schematic	 of	 screen	 for	 MCF7-CT	 lines.	 We	 aimed	 to	 label	 10	 million	 labelled	 cells.	
Puromycin	 selection	 was	 completed	 as	 previously	 described	 and	 resulting	 cells	 pooled.	
Plating	was	such	that	resistant	and	control	replicates	of	the	same	number	(e.g.	MCF7-CT	
res1	 and	MCF7-CT	 con1)	 were	 derived	 from	 the	 same	 originating	 Eppendorf,	 allowing	
direct	 comparisons	 to	 be	 drawn.	 To	 accommodate	 the	 need	 for	 100	 million	 cells	 per	
replicate,	 biological	 replicates	 (5	 in	 each	arm)	 consisted	 themselves	of	5	 x	15cm	dishes	
(seeding	density	of	4,000,000).	These	technical	replicates	were	maintained	and	expanded	
separately.	Thus,	5x	resistant	and	control	pairs	(consisting	of	5x	technical	replicates)	were	



























































































barcodes	 are	 ligated	 before	 150bp	 paired	 end	 (PE)	 sequencing.	 After	 standard	QC	 and	
demultiplexing	with	FastX	(barcode	splitter	function),	total	usable	reads	are	tabulated,	and	


































































Confirmation	 of	 4-OHT	 sensitivity	 in	MCF7-CT	 con	 cell	 lines.	 Dose	 response	 curves	 and	





































Confirmation	 of	 4-OHT	 resistance	 in	MCF7-CT	 res	 cell	 lines.	 Dose	 response	 curves	 and	






























































lowered	 ESR1	 and	 PGR	 on	 4-OHT	 treatment.	 No	 resistance	 results	 were	 statistically	
significant.	In	control	lines,	PGR	expression	was	significantly	elevated	in	both	lines	on	E2	


































































to	quantify	barcode	 abundance	 in	 each	 replicate.	Figure	 3.6.1	shows	 relative	barcode	
abundance	(RBA),	calculated	as	the	proportion	of	total	usable	barcodes	in	the	sample,	



















proportion	 of	 patients.	 It	 is	 thought	 that	 oncogene	 activation	 is	 caused	 by	 viral	
integration	 in	 specific	 genomic	 regions	 (364).	 Lentiviral	 based	 vectors	 are	 generally	








for	 control	 cell	 lines,	 we	 defined	 enrichment	 as	 any	 barcode	 present	 at	 a	




barcodes	enriched	 in	 the	 resistance	 cell	 lines	were	not	also	enriched	 in	 control	 lines,	

















Barcode	 counts	 (Relative	 Barcode	 Abundance;	 RBA)	 for	MCF7-CT	 Res1	 and	 Con1	were	
computed	from	NGS	of	6-month	cell	cultures	using	the	ClonTracer	bioinformatics	pipelines	


































little	 specific	 barcode	 enrichment	 compared	 to	 resistant	 cells.	 Each	 line	 represents	 a	
specific	unique	barcode,	with	abundance	represented	by	y-axis	height.	We	computed	the	
Shannon	Diversity	Index	for	each	cell	line	as	a	measure	of	population	diversity.	The	index	is	
more	 often	 used	 in	 ecology	 studies	 but	 has	 been	 applied	 to	 cell	 line	 diversity	 studies	
previously	 (204,363).	 Enrichment	 of	 barcodes	 was	 compared	 by	 one-way	 ANOVA	 with	
Bonferroni	 correction	 to	 correct	 for	 multiple	 comparisons.	 Reduction	 of	 diversity	 is	
observed	in	each	resistant	line	relative	to	its	paired	control	line	(con1-res1	p=0.045;	con1-
























































































indicated	 by	 barcode	 abundance	 should	 the	 same	 barcodes	 be	 enriched	 in	 multiple	
replicate	plates.	Figure	3.7.1	shows	the	correlation	between	RBAs	for	the	top	50	enriched	
barcodes	 from	each	of	 two	 replicates	of	MCF7-CT	 res1,	 two	replicates	 from	MCF7-CT	
res2,	 two	 replicates	 from	 MCF7-CT	 con1	 &	 two	 replicates	 from	 MCF7-CT	 con2.	





3.7.2.2),	 this	 analysis	was	 also	 expanded	 to	 the	 top400	 barcodes	 (from	 top50	 shown	
earlier).	 The	mean	 correlation	 score	 (Pearson’s	 r)	 between	 control	 replicates,	 i.e.	 the	
average	 intra-replicate	 concordance,	was	 -0.01672,	with	 the	highest	 concordance	of	 -
0.0084	 seen	 in	 MCF7-CT	 con5	 (Figure	 3.7.2.1),	 no	 control	 line	 showed	 statistically	
significant	overlap	 in	enriched	barcodes.	By	contrast,	overlap	across	the	 independent	
resistance	 replicates	 was	 highly	 statistically	 significant	 on	 the	 basis	 of	 a	 Pearson	
correlation	test	(mean	r	=0.41776,	p<0.00001;	Figure	3.7.2.2).	The	most	concordant	cell	

































Example	 correlations	between	RBA	of	 the	 top	50	 (by	 cumulative	RBA	across	 replicates)	
barcodes	found	in	two	sensitive	and	two	resistant	cell	lines.	Good	Pearson’s	r	score	suggests	











































Combining	 Pearson’s	 r	 scores	 for	 each	 pairwise	 comparison	 between	 control	 cell	 line	
replicates	to	create	a	boxplot.	Results	show	the	average	correlation	between	each	replicate	
































reproducibly	high	 correlations	between	 replicates	of	 resistance	 lines	and	 therefor	 likely	
clonal	selection	of	the	same	cellular	progeny.	Mean	Pearson’s	r	scores	were	0.4261	(res1),	


























also	 enriched	 in	 each	 of	 the	 other	 four.	 Only	 8%	 of	 the	 most	 frequent	 barcodes	 were	
uniquely	enriched	in	that	cell	line	only.	B)	In	control	lines,	an	average	of	86%	of	barcodes	





















first	 investigate	 genomic	 selection	 in	 our	 resistance	 models,	 before	 reviewing	 the	
dynamics	of	barcode	selection.		
	
The	 development	 of	 tamoxifen	 resistance	 has	 been	 linked	 to	 reprogrammed	 FOXA1	












to	 support	 any	 evidence	 of	 selection	 for	 specific	 resistance	 conferring	 SNVs.	 Indeed,	
MCF7s	 appear	 to	 be	 relatively	 genomically	 stable	 during	 long	 term	 culture.	Next,	we	
applied	PyClone,	a	Bayesian	clustering	method	for	grouping	sets	of	somatic	mutations	
into	 putative	 clonal	 clusters.	 PyClone	 estimates	 cellular	 prevalence	 of	 clones	 and	
accounts	 for	allelic	 imbalances	 introduced	by	segmental	 copy	number	 changes	 (199).	





development	 of	 tamoxifen	 resistance	 in	 our	 models35 	(Figure	 3.8.1	 C).	 Interestingly,	
these	data	do	support	that	a	long-established	cell	line	is	capable	of	maintaining	several	
stable	genomic	clusters.	From	these	results,	we	can	putatively	assume	that	reproducibly	








their	 growth	 patterns.	 Of	 the	 five	 growth	 patterns	 described,	 ‘Type	 IV’	 clones	 were	
defined	as	being	below	the	level	of	detection	in	some	passages	but	reappearing	in	the	
tumour	later.	The	authors	describe	these	Type	IV	clones	as	being	quiescent	in	nature	and	
found	 them	 particularly	 likely	 to	 repopulate	 the	 tumour	 after	 chemotherapeutic	
treatment	(196).		
	




3months)	 and	 analysed	 the	 barcode	 abundance	 in	 comparison	 to	 that	 of	 the	 final	 6-
month	timepoint	(T-6months).	Figure	3.8.2.1	shows	average	RBA	in	MCF7-CT	control	cell	
lines	 and	 Figure	 3.8.2.2	 resistant	 cell	 lines.	 In	 each	 case,	 RBA	 was	 averaged	 across	











(Figure	 3.8.2.2).	 This	 was	 not	 the	 case	 in	 sensitive	 cell	 lines	 (Figure	 3.8.2.1)	 where	
abundance	of	specific	barcodes	at	3	and	6	months	was	relatively	stable.	It	appears	from	
these	results	that	the	eventual	dominant	resistant	clones	are	not	the	same	clones	with	










‘quiescent’	 clones	 as	 those	which	were	 not	 part	 of	 the	 top200	most	 frequently	 seen	
barcodes	in	any	of	the	control	lines.	Of	these,	we	ranked	based	on	prevalence	in	the	final	
(6	month)	resistant	pool.	100	of	such	barcodes	are	shown	in	Figure	3.8.3	A,	although	our	
analysis	 selects	 for	 these	 phenotypes,	 it	 is	 clear	 that	 relatively	 quiescent	 cells	 are	
contributing	to	the	development	of	resistance	to	tamoxifen.	Moreover,	if	we	consider	the	
most	 frequent	100	barcodes	seen	at	T-3months	and	T-6months	 in	our	treatment	arm	
and	 analyse	 their	 corresponding	 abundance	 in	 control	 lines	 (Figure	 3.8.3	 B)	we	 find	
significantly	higher	prevalence	of	T3-month	barcodes	 in	 the	 control	 lines	 than	at	T6-






































blue	 bars	 (range	 over	 2	 replicates)	 suggest	 SNV	 enrichment.	 None	 is	 seen.	 C)	 PyClone	



















































































































































long-term	oestrogen	 free	 culture	 in	 the	 presence	 of	 4-OHT.	 Firstly,	we	 designed	 and	




of	 oestrogen	 (TamC3	 and	 TamC6).	 TamR7	 cells	 were	 additionally	 cultured	 in	 the	
presence	 of	 oestrogen	 (345).	 Large	 differences	 in	 cell	 lines	 were	 uncovered	 in	 DNA	
content	 (ploidy),	 mode	 cell	 volume	 and	 cell	 cycle	 time.	 Cell	 lines	 could	 be	 further	
classified	based	on	drug	sensitivity.	Rapamycin	alone	or	in	combination	with	tamoxifen	
increased	 the	 level	 of	 phospho-Akt	 in	 parental	 MCF7	 cells	 and	 TamR7,	 TamC6	 and	
TamR6.	 Increases	 in	 phospho-Akt	 in	 some	 cells	 are	 due	 to	 an	 inhibitory	 feedback	
mechanism	between	the	mTOR	effector	p70	S6K	and	the	insulin	receptor	substrate-	PI3K	
upstream	of	Akt	(369).	Although	difficult	to	profile	in	vitro,	culture	conditions	used	in	
this	 Chapter	 (lack	 of	 exogenous	 oestrogens	 and	 increasing	 concentration	 of	 4-OHT)	
would	likely	result	 in	an	oestrogen	 independence	phenotype,	characterised	by	 lack	of	
sensitivity	to	both	4-OHT	and	AIs.	Resistant	cell	lines	derived	through	our	protocol	were	
characterised	 by	 a	 ~10-15x	 increased	 IC50	 for	 4-OHT,	 ERα	 expression	 but	 a	 lack	 of	





lines	 described	 in	 the	 literature.	 In	 the	 example	 by	Leung	 et	 al.,	 lines	 cultured	 in	 the	







lines	 cultured	 in	 the	 presence	 of	 oestrogen	 (with	 tamoxifen),	 in	 contrast,	 tended	 to	
decrease	ERα	expression.	ERα	shows	greater	binding	affinity	for	4-OHT	than	E2	in	most	










impact	 on	 the	 long-term	 response	 to	 endocrine	 therapy	 (375).	 Despite	 this,	 recent	
studies	in	ERα+	(luminal)	breast	cancers	have	found	that	driver	coding	mutations	do	not	
significantly	change	between	primary	and	metastatic	sites,	with	the	notable	exception	of	
ESR1	 mutations	 (157),	 suggesting	 that	 alternative	 non-genetic	 mechanisms	 may	
contribute	 to	 progression	 and	 resistance	 to	 endocrine	 therapy	 (157,376).	 Indeed,	
epigenetic	modifications	have	been	shown	to	modulate	ERα	binding	to	enhancers,	 for	
example	 by	 interacting	with	 ERα-associated	 pioneer	 factors	 (236,377).	 In	 addition,	 a	
recent	study	from	Hinohara	et	al.,	found	that	genetic	deletion	or	inhibition	of	the	KDM5	
histone	 H3	 lysine	 4	 demethylase	 family	 increased	 sensitivity	 to	 anti-oestrogens	 by	
modulating	ERα	signalling	and	decreasing	cellular	transcriptomic	heterogeneity	(483).		
	










uncovered	 a	 set	 of	 enhancers	marking	 phenotypic	 clones	 that	 significantly	 expanded	
during	 disease	 progression.	 The	 authors	 go	 on	 to	 present	 evidence	 that	 progressive	
activation	of	FOXA1	and	its	network	in	metastatic	samples	is	a	consequence	of	expansion	








Further	evidence	 for	 the	 functional	 role	of	FOXA1	 in	 resistance	 to	endocrine	 therapy	
comes	 from	 a	 study	 by	 Ross-Inness	 et	 al.,	 (248).	 In.	 this	 study,	 the	 authors	 mapped	
genome-wide	 ERα-binding	 events	 in	 primary	 breast	 cancer	 by	 chromatin	
immunoprecipitation	followed	by	high-throughput	sequencing	(ChIP-seq).	They	found	








to	 the	 selection	 of	 a	 rare	 subpopulation	 of	 cells,	 rather	 a	 FOXA1-mediated	
reprogramming	of	ERα	binding	on	a	rapid	timescale	(248).	
	
More	 broadly,	 genomic	 intratumour	 heterogeneity	 is	 thought	 to	 drive	 a	 majority	 of	





genetically	 unstable	 and	 this	 instability	 drives	 heterogeneity	 in	 even	 established	
tumours	(383).	Indeed,	the	wider	the	diversity	of	minor	clonal	populations	in	a	tumour,	
the	 more	 likely	 it	 is	 that	 resistance	 will	 arise.	 Such	 an	 association	 between	 tumour	








NGS	 has	 been	 heavily	 relied	 on	 in	 studies	 to	 elucidate	 the	 clonal	 origins	 of	 drug	
resistance.	However,	it	is	limited	to	a	sensitivity	of	0.1%	allelic	fraction	(385).	Given	that	
the	detectable	tumour	burden	is	estimated	to	be	approximately	10	x109	tumour	cells	at	
the	 time	 of	 diagnosis	 (134),	 this	 level	 of	 resolution	 is	 clearly	 insufficient	 to	
comprehensively	assess	pre-existing	cancer	subpopulations.	We	reasoned	that	cellular	
barcoding,	 which	 has	 been	 used	 to	 trace	 lineage	 during	 hematopoietic	 stem	 cell	
differentiation	 (201–203),	 could	 be	 used	 to	 address	 this	 question	 and	 overcome	 the	
limited	 sensitivity	 of	 current	 NGS	 approaches.	 To	 trace	 the	 origins	 of	 resistant	
populations	in	our	model	of	tamoxifen	resistance,	we	opted	to	use	the	high	complexity	
barcode	 library,	 ClonTracer,	 (see	 Figure	 3.4.1).	 These	molecular	 barcodes	 enable	 the	
labelling	and	tracking	of	>10	million	individual	cells	with	a	unique	30-nucleotide	long	
semi-random	DNA	sequence	tag	(135).	The	ClonTracer	library	was	designed	to	have	a	
balanced	 GC	 content	 to	 ensure	 uniform	 PCR-amplification	 efficiency	 and	 has	 a	
theoretical	 complexity	 of	 73	 million	 unique	 barcodes	 (135).	 Having	 established	 a	














and	 control	 pairs	 (consisting	 of	 5x	 technical	 replicates)	 were	 established	 and	
propagated.	 Resistance	 phenotypes	 were	 as	 expected	 from	 our	 optimisation	 steps	
(Figures	 3.5.3.1,	 3.5.3.1,	 3.5.4	 &	 3.5.5).	 Interestingly,	 resistant	 lines	 were	 found	 to	 be	
relatively	 insensitive	 to	 exogenous	 E2	 (in	 terms	 of	 ESR1	 and	 PGR	 transcription),	 in	
keeping	with	 the	 assumption	 that	 long	 term	 culture	 in	 the	 absence	 of	 E2	 (alongside	
exogenous	 4-OHT)	 could	 lead	 to	 oestrogen	 independence.	 Further	 studies	 should	





We	 reasoned	 that	 as	 each	 originating	 cell	 would	 be	 uniquely	 marked	 by	 the	 highly	
complex	 barcode	 library,	 fitness	 of	 cellular	 clones	 would	 be	 indicated	 by	 barcode	





control	 lines,	 though	 not	 to	 the	 same	 extent	 as	 the	 resistance	 lines	 (Figure	 3.6.3).	
Retroviral	based	therapies	have	long	been	known	to	induce	oncogenic	transformation	in	
a	 proportion	 of	 patients.	 It	 is	 thought	 that	 oncogene	 activation	 is	 caused	 by	 viral	
integration	 in	 specific	 genomic	 regions	 (364).	 Lentiviral	 based	 vectors	 are	 generally	
















or	 genomic	 clonal	 populations	 as	 previously	described	 (Figure	 3.8.1)	 (317),	 although	
non-coding	SNVs	would	not	have	been	detected	by	our	analysis.	Thus,	it	appears	that,	at	
least	in	our	model,	prolonged	exposure	to	tamoxifen	results	in	the	expansion	of	isogenic	
clonal	 populations	 predisposed	 to	 tamoxifen	 resistance.	 In	 the	 majority	 of	 reported	
cases,	 clonal	 selection	 of	 resistance	 populations	 in	 cancer	 is	 associated	 with	 the	
outgrowth	of	a	genetically	distinct	subclone.	For	example,	the	development	of	resistance	
to	AIs	 in	ERα+	breast	cancer	has	been	 linked	to	activating	mutations	 in	 the	ERα	gene	
itself	 (ESR1)	(386,387).	Subclonal	activating	mutations	are	thought	 to	be	present	 in	a	
third	 of	 patients	 with	 prior	 AI	 exposure	 (388–391),	 and	 detection	 of	 specific	 ESR1	
mutations	in	circulating	tumour	DNA	(ctDNA)	has	recently	been	shown	as	an	effective	
early	 biomarker	 of	 AI	 resistance	 (392).	 Our	 results	 are	 relatively	 novel	 in	 showing	





of	 KDM5A/B	 or	 inhibition	 of	 KDM5	 activity	 increased	 overall	 sensitivity	 to	 anti-






a	 link	 between	 KDM5B	 expression	 and	 transcriptomic	 heterogeneity.	 Crucially,	
molecular	 barcoding	 of	 MCF7s	 using	 the	 ClonTracer	 system	 (135)	 revealed	 that	
development	of	both	tamoxifen	and	fulvestrant	resistance	was	due	to	the	selection	of	a	




Finally,	 in	 this	 Chapter,	 we	 sought	 to	 profile	 the	 dynamics	 of	 the	 development	 of	
tamoxifen	 resistance.	 Quiescent	 cellular	 populations	 have	 been	 described	 to	 drive	
resistance	to	cytotoxic	therapies	in	at	least	one	model	(83).	Because	of	limited	sampling	
points	 in	 our	 experiments,	 we	 opted	 to	 define	 quiescent	 clones	 based	 on	 barcode	
abundance	in	control	lines,	before	looking	to	the	contribution	of	these	populations	in	our	
resistance	 models.	 There	 was	 a	 clear	 tendency	 toward	 early	 dominant	 populations	















































oncogenic	 signalling	 pathways,	 such	 as	 PI3K/EGFR/HER2	 (258,266,344,345),	
typically	resulting	 in	Akt	activation,	or	reprogramming	of	ERα	recruitment	to	 the	
chromatin,	 involving	PAX2/GATA3/FOXA1	(236,238,272).	These	mechanisms	are	






maintenance	 in	 the	normal	human	mammary	gland	(236,237).	 Indeed,	 it	 is	 these	
pioneer	 factors	 which	 determine	 the	 specific	 cellular	 context	 dependent	 role	 of	
oestrogen.	 For	 example,	 FOXA1	 is	 highly	 expressed	 in	 luminal	 cells	 and	 has	 an	
essential	role	in	formation	of	the	terminal	end	bud	(TEB).	Loss	of	GATA3	similarly	
results	in	severe	defects	in	mammary	development	due	to	failure	of	TEB	formation.	
Furthermore,	 GATA3	 has	 been	 shown	 to	 participate	 in	 luminal	 epithelial	







of	 stem	cells	 in	 the	normal	gland	 (276).	Embryonic	 transcription	 factors	NANOG,	
POU5F1,	 and	SOX2	 expression	decreases	upon	differentiation	and	with	oestrogen	






(276).	 Given	 the	 role	 of	 ERα	 in	 the	 developing	 mammary	 gland,	 and	 the	 direct	
regulation	 of	 embryonic	 transcription	 factors	 by	 oestrogen,	 it	 is	 probably	
unsurprisingly	that	resistance	to	ERα	inhibitors	has	been	linked	to	dedifferentiation.	
All	three	canonical	factors	required	for	iPSCs	have	been	variably	linked	to	tamoxifen	
treatment	 or	 resistance.	 For	 example,	 tamoxifen	 resistant	 cells	 are	 enriched	 for	
mammosphere	forming	cells	and	show	higher	expression	of	SOX2.	Silencing	of	SOX2	
by	siRNA	reduces	the	stem/progenitor	cell	population	and	restores	sensitivity	 to	
tamoxifen	 (277).	 Secondly,	 OCT4	 expression	 was	 shown	 to	 be	 independently	
associated	with	poor	prognosis	in	319	cases	of	invasive	breast	cancer	(281),	and	has	
recently	been	described	as	a	novel	ERα-associated	transcription	factor	involved	in	
ERα	recruitment	 to	 tamoxifen,	but	not	oestrogen,	 associated	 transcriptional	sites	
(282).	Conversely,	KLF4	is	generally	associated	with	a	favourable	outcome	in	breast	






to	 be	 slow	 cycling	 and	 highly	 expressing	 ABC	 multidrug	 resistant	 transporter	
proteins;	 both	 enriched	 following	 cytotoxic	 chemotherapy	 and	 endowed	 with	
inbuilt	resistance	(181,183).	This	phenotype	has	been	associated	with	upregulation	
of	ALDH1A1	(166,396),	downregulation	of	miR-375	(397),	downregulation	of	FOXA1	
with	 induction	 of	 IL6	 (398)	 and	 countless	 other	 mechanisms	
(104,149,187,188,399).	 Numerous	 studies	 have	 also	 linked	 breast	 cancer	 drug	
resistance	to	EMT	(104,393),	and	EMT	to	the	acquisition	of	a	BC-TIC-like	phenotype	








al.,	(285).	The	authors	 found	that	 in	 tamoxifen	resistance,	DNA	hypermethylation	
occurred	 at	 oestrogen-responsive	 enhancers.	 This	 was	 associated	 with	 reduced	
ERα-chromatin	 binding	 and	 consequently	 decreased	 gene	 expression	 of	 key	
oestrogen	regulators.	In	another	study	by	this	group,	promotor	demethylation	with	
5-Aza,	coupled	with	E2,	restored	ERα-regulated	gene	expression	in	TamR	lines	and	




authors	 to	 build	 a	 comprehensive	 picture	 of	 clinically	 relevant	 active	 regulatory	
regions	 in	 clinical	breast	 cancer	 samples.	The	authors	 identified	YY1	as	a	 critical	
determinant	 of	 ERα	 transcriptional	 activity	 and	 a	 marker	 of	 phenotypic	 clonal	
populations	involved	in	the	development	of	resistance	to	endocrine	therapies	(376).	
Interestingly,	 an	earlier	 study	by	 the	 same	authors,	 linked	an	 invasive,	EMT,	 like	
phenotype	 to	 the	 development	 of	 acquired	 resistance	 to	 AI	 and	 to	 AI-induced	
epigenomic	 reprogramming,	 highlighting	 the	 potentially	 interdependency	 of	 an	
EMT-like	phenotype	and	resistance	to	endocrine	therapies	(401).			
	
Cumulatively,	 these	 results	 highlight	 a	 novel	 role	 for	 ERα	 response	 element	
methylation,	and	more	broadly	phenotypic	heterogeneity	in	the	epigenome,	in	the	
induction	 of	 resistance	 to	 endocrine	 therapies.	 Interestingly,	 embryonic	
transcription	 factors	 OCT4,	 SOX2	 and	 KLF4	 each	 have	 roles	 in	 regulating	 the	
epigenome	 of	 stem	 and	 progenitor	 cells	 to	 control	 differentiation	 (286,287).	
Additionally,	the	oncogenic	histone	methyltransferase	and	key	embryonic	regulator,	
EZH2,	 has	 been	 shown	 to	 contribute	 to	 tamoxifen	 resistance	 by	 silencing	 the	
expression	 of	 ERα	 cofactor	 GREB1	 (288).	 Together,	 these	 results	 highlight	 a	









due	 to	 selection	 of	 a	 specific	 genomic	 cluster	 defined	 by	 coding	 mutations,	 but	
polyclonal	in	nature	(see:	Chapter	3),	we	sought	to	profile	further	the	potential	roles	
of	EMT	and	BC-TIC-like	phenotypes	in	the	resistance	process.	Given	the	role	of	ERα	
in	 controlling	 differentiation	 in	 the	 normal	 human	 mammary	 gland,	 resistance	
induced	 pluripotency	 seems	 a	 plausible	 avenue	 in	 explaining	 the	 multitude	 of	
resistance	 mechanisms	 described	 in	 anti-oestrogen	 therapy.	 Specifically,	 in	 this	
chapter	we	profile	the	expression	and	function	of	pluripotency	related	transcription	
factors	 in	 the	 development	 of	 resistance	 and	 the	 maintenance	 of	 a	 BC-TIC	
phenotype.	 We	 use	 a	 BC-TIC	 surrogate	 assay	 of	 mammosphere	 formation	 to	
investigate	the	contribution	of	4-OHT	to	mammosphere	initiating	cells	(M-ICs).	Our	
analyses	uncover	a	tamoxifen-inducible	BC-TIC/M-IC	phenotype	in	cell	line	and	PDX	




















Resistance	 to	 tamoxifen	 has	 been	 linked	 to	 expression	 of	 several	 master	
transcription	factors	typically	associated	with	guiding	embryonic	stem	cell	fate	and	




OCT4	 (POU5F1),	 SOX2,	NANOG	 &	 KLF4	 alongside	 markers	 of	 BC-TICs	 CD44	 and	
PROCR	(167,402),	results	are	presented	as	fold-change	relative	to	MCF7	parental,	






are	 seen	 between	 sensitive	 and	 resistant	 groups	 (by	 one-way	 ANOVA	 with	
Bonferroni	correction)	for	POU5F1	(p=0.0023),	SOX2	(p=0.0057),	KLF4	(p=0.0015)	
&	 PROCR	 (p=0.00027)	 expression.	 There	 is	 also	 a	 slight	 enrichment	 in	 CD44	
expression	 in	 the	 resistant	 lines,	 though	this	 is	not	statistically	 significant.	These	
results	appear	to	be	in	keeping	with	the	literature:	KLF4	has	been	associated	with	
good	prognosis	and	 is	preferentially	enriched	 in	 sensitive	models	 (284);	 SOX2	&	
OCT4	have	been	directly	linked	to	tamoxifen	resistance	(277,282),	and	are	enriched	
in	our	resistant	models;	surface	markers	CD44	&	PROCR	are	thought	to	mark	BC-
TICs	 and/or	 mammary	 stem	 cells	 (164,167,403)	 and	 again	 are	 enriched	 in	 our	
resistant	models.		
	












signalling	 pathways	 (169)	 and	 their	 formation	 efficiency	 correlates	 with	 the	





in	 the	presence	of	drug.	After	4	days,	 first	 generation	 spheres	would	 form,	 these	




















barcoded	 resistant	 cell	 lines	 have	 significantly	 increase	 MFE	 relative	 to	 MCF7	
parental	and	MCF7-CT	control	lines	(statistical	significance	by	one-way	ANOVA	with	
Bonferroni	correction	denoted	(*p<0.05;	**p<0.01;	***p<0.001;	****p<0.0001).	The	










However,	 the	addition	of	either	 ligand,	 in	 this	experiment,	served	to	significantly	
reduce	TamR	expression	of	CSC	markers	(p<0.001	for	SOX2	&	PROCR;	p<0.05	for	
POU5F1	 (only	significant	with	E2)).	 Interestingly,	 increased	PROCR	expression	 in	
resistant	 versus	 control	 lines	 appeared	 to	 be	 relatively	 inconsistent	 between	




number	 of	 M-ICs	 ~3.5	 fold	 (Figure	 4.2.4	 B;	 p<0.01).	 The	 effect	 of	 4-OHT	 on	
mammosphere	size	appears	to	follow	a	dose-response	relationship:	Figure	4.2.4	B	










treated	 with	 4-OHT,	 it	 may	 hold	 more	 significance	 to	 the	 BC-TIC	 phenotype.	
Mechanistically,	there	are	several	oestrogen	response	element	(ERE)	binding	sites	
in	a	validated	promotor	region	of	POU5F1	(Figure	4.2.5	A)	(407).	Further,	this	site	
overlaps	 with	 both	 an	 ERα/FOXA1	 binding	 site	 previously	 associated	 with	 the	










the	 timing	 of	POU5F1	 induction	 by	 4-OHT	 treatment	 and	 so	 carried	 out	 a	 time-
course	qPCR	experiment	(Figure	4.2.5	B).	MCF7	monolayers	were	treated	in	24-well	
















4-OHT	 than	monolayer	 grown	 cells.	 Figure	 4.2.6	 A	 shows	 an	 IC50	 of	 0.85µM	 for	
MCF7s	grown	as	spheroids,	more	than	three	times	the	0.26µM	of	monolayer	cells	
(p<0.0001;	Extra	sum-of-squares	F-test).	This	is	a	feature	specific	to	M-ICs,	rather	
than	any	nuances	of	drug	penetration	 in	3D	structures.	We	 find	24hrs	 treatment	












biosynthesis	 pathway	which	 consequently	 promote	 oestrogen-independent	 ERα-
chromatin	 binding	 at	 putative	 regulatory	 regions	 (401).	 It	 is	 conceivable	 that	
similar,	drug-induced,	transcriptional	changes	are	occurring	in	our	4-OHT	treated	
MCF7s.	 	 Thus,	 from	 the	 results	 presented,	 there	 are	 at	 least	 two	 plausible	
mechanisms:	either	ERα	bound	4-OHT	is	directly	increasing	the	absolute	number	of	
M-ICs,	 perhaps	 through	 induction	 of	 POU5F1	 expression,	 or	 4-OHT	 treatment	 is	
selectively	toxic	in	the	non-M-IC	population,	meaning	that	treatment	causes	de	facto	
enrichment	for	M-ICs.	A	schematic	of	two	possible	scenarios	is	presented	in	Figure	
4.2.7.	 We	 reasoned	 that	 if	 the	 same	 population	 of	 cells	 were	 responsible	 for	
resistance	to	4-OHT	and	comprised	the	bulk	of	M-ICs,	Figure	4.2.7	A,	then	we	would	






were	 predisposed	 to	 become	 resistant,	 i.e.	 if	 a	 4-OHT	 inducted	 process	 led	 to	
resistance	 in	only	 a	 certain	 fixed	 treatment	 naïve	 phenotype.	 Alternatively,	 as	 in	
Figure	 4.2.7	 B,	 4-OHT	 could	 induce	 the	 same	 process	 across	 all	 cell	 phenotypes	
(perhaps	the	induction	of	POU5F1),	which	enables	some	degree	of	transcriptional	
plasticity	and	the	(relative)	stochastic	development	of	resistance	by	any	cell	in	the	
population.	This	 transient	 state	of	 enhanced	plasticity	may	enable	more	efficient	
mammosphere	formation,	or	the	final	resistant	cell	type	may	share	properties	of	M-







(sensitive	 to	 4-OHT)	 and	 MCF7	 res	 (resistant	 to	 4-OHT)	 2nd	 generation	
mammospheres	(shown	in	Figure	4.2.3	C).		Figure	4.2.8	A	shows	summary	data	for	
correlations	 between	 barcodes	 enriched	 in	 MCF7-CT	 res	 cell	 lines	 described	 in	




















































































































































































































































































































































































































































































































































































































and	 sensitive	 groups.	 POU5F1,	 SOX2,	 CD44	&	 PROCR	were	 higher	 in	 resistant	 than	











































































had	 significantly	 higher	 MFE	 than	 sensitive	 lines.	 Statistical	 significance	 was	
computed	 by	 one-way	 ANOVA	 with	 Bonferroni	 correction	 and	 is	 presented	 versus	



































































and	without	 4-OHT	 treatment	 (100nM	 4-OHT	 or	 200nM	 4-OHT	 for	 24hrs).	 4-OHT	
treatment	increased	MFE	but	decreases	size	of	mammospheres	in	MCF7s.	4-OHT	also	
significantly	 reduced	 the	 size	of	TamR	mammospheres	 (p<0.001)	but	 there	was	no	
statistically	 significant	 effect	 on	 TamR	 MFE.	 Statistical	 analysis	 was	 by	 one-way	


































































































A)	 2nd	 generation	 mammospheres	 were	 passaged	 and	 plated	 as	 monolayers	 and	



















































































lines	 (con1-5)	 with	 each	 of	 the	 4-OHT	 resistant	 cell	 lines	 (MCF7-CT	 res1-5).	 Data	











epigenetic	 activation	 of	 cell-type-specific	 distal	 regulatory	 elements	 involved	 in	
determining	 cell	 identity	 during	 development	 and	 differentiation	 (409,410).	
Moreover,	 the	 ectopic	 expression	 of	 these	 transcription	 factors	 can	 lead	 to	
epigenetic	 reprogramming	 and	 the	 reacquisition	 of	 pluripotency	 (i.e.	 iPSCs)	
(410,411).	 Aside	 from	 the	 key	 regulatory	 roles	 of	OCT4,	 SOX2	 and	 other	master	
transcription	 factors,	 this	 highlights	 the	 degree	 of	 plasticity	 retained	 by	 the	
epigenome	 (401,411,412).	 Cancer	 cells	 have	 also	 been	 shown	 to	 remodel	 the	
epigenomic	 landscape	 in	 response	 to	 the	 selective	 pressures	 associated	 with	
therapy	(86,413),	for	example,	in	the	adaptation	to	oestrogen	deprivation	(413)	and	
to	 treatment	with	AIs	 (401),	 and	 there	 is	 a	 specific	 association	 between	 the	 CSC	
phenotype	and	epigenetic	remodelling	(414).	In	this	section,	we	sought	to	directly	









Treating	 MCF7s	 with	 4-OHT	 appeared	 to	 have	 little	 effect	 on	 gross	 sphere	
morphology	 (relative	 to	 Sham	 controls),	 whereas	 siOCT4	 visually	 appeared	 to	
reduce	sphere	size	and	potentially	aggregation	(Figure	4.3.2	A).	As	before,	treatment	
with	 4-OHT	 reduced	 the	 size	 of	mammospheres	 formed	 but	 enriched	 for	 M-ICs	





mammosphere	growth	 (not	significant)	 and	 slightly	 increased	M-IC	number	 (not	
significant),	perhaps	suggesting	that	aggregation	of	smaller	spheres	into	larger	was	
inhibited.	 Interestingly,	 4-OHT	 treatment	 in	 the	 presence	 of	 siOCT4	 completed	
ablated	 the	 M-IC	 enhancing	 effects	 of	 4-OHT	 (p<0.01;	 one-way	 ANOVA	 with	
Bonferroni	correction).	Furthermore,	MFE	was	significantly	reduced	by	4-OHT	in	
the	 presence	 of	 siOCT4	 relative	 to	 siOCT4	 alone	 (p<0.05;	 one-way	 ANOVA	 with	
Bonferroni	 correction),	 suggesting	 that	 4-OHT	 becomes	 toxic	 to	 MCF7	
mammospheres	 in	 the	 absence	 of	 OCT4.	 In	 contrast,	 siSOX2	 almost	 completely	
removed	 the	 ability	 of	 cells	 to	 form	 mammospheres	 in	 either	 the	 presence	 or	
absence	 of	 4-OHT,	 suggesting	 that	 SOX2	 is	 a	 requirement	 for	 cells	 to	 form	
mammospheres	(Figure	4.3.2	A	and	B).	This	appears	to	be	 in	agreement	with	the	







IC	 fraction	 of	 TamR	 cells.	Figure	 4.3.3	 A	&	B	 show	 that	 both	 siOCT4	 and	 siSOX2	
drastically	reduced	mammosphere	formation	in	TamRs.	As	before	(Figure	4.3.2	B)	
we	see	a	slight,	non-significant	decline	in	the	MFE	of	TamRs	after	treating	with	4-
OHT	 (Figure	 4.3.3	 A	 &	 B).	 POU5F1/OCT4	 appears	 to	 have	 only	 a	 slight	 role	 in	
















































A)	 Representative	 phase	 contrast	microscopy	 of	mammospheres	 formed	 by	MCF7s	
with/without	4-OHT	pretreatment	(200nM	for	24hrs)	and/or	siRNA	for	OCT4/SOX2.	
Mammospheres	 appear	 smaller	 in	 siOCT4	 and	 siSOX2	without	 4-OHT.	With	 4-OHT,	







































































and	 a	 highly	 statistically	 significant	 drop	 in	mammosphere	 size	 and	 number	when	














































positivity	 of	 83.7%	 GFP,	 we	 opted	 to	 sort	 a	 selection	 of	medium-intensity	 GFP-
positive	cells,	 in	order	to	capture	some	population	heterogeneity	in	terms	of	viral	
integrations	 and	POU5F1	 expression.	 The	 resulting	 cell	 line,	 OCT4-Vex-Poly	was	
maintained	 in	 standard	 monolayer	 culture	 conditions	 used	 for	 parental	 MCF7s.	
Figure	 4.4.1	 D	 shows	 qPCR	 results	 for	POU5F1	 expression,	 showing	 significantly	




















(Figure	 4.4.3	 A).	 Surprisingly,	 OCT4-Vex-Poly	 had	 no	 greater	 ability	 to	 form	 2nd	
generation	 mammospheres	 than	 MCF7	 parental	 (plus	 a	 control	 siRNA	 for	 GFP).	
However,	we	confirmed	earlier	findings	that	pre-treatment	with	4-OHT	significantly	
increased	MFE	 in	 the	 parental	MCF7	 cell	 line	 (p<0.01).	Moreover,	we	 found	 this	
affect	was	markedly	amplified	 in	 the	OCT4-Vex-Poly	cell	 line.	OCT4-Vex-Poly	had	
10-fold	greater	MFE	when	pre-treated	with	4-OHT	compared	to	control	(p<0.001).	
As	we	had	found	earlier,	siRNAs	for	POU5F1	made	little	difference	to	M-ICs	when	
cells	 were	 treated	 with	 EtOH	 alone,	 but	 with	 the	 addition	 of	 4-OHT,	 MFE	 was	














parental	 (plus	 control	 siRNA)	and	1/872.7	 for	 siOCT4	 (Figure	4.4.4	A).	When	we	
dose	 1st	 generation	 mammospheres	 with	 4-OHT	 prior	 to	 conducting	 the	 assay,	
OCT4-Vex-Poly	had	the	highest	M-IC	frequency	at	1/13.2	cells,	this	was	1/36.2	for	
MCF7	parental	 (plus	 control	siRNA)	and	1/1452.2	 for	siOCT4	 (Figure	4.4.4	B).	 In	

























A)	 Diagram	 of	 OCT4-Vex-GFP	 insert.	 Insert	 was	 packaged	 in	 lentiviral	 vector	 (2nd	
generation)	 as	 described	 in	Methods,	 section	 2.3.2,	 and	 lentiviral	 particles	 used	 to	
infect	MCF7s.	B)	Shows	 flow	 cytometry-based	 analysis	 of	 infection	 efficiency,	mode	
normalised	GFP	detection	by	405nm	laser	is	shown.	C)	Shows	derivation	of	the	OCT4-
Vex-Poly	cell	line	from	the	infected	MCF7	population.	OCT4-Vex-Poly	were	cell	sorted	
from	 the	 central	 region	 of	 VexGFP	 positive	 cells.	 83.7%	 of	 cells	 were	 positive	 for	
vexGFP.		D)	Confirmation	by	qPCR	of	over-expression	of	POU5F1	in	OCT4-Vex-Poly	cell	









































































































than	MCF7	 parental;	 pre-treatment	 with	 4-OHT	 significantly	 increased	MFE	 in	 the	
parental	MCF7	cell	 line	(p<0.01);	this	affect	was	amplified	in	the	OCT4-Vex-Poly	cell	
line	 (10-fold	 greater	MFE	when	 pre-treated	with	 4-OHT	 (p<0.001))	&	 siOct4	made	
little	 difference	 to	 vehicle	 treated	 MFE,	 but	 completed	 ablated	 MFE	 with	 4-OHT	






































IC	 frequency	 at	 1/13.2	 cells,	 MCF7	 parental	 (plus	 control	 siRNA)	 had	 1/36.2	 and	













































apoptosis	 (419),	 as	well	 as	 stem	 cell	 survival	 and	 self-renewal	 (417,420,421).	 In	




We	 next	 sought	 to	 understand	 the	 potential	 contributions	 of	 EMT	 to	 tamoxifen	
resistance	in	our	models.	Mammospheres	from	OCT4-Vex-Poly	experiments	(Figure	
4.4.3)	were	harvested	and	prepared	for	IHC	(Figure	4.5.1).	ERα	and	Ki67	were	seen	
to	 colocalise	 in	 OCT4-Vex-Poly,	 suggesting	 at	 least	 some	 oestrogen	 dependence.	
Moreover,	 OCT4-Vex-Poly	 mammospheres	 appeared	 variably	 enriched	 for	 the	
ALDH1A	marker	 of	 CSCs/BC-TICs.	N-Cadherin,	 E-Cadherin	 and	EpCam	were	 also	
profiled	 to	 investigate	 whether	 OCT4-Vex-Poly	 mammospheres	 had	 undergone	
EMT.	However,	no	major	differences	between	markers	expressed	by	MCF7	parental	
and	OCT4-Vex-Poly	mammospheres	is	immediately	obvious.	As	OCT4-Vex-Poly	are	

















comparing	 gene	 expression	 patterns	 of	 TamRs	 and	 MCF7s	 in	 monolayer	 and	
mammosphere	culture,	we	find	that	mesenchymal-type	genes	dominate	in	TamRs	
whereas	 epithelial-type	 genes	 dominate	 in	 MCF7s	 (Figure	 4.5.3	 A).	 This	 is	 most	
apparent	in	mammosphere	(3D)	conditions.		
	




expected	 to	 be	 up-regulated	 significantly	 after	 EMT	 and	 follow	 a	 fibrous	 type	
expression	 pattern,	 whereas	 in	 our	 studies	 expression	 changes	 are	 minor	 and	
Vimentin	 appears	 to	 be	 localised	 in	 foci	 in	 TamRs	 (425).	 Vimentin	 intermediate	
filaments	 have	 been	 shown	 to	 interact	with	 the	 centrosome	 if	 expression	 is	 low	
(426),	suggesting	that	whilst	Vimentin	is	up-regulated	in	TamRs	protein	levels	are	
still	 low.	 Interestingly,	E-Cadherin	loss	 is	seen	as	 the	hallmark	of	EMT	and	TamR	
cells	 show	 evidence	 of	 two	 distinct	 populations	 distinguished	 by	 differential	 E-













mammosphere	 cultures,	 over-expression	 of	 E-cadherin	 allowed	 them	 to	 form	






















Mammospheres	 from	Figure	4.5.5.1	were	harvested	and	prepared	 for	 IHC.	ERα	and	
Ki67	 were	 seen	 to	 colocalise	 in	 OCT4-Vex-Poly.	 OCT4-Vex-Poly	 mammospheres	
appeared	enriched	 for	ALDH	versus	parental	MCF7s.	No	major	 differences	between	


















































mesenchymal-like	 TamR	 cell	 shape.	 B)	 Wound	 healing	 assay	 showing	 TamRs	 are	
significantly	 (p<0.001)	 more	 migratory	 than	 MCF7s.	 In	 both	 cell	 lines,	 4-OHT	 is	
inhibitory	to	migration	at	100nM,	suggesting	ERα	response	is	still	active	in	TamRs	in	
terms	 of	 migratory	 repression.	 Statistical	 analysis	 was	 by	 non-linear	 mixed	 effect	

























































































A)	 qPCR	profiling	of	EMT	markers	 in	 each	 cell	 line	and	 in	2D	 (monolayer)	 and	3D	
(mammosphere)	culture.	Relative	expression	is	computed	by	comparative	CT	method	
(2-ΔΔ𝐶T)	 (333)	 to	 the	 geometric	 mean	 of	 B2M	 and	 GAPDH,	 and	 MCF7	 expression.	
Significance	was	calculated	by	one-way	ANOVA	with	Bonferroni	to	correct	for	multiple	
comparisons	(*p<0.05;	**p<0.01;	***p<0.001;	****p<0.0001).	B)	Immunofluorescence	












































vitro	 than	 its	 parental	 line	 (Figure	 4.4.2).	 We	 have	 also	 found	 evidence	 of	 ERα	
dependent	growth	in	this	line,	in	terms	of	Ki67	and	ERα	staining	overlap	by	IHC	of	
mammospheres	(Figure	4.5.1).	We	sought	to	investigate	the	tumour	forming	ability,	
and	oestrogen	dependence,	of	OCT4-Vex-Poly	 compared	 to	parental	 lines.	Figure	
4.6.1	A	shows	in	vivo	growth	curves	of	subcutaneously	injected	MCF7	and	OCT4-Vex-
Poly	 cell	 lines	 in	 NSG	mice	with	 slow	 release	 human	 oestrogen	 pellets	 to	 aid	 in	
tumour	growth.	OCT4-Vex-Poly	tends	to	form	palpable	tumours	in	a	high	oestrogen	
environment	at	a	slightly	slower	rate	than	parental	MCF7s	(Figure	4.6.1	A).	Figure	
4.7.1	B	shows	 tumours	harvested	 from	 the	 flanks	of	NSG	mice	80	days	 following	
implantation,	 reasonable	 concordance	 between	 palpable	 tumour	 size	 and	 actual	
volume	can	be	confirmed	visually,	as	can	the	slower	growth	rate	of	MCF7	OCT4-Vex-
Poly	 tumours	 relative	 to	 parental.	 Next,	 we	 repeated	 this	 experiment	 in	 non-
oestrogen	 supplemented	NSGs.	 Interestingly,	 in	 this	 low	oestrogen	 environment,	
OCT4-Vex-Poly	cell	lines	form	palpable	tumours	at	a	markedly	faster	rate	than	MCF7	
















Next,	 we	 sought	 to	 investigate	 the	 presence	 of	 BC-TICs	 in	 OCT4-Vex-Poly	 and	
parental	MCF7s,	with	and	without	exposure	to	4-OHT.	Thus,	we	turned	to	the	in	vivo	
version	of	the	LDA	assay,	injecting	increasingly	dilute	numbers	of	pre-treated	cells	


















































estimated	 periodically	 by	 palpation.	 OCT4-Vex-Poly	 derived	 tumours	 tended	 to	 be	






























































A)	 OCT4-Vex-Poly	 and	 MCF7	 cells	 were	 injected	 into	 the	 flank	 of	 NSG	
immunocompromised	mice,	without	oestrogen	pellets,	 to	assay	 tumour	growth	 in	a	
low	 oestrogen	 environment.	 OCT4-Vex-Poly	 appeared	 to	 initiate	 tumours	 more	






























































IHC	 for	 GFP,	 ERα	 &	 Ki67	 and	 morphology	 investigated	 by	 H&E.	 OCT4-Vex-Poly	
exhibited	a	fibrous	tumour	morphology	by	H&E,	with	reduced	cellularity	relative	to	
MCF7	 parental.	 GFP	 is	 clearly	 stained,	 confirming	 OCT4-Vex-Poly	 integration	 and	




















































































Shows	 results	 of	 an	 in	 vivo	 LDA.	 Following	 pre-treatment	 with	 4-OHT,	 where	
appropriate	(24	hrs	at	200nM),	cells	were	harvested,	serially	diluted	and	resuspended	
in	50%	Matrigel.	50μl	dilutions	containing	1,000,	100	or	10	cells	as	appropriate	were	
injected	 into	 the	4th	mammary	 fat	 pads	of	NSG	mice.	NSGs	were	 also	 injected	with	
0.72mg/90day	slow	release	E2	pellets.	Tumour	injection	sites	were	palpated	for	signs	
of	 tumour	 growth	 twice	 weekly	 for	 up	 to	 6	 months.	 Statistical	 analysis	 by	 ELDA	
revealed	estimates	of	1/87.70	BC-TICs	in	a	pool	of	MCF7s,	raising	to	1/14.33	when	pre-













































model	 was	 dissociated	 into	 PDTCs	 for	 short	 term	 ex	 vivo	 culture	 as	 previously	
described,	(198).	PDTCs	were	then	treated	with	an	escalating	dose	of	4-OHT	and	
IC50s	were	calculated.	Figure	4.7.1	A	shows	combined	dose	response	curves	for	each	
model,	 with	 IC50	 values	 (in	Molar	 concentration)	 in	 the	 figure	 legend.	We	 have	
previously	 calculated	 area	 under	 the	 curve	 (AUC)	 from	 dose	 response	 curves	 of	
multiple	 PDX	 models	 for	 multiple	 drugs	 and	 combination	 therapies	 by	 high	
throughput	 screens	 (HTS)	 (198).	 Eight	 models	 had	 data	 available	 for	 4-OHT	
treatment.	Figure	4.7.1	B	shows	good	correlation	between	IC50s	calculated	in	these	
experiments	 and	 previously	 found	 AUCs	 (R2	 =	 0.6533;	 p	 =0.0047),	 hence	 we	
interpolated	AUCs	from	models	not	tested	in	HTS.	Results	were	as	follows:	IC06-x5	





HCI005,	 HCI006,	 VHIO098,	 VHIO131	 &	 VHIO244),	 and	 six	 deemed	 resistant	
(STG143,	IC06,	IC06_TAMR,	HCI011,	STG201,	&	IC07).		
	
As	 discussed,	 resistance	 to	 tamoxifen	 has	 been	 linked	 to	 expression	 of	 several	
master	transcription	factors	typically	associated	with	guiding	embryonic	stem	cell	
fate	 and	 differentiation.	 We	 profiled	 each	 selected	 PDX	 model	 for	 embryonic	
transcription	factors	OCT4	(POU5F1),	SOX2,	NANOG	&	KLF4	alongside	putative	BC-







mean	expression	 for	each	marker	 in	each	model.	 Significant	differences	are	 seen	





cancer	 precursor	 cells	 of	 various	 lineages,	 including	 hematopoietic,	 mammary,	
endothelial,	mesenchymal,	and	neural	(428).	We	next	used	an	ALDH	activity	assay	
(ALDEFLUOR,	see	Methods,	section	2.3.6)	to	assay	PDX	models,	treated	with	200nM	
4-OHT	 for	 24hrs	 by	 flow	 cytometry.	 Figure	 4.7.4	 A	 shows	 a	 representative	 flow	








gating	 strategy	 to	 derive	 ALDH+	 and	 ALDH-	 populations	 from	 STG335-x4.	 Flow	
sorted	cells	were	separately	plated	and	grown	for	up	to	seven	days	ex	vivo	as	PDTCs,	




cases,	 the	 ALDH+	 population,	 is	 significantly	more	 resistant	 to	 4-OHT	 treatment	
than	 either	 the	 bulk	 population	 or	 the	 ALDH-	 cells	 (by	 one-way	 ANOVA	 with	


























































































































































activity	 increasing	 in	 STG335	 after	 24hrs	 of	 200nM	 4-OHT.	 B)	 Shows	 this	 assay	
repeated	 across	 PDTC	 models.	 Overall,	 we	 found	 3	 out	 of	 6	 resistant	 models	 had	
significantly	reduced	ALDH+	cells	following	treatment.	Conversely,	6	out	of	8	sensitive	
models	 were	 significantly	 enriched	 for	 ALDH+	 cells	 following	 treatment.	 Statistics	












































A)	 PDTCs	 isolated	 from	 four	 PDX	 models	 were	 assayed	 for	 ALDH	 activity.	 Gating	
strategy	is	shown	for	selection	of	high	ALDH	activity	(ALDH+)	and	low	ALDH	activity	















































Having	 shown	 significant	 enrichment	 of	 markers	 for	 BC-TIC	 activity	 in	 our	
tamoxifen	resistant	models,	we	sought	to	understand	the	potential	clinical	impact	
by	 interrogating	 the	 METABRIC	 dataset	 of	 >2000	 breast	 cancer	 patients	 (7,73).	
Several	 differences	 exist	 in	marker	 expression	 across	 the	 11	 integrative	 clusters	
(ICs)	of	breast	cancer,	Figure	4.8.1.	For	example,	SOX2	appeared	to	be	enriched	in	
IC1	 (ERα+)	&	 IC5	 (HER2+	&	ERα+/HER2+).	 Interestingly,	 the	opposite	pattern	 is	
seen	with	CD44,	which	had	the	lowest	expression	in	IC1	&	IC5.	KLF4	and	PROCR	were	
highly	variably	expressed	between	the	clusters,	with	KLF4	appearing	to	show	some	
enrichment	 in	 IC3	 and	PROCR	 in	 IC4	ERα-.	POU5F1	 and	NANOG	 are	more	 stable	
across	the	clusters,	with	no	obvious	bias.	Surprisingly,	we	find	none	of	the	BC-TIC	
markers	or	transcription	factors	were	enriched	in	IC10,	a	cluster	highly	enriched	for	
TNBC,	 typically	 thought	 to	 be	 dedifferentiated	 and	 BC-TIC	 rich	 (173,429–431).	
NANOG	in	particular	has	recently	been	 linked	 to	TNBC,	with	one	study	reporting	






4.8.2	 A).	 Both	 PROCR	 and	 KLF4	 were	 significantly	 enriched	 in	 both	 ERα+	 and	
hormone-treated	 patient	 groups	 (p<0.05;	 one-way	 ANOVA	 with	 Bonferroni	
correction).	 However,	 taking	 overexpression	 as	 a	 z-score	 threshold	 of	 2.0	 (from	
Illumina	 Human	 v3	 microarray),	 we	 find	 relatively	 little	 difference	 in	 overall	
survival	 for	 patients	 enriched	 for	 any	 of	 our	 BC-TIC	 markers	 versus	 the	 ERα+	
population	as	a	whole	(Figure	4.8.2	B).	Though	differences	do	exist	in	median	overall	
survival,	 for	 example	 with	 POU5F1	 overexpression	 translating	 to	 151	 months	








To	 further	 investigate	 the	 role	 of	 OCT4	 in	 tamoxifen	 resistance,	 we	 compared	
POU5F1	 expression	 in	 ERα+	 patients	 from	 the	 METABRIC	 cohort	 who	 had	 not	
responded	 to	 their	 hormone	 therapy	 and	 ultimately	 died	 of	 their	 cancer,	 versus	
those	 treated	 with	 hormone	 therapy	 and	 still	 alive.	 Interestingly,	 we	 found	





test)	 (Figure	 4.8.3	 B).	 These	 analyses	 highlight	 the	 potential	 role	 of	 BC-TICs	











expression	 across	 the	 2000	 breast	 cancer	 patients	 of	 the	 METABRIC	 dataset	 are	




































expression	was	 significantly	 (though	 not	markedly)	 reduced	 in	 ERα+	 patients	 who	
have	gone	through	hormonal	therapy,	but	not	in	the	ERα+	subgroup	as	a	whole,	PROCR	
and	 KLF4	 were	 significantly	 enriched	 in	 both	 ERα+	 and	 hormone-treated	 patient	
groups	 (p<0.05;	 one-way	 ANOVA	 with	 Bonferroni	 correction).	 B)	 Taking	





































disease	 versus	 those	 who	 are	 alive	 (p=0.0052;	 two-tailed	 t-test).	 B)	 POU5F1	 has	
prognostic	 value	 in	 ERα+	 patients	 undergoing	 hormonal	 therapy,	 high	 POU5F1	





















































The	 CSC	 theory	 of	 tumour	 initiation	 and	 progression	 was	 born	 from	 early	
observations	that	 tumour	cells	differ	 in	 their	ability	 to	xeno-	and	auto-transplant	
(17)	 and	 added	 to	 by	 seminal	 studies	 of	 teratocarcinomas	 (18),	 small	 cell	 lung	
carcinomas	 (19)	 and	 mammary	 adenocarcinomas	 (20).	 The	 theory	 posits	 that	
cancer	 follows	 the	same	principles	as	embryogenesis	 and	normal	 tissue	 renewal.	
Thus,	cancer	‘stem’	cells	produce	all	compartments	of	the	tumour	much	as	normal	
stem	 cells	 produce	 differentiated	 cells	 of	 the	 adult	 tissue	 (24).	 This	 model	 is	
sometimes	 seen	as	 controversial,	particularly	as	 robust	markers	 for	 the	 isolation	
and	purification	of	CSCs	are	not	available	for	all	malignancies.	Nevertheless,	stem	
cell	 signatures	 do	 show	prognostic	 features	 across	multiple	 tumour	 types	 (431–
434)	 and	 that	 fact	 that	 tumour	 cells	 differ	 in	 their	 capacity	 to	 xeno-	 and	 auto-








found	 to	 contain	 dormant	 or	 quiescent	 stem	 cell	 populations	with	 the	 ability	 to	




phenotypes	 within	 genomic	 clones	 may	 adopt	 a	 ‘dormant’	 state	 but	 be	 able	 to	
reacquire	 malignancy	 in	 a	 context	 specific	 manner.	 Thus,	 the	 CSC	 and	 clonal	






In	Chapter	 3,	we	 identified	 isogenic	 cellular	 clones	which	 gave	 rise	 to	 tamoxifen	
resistance	 in	 MCF7s	 (Figures	 3.6.2,	 3.7.2.2,	 3.7.3	 &	 3.8.1).	 Considerable	 overlap	
between	 barcodes	 enriched	 in	 separate	 replicates	 was	 observed,	 leading	 us	 to	
conclude	that	an	average	of	49.6	resistant	clonal	populations	were	present	in	each	
replicate	and	that	83%	were	enriched	consistently	in	more	than	one	cell	line.	This	
enrichment	 process	 was	 not	 the	 result	 of	 genomic	 clonal	 selection,	 however	
resultant	 resistant	 phenotypes	 did	 show	 heterogeneity	 (for	 example	 in	 4-OHT	
sensitivity,	 ERα	 function,	 rapamycin	 sensitivity	 and	 proliferation;	 Figures	 3.5.3.2,	
3.5.4	&	3.5.5).	Moreover,	we	 found	evidence	 that	 resistant	 cellular	 clones	may	be	
slow-cycling	or	even	quiescent	in	nature	(Figures	3.8.2.2	&	3.8.3).	If	barcoded	clones	
enriched	 in	 tamoxifen	 resistance	 were	 indeed	 dedifferentiated,	 this	 could	 help	
explain	the	heterogeneity	we	observed	in	isogenic	populations	in	our	system	and	















POU5F1;	 but	not	KLF4	or	NANOG;	Figures	4.2.1	&	4.2.2).	Each	of	 the	 four	assayed	
transcription	factors	have	been	linked	to	tamoxifen	treatment	or	resistance.	We	find	
enrichment	 of	 POU5F1	 and	 SOX2	 in	 resistant	 models,	 each	 of	 which	 has	 been	
positively	 associated	 with	 the	 development	 of	 resistance	 (277,438),	 SOX2	






4.2.3)	 and,	 perhaps	 unsurprisingly,	 we	 find	 mammospheres,	 but	 not	 other	 3D	
cultures,	 are	 resistant	 to	 4-OHT	 treatment	 (Figure	 4.2.6).	 Treatment	 of	 first	
generation	 mammospheres	 with	 4-OHT	 also	 enriches	 for	 MFE	 (Figure	 4.2.4).	
Moreover,	 we	 find	 similar	 cellular	 populations	 are	 enriched	 in	 mammosphere	
culture	(i.e.	M-ICs)	and	in	tamoxifen	resistance	(Figure	4.2.8).	Together	these	results	
suggest	 that	4-OHT	 treatment	preferentially	affects	non-M-ICs	and	will	 therefore	












OCT4	 appears	 to	 be	 functionally	 tied	 to	 4-OHT-selection	 of	 BC-TICs	 in	 MCF7s	
(Figures	4.4.2	&	4.4.3).	Moreover,	we	find	a	plausible	mechanism	by	which	4-OHT	
could	 trigger	 OCT4	 activity:	 a	 validated	 promotor	 region	 in	 the	 POU5F1	 gene	
containing	 EREs	 (407),	 a	 poor	 prognosis	 ERα/FOXA1	 binding	 site	 (248)	 and	
putative	 tamoxifen-ERα	specific	binding	 site	 (408)	 (Figure	4.2.5).	 In	profiling	our	
OCT4-Vex-Poly	 MCF7	 cell	 line,	 we	 also	 found	 evidence	 of	 pre-existing	 4-OHT	
resistance	(Figure	4.4.2)	and	a	reduced	necessity	 for	E2-mediated	growth	(Figure	
4.6.1	&	Figure	4.6.2).	Phenotypically,	we	find	OCT4-Vex-Poly	to	be	slow	growing	and	
enhanced	 in	 BC-TICs	 /M-ICs	 by	 LDA,	 both	 of	which	 traits	were	 profiled	 in	 vitro	
(Figures	4.4.2	&	 4.4.4)	 and	 in	 vivo	 (Figures	4.6.2	&	4.6.4).	Most	 strikingly,	we	 find	
OCT4	 co-operates	 with	 4-OHT	 selection	 to	 increase	 BC-TIC	 activity	 in	 the	 Gold-
Standard,	in	vivo,	LDA.	Together	these	results	hint	at	a	functional	role	for	OCT4	in	
the	 development	 of	 tamoxifen	 resistance.	 Whilst	 many	 of	 the	 reports	 in	 the	
















FAK	 (429).	 In	 our	 analysis,	 however,	 NANOG	 is	 neither	 associated	 with	 the	
development	 of	 resistance	 or	 enrichment	 in	 the	 TNBC	 rich	 Integrative	 Clusters	
(IntClusters)	such	as	IC10	(Figures	4.8.1	&	4.8.2).		
Recently,	Bhatt	et	al.,	characterised	the	role	of	OCT4	as	a	novel	ERα	binding	partner	
involved	 in	 a	 tamoxifen	 specific	 ERα	 binding	 program	 and	 ultimately	 tamoxifen	
resistance	(438).	The	authors	performed	motif	analysis	of	tamoxifen	specific	ERα	
binding	sites	identified	by	Welboren	et	al.,	in	MCF7s	(408)	and	found	an	enrichment	
for	 Nkx3-1	 and	 Oct-transcription	 factor	 homodimer	 motifs.	 The	 finding	 was	
subsequently	 confirmed	 by	 ChIP	 assays	 for	 OCT4,	 demonstrating	 its	 specific	
recruitment	to	regulatory	sites	of	genes	induced	by	tamoxifen,	but	not	oestradiol,	
bound	 ERα.	 Interestingly,	 further	 experiments	 found	 POU5F1	 expression	 to	 be	
basally	 repressed	 by	Nkx3-1	 in	MCF-7	 cells,	 and	 that	 4-OHT	was	 able	 to	 elevate	
Nkx3-1	 degradation	 through	 a	 p38MAPK-dependent	 phosphorylation	 of	 the	 E3	
ligase,	Skp2.	The	authors	conclude	by	presenting	evidence	that	OCT4	participates	in	
ERα	 transcriptional	 complexes	 along	 with	 p38MAPK	 and	 Skp2	 in	 a	 tamoxifen-





as	 mammospheres	 (439).	 The	 authors	 found	 that	 CHIP	 depletion	 increased	
mammosphere	 formation,	 whereas	 over-expression	 reduced	 formation.	 By	mass	
spectrometry	 interactome	reconstruction,	 the	authors	 identified	OCT4	as	a	direct	
binding	partner	of	CHIP,	and	 later	 functional	studies	 found	CHIP	over-expression	
decreased	 OCT4	 stability	 through	 ubiquitination	 and	 proteasomal	 degradation,	
together	with	decreased	proliferation	and	CSC-like	side-population	size	(439).	The	




















































fleeting,	 often	 adding	 only	 6-12	months	 before	 disease	 progression	 (339).	 	We	 have	
argued	previously	that	these	limitations	are	driven,	at	least	in	part,	by	extensive	reliance	
on	preclinical	models	 that	 fail	 to	accurately	reflect	 tumour	heterogeneity	(23,289).	 In	
order	 to	 halt	 unsustainable	 rates	 of	 attrition	 in	 the	 drug	 discovery	 process,	 and	 to	
develop	 cancer	 medicines	 giving	 lasting	 patient	 benefit,	 we	 must	 develop	 a	 new	
generation	of	preclinical	models	capable	of	reflecting	the	complex	heterogeneity	found	
in	human	cancers.	PDX	models	prevail	 as	arguably	 the	most	powerful	 in	 this	 regard;	
because	they	capture	multiple	aspects	of	tumour	heterogeneity	(195,196,198).			
	
By	 capturing	 intra-	 as	 well	 as	 intertumour	 heterogeneity,	 PDX	 models	 have	 a	 clear	
advantage	over	traditional	models,	supporting	their	use	in	oncological	drug	discovery	
and	 preclinical	 development.	 PDX	 models	 recapitulate	 cell-autonomous	 drivers	 of	










from	 a	 basal	 like	 breast	 cancer	were	more	 representative	 of	 the	 patient’s	metastatic	
lesion	 than	 primary	 tumour	 (153).	 Together,	 these	 observations	 suggest	 that	
deterministic,	fitness-based	mechanisms	underline	tumour-dependent	clonal	selection	





Moreover,	 phenotypically	 distinct	 isogenic	 cellular	 clones	 have	 been	 shown	 to	 drive	
resistance	to	chemotherapy	in	colorectal	PDX	models	(196).	In	an	elegant	study	by	Kreso	
et	 al.,	 it	 was	 found	 that	 minor	 ‘Type	 IV’	 subclones	 in	 colorectal	 PDXs	 were	 able	 to	
repopulate	the	tumour	bulk	after	treatment	with	chemotherapy	(196).	These	quiescent	
cell	populations	were	genetically	similar	to	their	highly	proliferative	counterparts,	and	
were	 later	 linked	to	the	BMI1+	population	thought	 to	act	as	reserve	stem	cells	of	 the	




















stability	of	multiple	 sub-dominant	 cellular	 clones	within	a	 tumour	 (124).	The	TME	 is	
further	 characterised	 by	 an	 influx	 of	 stromal	 cells.	 Infiltrating	 cancer	 associated	
fibroblasts	(CAFs)	can	often	confer	resistance	to	cytotoxic	and	targeted	therapies	(442),	




stromal	 cells	 are	 gradually	 replaced	 by	murine	 equivalents	 upon	 engraftment	 in	 the	
mouse,	 suggesting	 that	 implanted	 human	 cells	 retain	 the	 ability	 to	 recruit	 murine	
accessory	cells	to	their	niche	(23,198).	However,	it	should	be	noted	that	some	differences	




Finally,	 considering	 the	 crucial	 role	 of	 the	 immune	 system	 in	 tumour	 progression,	
perhaps	 the	 most	 obvious	 limitation	 of	 PDX	 models	 is	 the	 necessity	 for	 severely	
immunodeficient	 host	 animals	 (23).	 The	 pro-inflammatory	 microenvironment	
established	by	CD8+	T	 cells,	M1	polarised	TAMs,	NK	cells	 and	others	 can	 lead	 to	 the	
recruitment	 of	 numerous	 immune	 suppressive	 components	 inhibitors	 (23,43,444).	
TAMs	and	myeloid	derived	suppressor	cells	have	been	implicated	in	resistance	to	anti-
angiogenic	 therapy.	 Additionally,	macrophage	and	CD4+	T	 cell	 recruitment	 following	
intensive	 chemotherapy	 in	 breast	 cancer	 patients	 is	 associated	 with	 significantly	


























our	breast	 cancer	PDX	cohort.	The	ability	 to	deconvolute	 cellular	and	genomic	 clonal	
dynamics	in	these	highly	complex	models	of	human	malignancy	offers	the	potential	to	
redefine	our	understanding	of	tumour	heterogeneity	(289).	Our	models	have	established	
















rounds	 of	 PDX	model	 passage.	 It	was	 reasoned	 that	 a	 heritable	molecular	 barcoding	
strategy,	similar	to	those	detailed	in	Chapter	3,	would	allow	an	assessment	of	the	relative	





cells	 in	 order	 to	 begin	 capturing	 heterogeneity	 on	 the	 scale	 present	 in	 human	















label	 and	 track	 a	 highly	 diverse	 population	 of	 MCF7s	 during	 the	 development	 of	
resistance	 to	 4-OHT	 (Figures	 3.6.1,	 3.6.2	 &	 3.7.2).	 Here,	 we	 sought	 to	 use	 the	 same	










cultures	 tested	 were	 found	 to	 be	 resistant	 to	 puromycin	 at	 concentrations	 up	 to	
10,000ng/ml.	In	Figure	5.2.1	A	we	show	resistance	in	STG282-x3	at	concentrations	up	to	
5,000ng/ml.	 The	 ClonTracer	 insert	 contains	 a	 red	 florescent	 protein	 (RFP)	 reporter	
alongside	a	puromycin	resistance	cassette,	to	minimise	any	potential	off	target	effects	of	
puromycin	in	these	cells,	we	opted	for	flow	cytometry	based	viral	titration.	Figure	5.2.1	
B-F	 shows	 the	 gating	 strategy	 used	 when	 selecting	 RFP	 expressing	 (RFP+)	 cell	
populations.	 First,	 we	 selected	 a	 population	 based	 on	 forward	 (size)	 and	 side	
(granularity)	 scatters	 to	 likely	 minimise	 debris	 collection	 (Figure	 5.2.1	 B),	 doublet	
discrimination	 by	 both	 forward	 scatter	 (FSC),	 Figure	 5.2.1	 C,	 and	 side	 scatter	 (SSC),	






complex	 (MHC)	 pan	 MHC-I/MHC-II	 (H-2kb/H2-Db;	 Figure	 5.2.1	 F).	 Compensation	 for	
fluorescent	 bleed	 in	 this	 multicolour	 flow	 cytometry	 experiment	 was	 carried	 out	 in	

















were	 susceptible	 to	 lentivirus,	 however,	 HIV-ZsGreen1	 positive	 cells	 seem	 to	 be	
relatively	evenly	distributed	across	forward	and	side	scatter	distributions	(Figure	5.2.2	
B).	 Certain	 primary	 human	 cells,	 particularly	 those	 that	 are	 quiescent	 in	 nature,	 are	
reproducibly	 challenging	 to	 transduce	 with	 lentiviral	 constructs	 (449,450).	 Clearly,	




ZsGreen1+	 cells	 were	 isolated	 from	 the	 bulk	 ZsGreen1-	 STG282-x3	 population	 by	
fluorescence	activated	cell	sorting	(FACS)	and	implanted	into	the	flank	of	NSG	mice	as	
described	in	Methods,	Section	2.1.	Implanted	regions	were	palpated	periodically	for	signs	
of	 tumour	growth,	 and	estimated	tumour	volume	recorded	by	 the	BRU.	 Interestingly,	
implanted	ZsGreen1+	STG282	cells	were	markedly	slower	growing	when	compared	to	























RFP+	cells	 following	our	 live	human	singlet	 gating	process	detailed	 in	Figure	5.2.1.	A	
lentiviral	 dose	 of	 1.2	 x1011	 TU/ml	 resulted	 in	 9.34%	 RFP+	 cells	 by	 flow	 cytometry,	
suggesting	that	the	majority	of	cells	would	be	individually	labelled	(the	result	of	a	single	
integration	 event	 (360)).	 As	 with	 previous	 viral	 constructs,	 integration	 events	 were	




(348)	 following	 flow	 sorting	 but	 prior	 to	 implantation	 showed	 viability	 at	 64%.	 As	
before,	 infected	 cells	 resulted	 in	 slower	 growing	 tumours	 on	 first	 implantation,	 but	














subsequent	 flow	 sorting	 process.	 Visualisation	 is	 provided	 through	 the	 QDNaseq	
Bioconductor	package.	Figure	5.2.5	A	shows	the	originating	STG282	metastatic	tumour	
sample,	 Figure	 5.2.5	 B	 a	 representative	 example	 of	 STG282CT-x4	 and	 Figure	 5.2.5	 C	
STG282CT-x0.	No	overt	differences	were	observed	by	visual	or	quantitative	analysis	of	
the	copy	number	profiles	of	infected	STG282CT	and	either	the	originating	sample	or	a	











A)	 Shows	 resistance	 to	puromycin	 in	STG282	 (up	 to	5,000ng/ml),	 presented	as	 viability	
versus	 non-treated	 control	 (NT)	 by	 Cell-TitreGlo	 viability	 assay.	 B-F)	 show	 our	 gating	
strategy	 by	 flow	 cytometry	 to	 isolate	 individual,	 human,	 live	 cells	 carrying	 a	 lentiviral	
construct	of	 interest.	 Specifically,	B)	A	population	with	 suitable	 forward	 (size)	and	 side	
(granularity)	scatter	parameters	to	minimise	cellular	debris,	to	likely	minimise	debris.	C)	
doublet	 discrimination	 by	 forward	 (FSC)	 and	D)	 Side	 (SCC)	 scatter.	 E)	Dead	 cells	 are	
Excluded	by	DAPI	and	F)	murine	stromal	cells	were	excluded	by	pan	mouse	MHC-I/MHC-II	
(H-2kb/H2-Db).	 Multicolour	 flow	 cytometry	 compensation	 was	 carried	 out	 using	 the	
recommended	manufacturers	procedures	and	single	stained	samples	(DAPI	positive	control	
was	 achieved	 by	 boiling	 a	 suspension	 for	 20mins	 to	 reduce	 cell	 viability).	 Cells	 were	
analysed	and	sorted	using	the	BD	FACSAria	or	the	BD	Influx	FACS	machine	with	data	files	



























































determined	by	 functional	 titre	 in	HEK293-Ts	 (see;	Methods,	 Section	2.3.3)	 in	 conditions	
optimised	 to	 encourage	 lentiviral	 infection.	 8.22%	 of	 viable	 human	 single	 cells	 were	





























































STG282x3	cells	were	 infected	with	the	same	ClonTracer	 lentiviral	 library	developed	and	
validated	in	Chapter	3	(Section	3.4)	and	Chapter	2	(Methods,	Section	2.3).	A)	1	x107	PDTCs	






by	trypan	blue	exclusion	(348)	 following	 flow	sorting	but	prior	 to	 implantation	showed	























































Representative	 images	 of	 samples	 STG282CT-x0.	 Staining	 shows	 H&E	 and	 EpCam	 &	
ECadherin	IHC.	Comparison	to	parental	 lines	shows	maintained	heterogeneity	in	protein	




























































STG282CT	 was	 profiled	 by	 sWGS	 to	 identify	 copy	 number	 variations	 associated	 with	
lentiviral	 integration	 hotspots,	 and/or	 a	 loss	 of	 heterogeneity	 associated	with	 selective	























































After	 lentiviral	 infection,	 flow	 sorting	 and	 implantation	 (Figure	 5.2.3),	 we	 estimated	
labelling	of	approximately	900,000	individual	PDTCs.	Viability	staining	by	trypan	blue	
exclusion	(348)	found	36%	of	cells	were	non-viable,	suggesting	~600,000	individually	





would	 result	 in	>150-fold	 library	 representation.	PDTCs	 from	 this	STG282CT-x1	pool	
could	then	be	mixed	and	re-implanted	into	NGS	to	allow	equal	barcode	distribution	in	
passage	x2	models.	We	hoped	to	validate	this	library	expansion	and	representation	so	
that	 future	 drug	 resistance	 lines	 could	 directly	 compare	 the	 fate	 of	 cellular	 clones	 in	
treatment	and	control	arms	of	a	drug	resistance	study,	similar	to	that	designed	in	Chapter	














barcode	 sequences	 in	 a	 sampling	 of	 mixed	 cells	 from	 10	 STG282CT-x1	 models	
(STG282CT-x1_mix;	Figure	5.3.2	B).	In	total,	1	x106	cells	from	this	pool	were	sequenced,	




three	 were	 sequenced	 for	 barcode	 analysis.	 These	 second-generation	 tumours	
























were	 sequenced	 alongside	 barcoded	 PDX	 and	 cell	 line	 xenograft	 models	 in	 order	 to	
estimate	 cell	 number	 from	 relative	 barcode	 abundance	 (197).	 We	 sought	 to	 further	
understand	 the	dynamics	of	 clonal	repopulation	 in	our	models	by	 following	a	similar	
protocol.	Hence,	we	prepared	clonally	derived	(i.e.	single	barcode	sequence)	ClonTracer	
constructs	prepared	by	E.	coli	transfection,	prepared	lentiviral	constructs	in	HEK293-Ts	
and	 transduced	 fresh	 HEK293	 cell	 preparations	 at	 <10%	 MOI	 (0.5-1.5	 x109	 TU/ml	
concentrated	viral	titres	for	each	individual	barcode).	After	puromycin	selection,	known	




Across	 24	 sequenced	 PDX	 samples,	 barcodes	 spiked	 in	 at	 500	 or	 more	 cells	 were	
detectable	in	100%	of	cases,	and	a	good	correlation	was	observed	between	the	number	
of	 cells	 input	 and	 relative	 barcode	 abundance	 (r2	 =0.998,	p	<0.0001;	Figure	 5.3.3	 A).	
Below	 500	 cells,	 the	 correlation	 between	 input	 cells	 and	 barcode	 abundance	 was	
markedly	 less	 clear,	 and	 our	 ability	 to	 detect	 clones	 fell	 to	 60%.	 Of	 note,	 the	 strong	
correlation	between	 input	cell	number	and	relative	barcode	abundance	enabled	us	to	











to	 relate	 relative	 barcode	 abundance	 to	 actual	 clone	 size	 in	 future	 studies.	We	 set	 a	
barcode	 abundance	 threshold	 of	 ~4	 x10-6	 (equivalent	 to	 500	 cells),	 as	 our	 limit	 of	
confident	detection.	This	limit	was	slightly	variable	in	terms	of	RBA	in	each	model,	but	
always	 equivalent	 to	 500	 cells,	 offering	 a	 useful	 internal	 control	 to	 directly	 compare	
clonal	size	in	matched	replicate	implantations.	
	
Aside	 from	 estimating	 the	 absolute	 size	 of	 a	 clone,	 in	 terms	 of	 cell	 number,	 this	
relationship	 allowed	 us	 to	 estimate	 the	 clone-initiating	 cell	 (CIC)	 frequency,	 i.e.	 the	




barcode	count	was	 lower	than	originally	expected,	 this	 figure	 is	relatively	concordant	
with	a	study	by	Nguyen	and	colleagues,	who	used	barcoded	PDX	and	cell	line	xenograft	
models	to	study	tumour	initiation	(197).	The	authors	report	decreasing	CIC	frequency	








measure	 that	 reflects	 how	 many	 different	 species	 can	 be	 found	 in	 a	 dataset	 or	
community,	whilst	 simultaneously	 considering	how	evenly	 the	basic	 entities	 (such	as	
individuals)	are	distributed	among	those	species.	We	computed	one	such	measure,	the	
SDI	 (H’),	 to	 quantify	 diversity	 amongst	 cellular	 clones	 in	 our	 PDX	models	 (204,363).	


























































Shows	 our	 STG282CT	 expansion	 and	 pooling	 strategy	 to	 increase	 barcode	 library	
representation.	900,000	individual	lenti-ClonTracer	PDTCs	at	64%	viability	by	trypan	blue	
exclusion	(348)	were	subcutaneously	injected	into	the	flank	of	an	NSG	host,	the	resulting	
model	 -	 STG282CT-x0	–	was	 engrafted	 into	10	NSGs	 (STG282CT-x1)	before	PDTCs	were	
harvested,	mixed	 and	 re-implanted	 into	 10	 further	NSGs	 (STG282CT-x2)	 in	 an	 effort	 to	
increase	 library	 representation.	 PDX	 models	 were	 expanded	 down	 specific	 lineages	 as	
detailed	 in	 the	 figure.	 Lines	denote	 the	 flow	of	PDX	material	 into	 subsequent	hosts,	 red	



















































A)	 shows	 our	 STG282CT	 expansion	 and	 pooling	 strategy	 to	 increase	 barcode	 library	
representation.	B)	Despite	a	theoretical	complexity	of	900,000	uniquely	marked	cells,	with	
up	 to	 500-fold	 representation,	 only	 1,034	 unique	 barcode	 sequences	 were	 found	 in	 a	
sampling	of	mixed	cells	 from	10	STG282CT-x1.	 In	 total,	1	x106	cells	 from	 this	pool	were	
sequenced,	 to	a	depth	of	approximately	120	x106	reads,	with	resultant	analysis	showing	































































(in	 terms	of	RBA	value)	 is	 therefore	 slightly	 varied	 in	different	models.	B)	We	used	 the	






























































Cumulative	 relative	 barcode	 abundance	 (RBA)	 as	 a	 function	 of	 the	 number	 of	 unique	
barcodes	 counted,	alongside	 the	Shannon	Diversity	 Index	 (SDI;	H’)	 (204,363).	 A,	B	&	C)	
































dominance	 have	 been	 observed.	 In	 our	 own	models,	we	 have	 shown	 the	majority	 of	
outright	clonal	selection	occurs	on	initial	implantation,	but	that	approximately	20%	of	
clonal	 populations,	 defined	 by	 PyClone	 (199),	 have	 significant	 changes	 in	 cellular	
prevalence	 across	 several	 years	of	 in	 vivo	 culture	and	maintenance.	 Interestingly,	we	
could	 attribute	 a	 putative	 driver	mutation	 to	only	 four	 of	 the	 38	 clonal	 clusters	 that	
changed	significantly	during	serial	passage	(based	on	a	ratiometric	method	to	identify	
and	classify	driver	events	proposed	by	Vogelstein	et	al.,	(452)).	Moreover,	in	analysing	
matched	 PDX	models	 derived	 from	 primary	 and	metastasis,	 or	 from	multiple	 punch	
biopsies	of	 the	same	metastatic	site,	we	have	 shown	remarkable	similarities	between	
clonal	clusters.	In	at	least	one	case	(STG139),	shared	clusters	contained	~80%	of	all	SNVs	
detected,	 comprising	putative	 truncal	 clusters	and	 sub-clonal	 clusters	with	estimated	
cellular	prevalence	<5%	(198).		
	
However,	 in	 our	 studies,	 and	 in	 those	 reported	 in	 the	 literature,	 changes	 in	 clonal	
prevalence	across	passages	has	been	observed.	One	study	sought	to	determine	whether	
such	 directional	 clonal	 kinetics	 were	 associated	 with	 deterministic	 or	 stochastic	
processes,	 such	 as	 random	 genetic	 drift	 (195).	 The	 authors	 found	 that	 80%	 of	 the	

















appearing	 in	 one	 passage	 before	 falling	 below	 the	 limits	 of	 detection	 in	 subsequent	












point	 (representing	 >92%	 of	 cells)	 were	 plotted	 in	 this	 analysis	 for	 ease	 of	
interpretation.	 Dotted	 grey	 boxes	 connect	 matched	 implantations	 and	 black	 arrows	
denote	 the	 original	 sample	 from	 which	 the	 next	 passage	 (or	 matched	




or	 reduction	 in	 clone	 size	 and	 upward	 trends	 represent	 resurgence	 of	 old	 clones,	












Figure	 5.4.1	 A	depicts	 such	 clonal	 dynamics	 for	 the	 STG282CT-x2_1	 to	 STG282CT-x5	
expansion	arm.	This	is	the	largest	collection	of	models	studied	together,	both	in	terms	of	
passage	 (covering	 four	 passages)	 and	 replicates,	 with	 both	 STG282CT-x2_1	 and	
STG282CT-x4_1	 being	 implanted	 into	 three	 replicates	 and	 STG282CT-x3_1	 implanted	









relatively	 stable,	 coupled	with	 slight	 loss	 and/or	 downward	 trend	of	 clones	 typically	
seen	to	be	stable	in	prior	generations.	A	smaller	proportion	of	clones	showed	an	upward	
trend	 in	 STG282CT-x4_2	 than	 STG282CT-x4_1.	 These	 observations	 are	 quantified,	 in	
terms	of	the	percentage	of	clones	showing	divergent	(or	asymmetrical)	and	symmetrical	
growth	patterns	(positive,	neutral	or	negative)	between	replicates.	In	STG282CT-x3_1,	
all	 clone	 behaviours	 were	 largely	 symmetrical.	 STG282CT-x4_1	 showed	 >75%	 of	
downward	and	upward	trending	clones	following	the	same	pattern,	while	those	with	a	







In	Figure	 5.4.1	 B	 the	 expansion	 of	 STG282CT-x2_8	 is	 followed	 through	 two	passages.	
Generally,	 clones	 present	 in	 STG282CT-x3_b1	 follow	 similar	 patterns	 of	 symmetric	
growth	on	transplantation,	though	approximately	70%	of	clones	with	an	upward	trend	
are	asymmetric.	This	can	largely	be	attributed	to	the	detection	of	78	new	clones	in	one	
model	 but	 not	 the	 other.	 Reimplantation	of	 STG282CT-x4_b2	 results	 in	 a	majority	 of	
asymmetric	growth	patterns	across	all	three	type	of	clonal	growth	behaviours.	Finally,	
Figure	5.3.1	C	shows	this	set	of	analysis	for	the	STG282CT-x2_4	expansion	arm.	In	this	
case,	 the	 majority	 of	 cellular	 populations	 were	 neutrally	 trending	 on	 passage.	
Symmetrical	growth	patterns	between	the	three	analysed	replicate	models	were	seen	in	





patterns	 between	 replicates	 established	 from	 the	 same	 originating	 tumour.	 Growth	





































derived.	 For	 each	 parallel	 engraftment,	 we	 compare	 symmetric	 and	 asymmetric	
































































































































































simply	 passaging	 slow	growing	 clones	or	 non-viable	 cells	 between	models,	 but	were	
witnessing	divergent	growth	kinetics	of	the	same	cells	over	time.	This	prompted	us	to	









absence	 in	 the	 last	passage,	demonstrating	clones	with	limited	CIC.	Type	III,	 transient	
clones,	were	defined	by	detection	in	the	first	passage,	but	not	again	in	any	later	passage,	
irrespective	of	how	many	additional	transplants	were	carried	out.	Type	IV,	quiescent	or	






(197).	 In	 this	 case	 the	 authors	 relied	 on	 k-means	 clustering,	 a	 technique	 where	 n	







clone	 size,	 ii)	 a	 relative	 clone	 size	 increasing	on	passage	and	 iii)	 a	 relative	 clone	 size	
decreasing	in	the	second	passage.	In	a	second	MDA-MB-231	experiment,	a	further	two	
clusters	were	 defined,	 both	 characterized	 by	 delayed	 clonal	 growth.	One	 cluster	was	
further	 characterised	 by	 being	 detectable	 in	 secondary	 passages	 but	 decreasing	 in	
tertiary	passages.	 SUM-149	derived	xenografts,	despite	being	 expanded	over	 a	 single	
passage	in	vivo,	yielded	six	and	seven	clusters,	though	these	were	variations	of	the	same	
neutral,	positive	and	negative	growth	trends.	PDX	models	analysed	by	the	group	shared	








expanded,	 at	 most,	 into	 two	 subsequent	 passages,	 SUM-149	 into	 one	 subsequent	
passage,	 and	patient	derived	models	 (T1,	T2	&	T3)	 into	 two,	one	or	zero	subsequent	
passages	(197).	This	relatively	short	follow-up	makes	detection	of	Type	IV	and	V	clones	
particularly	 challenging.	Moreover,	k-means	 clustering	 is	heuristic,	meaning	 it	 is	best	
suited	for	clustering	Gaussian	distributions,	and	may	not	be	as	accurate	when	grouping	
cellular	 growth	 patterns,	 which	 are	 typically	 exponential	 in	 nature	 (454).	 In	 our	
experiments,	we	opted	to	define	clones	based	on	the	Kreso	et	al.,	classification.	However,	
86	unique	barcodes	failed	to	meet	the	criteria	for	classification	in	any	of	the	five	clusters.	
































Type	 III	 clones	 only	 showed	 a	 net	 loss	 (i.e.	median	RBA	<~4	 x10-6)	 from	passage	 x3	
onward,	whereas	a	great	deal	of	heterogeneity	across	passage	x2	replicates	was	seen,	
with	32%,	17%	&	48%	of	sequences	detected	in	STG282CTx1	lost	 in	STG282CT-x2_4,	





















A,	we	see	a	progressive	 loss	of	 first	Type	III,	 then	Type	II	 clones	 in	passage	x3	and	x4	
respectively.	 Loss	 of	Type	 III	 clones	 is	 accompanied	 by	 a	 reduction	 in	 the	 number	 of	
unique	barcodes	across	STG282CT-x3_1,	STG282CT-x3_2	&	xSTG282CT-x3_3,	from	608	
to	444,	385	&	383,	 respectively.	However,	 the	 loss	of	Type	 II	 clones	on	 the	 following	
transplantation	(i.e.	 in	STG282CT-x4_1	&	STG282CT-x4_2)	is	countered	by	substantial	
expansion	of	Type	IV,	slow	growing	or	quiescent,	clones	and	an	accompanying	increase	
in	overall	barcode	complexity	 in	 these	samples	(to	659	&	650).	Surprisingly,	 the	 fifth	
passage	 in	 this	 arm	 reverses	 this	 pattern	 again.	Type	 I	 clones	 are	 reduced	 in	 overall	
cellular	 representation,	 whereas	Type	 V	 transient	 clones	 increase	 in	 proportion,	 and	
Type	 IV	 clones	 remain	 relatively	 stable.	 Overall	 clonal	 count	 drops	 from	 659	 in	
STG282CT-x4_1	 to	380,	327	&	 305	 in	STG282CT-x5_1,	 STG282CT-x5_2	&	 STG282CT-
x5_3,	respectively.		
	
Thus,	 there	 is	 a	 reduction	 in	 total	 number	 of	 clones,	 representation	 of	Type	 I	 clones	
























now	see	 the	 five	 clonal	phenotypes	are	variably	dominant	 in	 repeat	 implantations	of	
STG282CTx3_b1	 (i.e.	 STG282CT-x4_b1	 &	 STG282CT-x4_b2).	 Indeed,	 the	 second	most	
























































Shows	 individual	 unique	 barcodes	 seen	 in	 any	 passage	 or	 replicate	 of	 our	 STG282CT	
expansion	 experiments,	 classified	 into	 Type	 I,	 II,	 III,	 IV	 &	 V	 clonal	 behaviours.	 Putative	
clusters	had	to	fulfil	the	requirements	of	their	clonal	group	in	each	of	the	three	expansion	






present	 in	STG282CTx1	and	STG282CTx2	 in	passage	x1	or	x2,	but	not	seen	 in	x3	or	any	
subsequent	passage.	D)	Shows	Type	IV	clones	defined	by	barcodes	which	were	below	the	
limit	of	detection	until	at	least	STG282CT-x3,	at	which	point	they	remained	detectable	in	




were	 defined	 as	 Type	 V.	 459	 barcodes	 were	 included	 in	 this	 classification,	 with	 the	
































































































Shows	the	percentage	of	each	clonal	phenotype	(Type	I,	 II,	 III,	 IV	&	V;	defined	 in	Figure	
5.5.1)	 by	 cell	 number.	 Inserts	 show	 the	 total	 number	 of	 unique	 barcodes	 seen	 in	 the	






























































































































































































































clinical	 behaviour	 and	 a	 lack	 of	 recognized	 molecular	 targets	 for	 therapy	 (455).	 On	
average,	TNBCs	carry	1.68	somatic	mutations	per	Mb	of	coding	regions	(~60	somatic	
mutations	in	each	tumour).	The	mutation	burden	is	not	uniform	across	TNBC,	and	some	
tumours	 have	 a	 high	 mutation	 burden	 (more	 than	 4.68	 somatic	 mutations	 per	 Mb)	
(38,336),	 and	 a	 frequent	 occurrence	 of	 multiple	 copy-number	 aberrations	 involving	
genes	that	lead	to	multiple	pathway	alterations	(7,38,73,78,198).	Our	group	has	helped	
delineate	 the	 diverse,	 variable	 genomic	 clonal	 composition	 of	 TNBC	 (456).	 By	 allelic	
frequency	 measurements	 of	 2,414	 somatic	 mutations	 in	 104	 TNBCs,	 a	 complete	
spectrum	of	molecular	and	clonal	compositions	was	characterised	at	diagnosis	(456).	




Metastases	 is	 the	ultimate	 cause	of	90%	of	 all	 cancer	deaths	 (147),	 though	questions	
remain	 around	 the	 origins	 and	 processes	 associated	 with	 metastatic	 spread.	 Distant	
metastases	has	been	reported	a	late	event	in	molecular	time,	though	we	reasoned	that	
through	lentiviral	lineage	tracing	in	our	PDX	models,	a	comprehensive	study	of	breast	
cancer	metastasis,	 together	with	 annotation	 of	metastatic-forming	 clonal	 populations	
could	 bring	 considerable	 advances	 to	 the	 field.	 Thus,	we	 sought	 to	 identify	 potential	
metastatic	deposits	across	our	STG282CT	expansion	arms.		
	
For	 each	 animal	 culled	we	 performed	 a	post-mortem	 procedure,	 detailed	 in	Methods,	






allowed	 samples	 from	 abdominal	 and	 inguinal	 mammary	 glands,	 together	 with	
suspected	 tumour	 draining	 lymph	nodes	 (inguinal	 and/or	 lumbar)	 to	 be	 taken	 along	
with	 tumour	harvesting.	Lungs,	 liver	and	 spleen	were	 inspected	 (visually	or	with	 the	
Xenogen	 IVIS	 small	 animal	 imaging	 system)	 for	 potential	metastatic	 sites.	 Harvested	
tissues	 could	 then	be	dissected	and	 interrogated	by	 IHC/histology	 if	 required.	Figure	
5.6.1	 A	 shows	 a	 representative	 image	 of	 suspected	 micro-metastatic	 sites	 identified	
around	 the	 base	 of	murine	 right	 lower	 lung	 lobule	 (black	 arrows),	 as	 imaged	 by	 the	
Xenogen	 system.	 These	 regions	 were	 dissected	 and	 stained	 with	 H&E	 for	 visual	
inspection.	 In	 each	 case	where	 potential	micro-metastatic	 sites	were	 identified;	H&E	
showed	 no	 obvious	 tumour	 structures.	 In	 total,	 we	 isolated	 and	 inspected	 >100	




the	 base	 of	 the	 4th	 (abdominal;	 arrow	 3)	 mammary	 gland	 near	 the	 site	 of	 tumour	
fragment	implantation	(arrow	1).	Though	this	mass	was	not	physically	attached	to	the	
tumour	bulk,	it	could	have	resulted	from	cells	becoming	dislodged	during	implantation	





clonal	 Type	 (I-V)	 based	 on	 repopulation	 dynamics	 in	 Figure	 5.5.1.	 Interestingly,	
















first	 recorded	metastatic	 lesion	 found	 in	 our	 analysis	 of	 >100	 glands	 and	 >50	 total	
instances	 of	 STG282CT	 injection	 into	 NSG	 mice.	 Hence,	 we	 reasoned	 that	 serial	
implantation	of	STG282CT-x3m	was	enriching	for	a	metastatic	phenotype.	Interestingly,	




To	 quantify	 any	 specific	 enrichment	 within	 phenotypic	 clonal	 Types	 I-V,	 we	 next	





abundance	between	secondary	metastases,	where	a	 significant	 correlation	 is	 seen	 (r2	
=0.402,	 p	 <0.0001).	 Figure	 5.6.3	 C	 compares	 abundance	 in	 STG282CTx3m	 versus	
secondary	 metastatic	 sites	 (STG282CTx3m_x1_1m	 in	 the	 left-hand	 panel;	
STG282CTx3m_x1_2m	in	the	right-hand	panel),	significant	correlations	are	seen	in	each	
case	 (r2=0.473,	p<0.0001	&	 r2=0.331,	p<0.0001).	Together,	 these	results	 indicate	 that	






















Finally,	we	 sought	 to	 rationalise	 the	 enrichment	 of	 clonal	populations	of	 a	 particular	
phenotype	to	metastatic	samples.	Aside	from	estimating	the	absolute	size	of	a	clone,	in	
terms	of	cell	number,	the	relationship	between	RBA	and	spiked	in	cell	number	derived	
in	 Figure	 5.3.3	 allowed	 us	 to	 estimate	 the	 “clone	 initiation	 capacity”	 (CIC),	 i.e.	 the	
proportion	of	input	cells	of	a	given	clone,	able	to	establish	a	detectable	clone	of	the	same	
































base	of	murine	right	 lower	 lung	 lobule	(black	arrows),	as	 imaged	by	the	Xenogen	small	
animal	 imaging	 system.	 These	 regions	 were	 dissected	 and	 stained	with	 H&E	 for	 visual	
inspection.	 In	 each	 case	 where	 potential	 micro-metastatic	 sites	 were	 identified;	 H&E	
showed	no	obvious	tumour	structures.	In	total,	we	isolated	and	inspected	>100	mammary	
glands	and	tumour	draining	lymph	nodes	without	finding	definite	metastatic	sites.	B)	We	
identified	 a	 <1	 cm3	 cell	 mass	 (arrow	 2)	 at	 the	 base	 of	 the	 4th	 (abdominal;	 arrow	 3)	
mammary	gland	near	the	site	of	 tumour	 fragment	 implantation	(arrow	1).	Though	this	
mass	was	 not	 physically	 attached	 to	 the	 tumour	 bulk,	 it	 could	 have	 resulted	 from	 cells	
































































Shows	 a	 schematic	 for	 expansion	 of	 this	micro-metastasis	 (designated	 STG282CT-x3m)	
together	with	the	results	of	ClonTracer	barcode	analysis.	Barcodes	seen	in	previous	samples	



































































primary	 STG282CT	 models.	 A)	 Compares	 secondary	 metastases	 to	 their	 paired	 non-
metastasis	primary	tumour.	B)	Directly	compares	RBA	in	secondary	metastases.	C)	Shows	
relative	 barcode	 abundance	 in	 STG282CTx3m	 versus	 secondary	 metastasis	 sites	
(STG282CTx3m_x1_1m	 in	 the	 left-hand	 panel;	 STG282CTx3m_x1_2m	 in	 the	 left-hand	









































































































































We	 have	 recently	 described	 a	 biobank	 of	 breast	 cancer	 PDX	models,	 with	 extensive	
molecular,	 genomic	 and	 clinical	 annotation	 (198).	 Through	 characterisation	 of	 the	
specific	repopulation	dynamics	of	genomic	clones	in	these	models,	we	add	to	a	growing	
body	 of	 evidence	 showing	 PDX	 models	 largely	 reflect	 the	 complex	 molecular	 and	












resistance	 in	 the	MCF7	 cell	 line.	 It	 is	 hoped	 that	 following	 these	 optimisation	 steps,	





supernatant	 using	 extensive	 ultracentrifugation	 with	 a	 sucrose	 gradient.	 Viral	 titres	
showed	our	supernatant	was	indeed	highly	concentrated	in	active	virions	(see:	Methods,	
Section	 2.3).	 Optimisation	 was	 primarily	 carried	 out	 with	 a	 biologically	 inert	 HIV-
ZsGreen1	 virus	 to	 avoid	 repeat	 freeze-thaw	 cycles	 or	 complete	 use	 of	 our	 validated	






based	 for	 HIV-ZsGreen1	 (Figure	 5.2.1).	 Puromycin	 is	 an	 amino	 nucleoside	 antibiotic	









potentially	 off	 target	 effects	 of	 using	 puromycin	 at	 high	 doses.	 Both	 HIV-ZsGreen1	




hold	 particular	 importance	 in	 our	 later	 functional	 studies	 (451),	 and	 a	 molecular	
barcoding	technique	which	selected	for	non-quiescent	cells	should	be	avoided.	However,	
each	second	passage	transduced	tumour	(i.e.	STG282-x3_ZsGreen1x1	&	STG282CTx1)	
grew	 at	 a	 rate	 not	 dissimilar	 to	wildtype	 tumours.	We	 reasoned	 delayed	 growth	 on	
implantation	could,	 thus,	be	at	 least	partially	attributed	to	the	process	of	 flow	sorting	
rather	than	selective	infection	of	a	slow	growing	sub-population	of	cells.	
	
Delayed	 onset	 of	 growth,	 together	 with	 difficulties	 in	 achieving	 a	 high	 infection	
efficiency,	 led	 us	 to	 question	whether	we	were	 selecting	 for	 a	 subpopulation	of	 cells	
within	our	PDX	models.	Clearly,	as	we	hoped	to	study	the	causes	and	consequences	of	
tumour	heterogeneity,	any	method	which	selected	for	a	rare	subpopulation	should	be	



























It	 is	 important	 to	 note	 that	 this	 reduction	 in	 clonal	 diversity	 does	 not	 necessarily	
translate	to	a	reduction	in	diversity	of	clonal	phenotypes.	The	probability	of	any	cellular	
clone	 contributing	 to	 any	 transplant	 is	 reflected	 in	 its	 relative	 distribution	 in	 the	
previous	donor	tumour;	abundant	clones	have	a	higher	probability	of	persisting	than	less	
abundant	clones.	Through	reconstruction	of	genomic	clonal	structures	(199),	we	have	
previously	 shown	 that	 the	 majority	 of	 outright	 clonal	 selection	 occurs	 on	 initial	







techniques	 such	 as	 single-cell	 RNAseq.	 Indeed,	 malignant	 cells	 can	 occupy	 diverse	
physiological	 states	 resulting	 from	 stress	 (hypoxia,	 DNA	 damage,	 starvation),	






model,	 we	 could	 study	 clonal	 selection	 and	 competition	 over	 time.	 Furthermore,	 by	
analysing	their	relative	abundance	we	could	derive	a	model	of	clonal	fitness.	Figure	5.3.1	
shows	 a	 schematic	 of	 the	 expansion	 of	 the	 STG282CT	model.	Model	 numbers	 in	 red	
represent	 those	 where	 NGS	 and	 barcode	 analysis	 was	 performed,	 and	 red	 triangles	
indicate	models	 in	which	micro	 or	 local	metastases	where	 found.	 In	 Figure	 5.4.1	 we	





Conceptually,	 variation	 in	 clonal	 behaviours	 could	 be	 stochastic	 or	 they	 could	 reflect	
specific	classes	of	breast	cancer	PDX	cells	 that	 function	 in	a	predictable	deterministic	
fashion.	 If	 the	 process	 is	 stochastic	 then	 the	 probability	 of	 any	 barcoded	 clone	
contributing	 to	 any	 transplant	 would	 be	 reflected	 in	 its	 relative	 distribution	 in	 the	
previous	donor	tumour;	abundant	clones	would	have	a	higher	probability	of	persisting	
than	less	abundant	clones.	By	contrast,	the	emergence	of	dominant	barcoded	clone	from	
minor	 or	 undetected	 barcodes	 would	 be	 a	 low	 probability	 event,	 especially	 if	 this	









(Figure	 5.5.2).	 The	 expansion	 arm	 following	 STG282CT-x2_1	 showed	 the	 most	
asymmetric	repopulation	dynamics.	For	example,	in	asymmetric	growth	in	STG282CT-
x3_b1	matched	transplants	(into	STG282CT-x4_b1	and	STG282CT-x4_b2;	Figure	5.4.1	B	
&	 Figure	 5.5.2	 B)	 was	 shown	 to	 be	 due	 to	 the	 appearance	 of	 a	 group	 of	 clones	 not	





We	 noted	 that	 the	 framework	 by	 which	 clonal	 phenotypes	 are	 defined	 is	 entirely	
dependent	on	experimental	design.	For	example,	a	Type	IV	clone	could	be	classified	as	a	
Type	V	had	the	experiment	consisted	of	a	further	passage	(presuming	it	was	undetected),	
likewise,	 a	Type	 I	or	 II	 clone	 could	 in	 fact	be	a	Type	 IV.	Nguyen	et	al.,	 defined	 several	
clusters	based	on	the	kinetics	of	repopulation	in	their	breast	cancer	cell-line	xenografts	
and	PDX	modes	(197).	In	this	case	the	authors	relied	on	k-means	clustering,	a	technique	
















change,	 decreasing	 or	 fluctuating;	 but	 not	 clones	 that	 increased	 in	 size	 or	 showed	
delayed	 growth	 onset	 (197).	 Ongoing	 work	 will	 aim	 to	 classify	 clonal	 repopulation	
dynamics	in	an	unsupervised	fashion.	This	will	likely	take	the	form	of	a	bespoke	model-
based	classifier:	k-means	clustering	is	heuristic,	meaning	it	is	best	suited	for	clustering	








phenotypes	 typically	observed	 in	models	of	 this	passage.	Of	not,	 two	of	 these	 second	
generation	 STG282CT-x3m	 models	 (STG282CT-x3m_1	 &	 STG282CT-x3m_2)	 also	
showed	local	metastasis,	and	these	metastases	were	again	enriched	for	Type	IV	clones.	






















molecular	 time	 from	 the	 primary	 site	 and	 progresses	 through	 the	 independent	
acquisition	 of	 mutations	 which	 may	 be	 different	 to	 the	 primary	 (124).	 A	 third	
mechanism,	 the	 concept	 of	metastasis-to-metastasis	 seeding,	 the	 cascade	 hypothesis,	
was	 proposed	 in	 1975,	 but	 until	 recently	 has	 remained	 somewhat	 under	 studied	
(154,155).	 This	 describes	 a	 process	 by	 which	 polyclonal	 seeding	 may	 result	 from	 a	
combination	of	 clones	 from	both	 the	primary	and	other	metastatic	 sites,	 as	has	been	
described	in	cases	of	lethal	metastatic	prostate	cancer	(461,462).	
	
In	 our	 models,	 we	 can	 consider	 similarity	 to	 the	 originating	 sample	 as	 indicative	 of	
parallel	progression	(as	both	metastasis	and	primary	are	seeded	by	the	same	proportion	
of	cells)	and	similarity	 to	 the	matched	primary	as	 indicative	of	 linear	progression	(as	
metastasis	is	seeded	from	a	late	stage	primary	with	the	corresponding	late	stage	primary	
composition	of	barcodes).	In	Figure	5.6.3	we	see	each	metastatic	site	has	a	higher	degree	
of	 concordance	with	 the	originating	sample	 than	 the	matched	primary.	This	 could	be	
indicative	of	parallel	seeding	of	metastasis;	however,	we	see	an	enrichment	of	Type	IV	
clones	 in	 all	 three	 cases	 of	 metastasis,	 but	 not	 primary	 PDX	 tumour	 derived	 from	






In	 summary,	 this	 chapter	 presented	 optimisation	 and	 establishment	 of	 a	 TNBC	 PDX	
model	with	a	methodology	 for	 clonal	 tracking	at	 a	 resolution	of	>500	cells.	Although	





asymmetric	 clonal	 kinetics	 in	 paired	 transplantation	 assays.	 We	 also	 define	 clonal	
phenotypes	 (Type	 I-V)	 and	 find	 quiescent,	Type	 IV,	 clones	 are	 enriched	 in	metastatic	
































The	 estimated	 global	 incidence	 of	 all	 cancer	 types	 in	 2015	 was	 17.5	 million	 (463).	
Fourteen	percent	of	all	deaths	in	2005	were	due	to	cancer,	which	increased	to	16%	in	
2015	 (464).	Breast	 cancer	 is	 the	most	 common	cancer	overall,	with	an	estimated	2.4	
million	new	diagnosis	 in	2015;	1	 in	14	women	and	1	 in	603	men	will	develop	breast	
cancer	 between	 birth	 and	 age	 79	 years.	 The	 vast	majority	 of	 breast	 cancers	 occur	 in	
women,	with	2.4	million	cases	versus	44,000	cases	in	men.	Breast	cancer	was	the	leading	























first	put	 forth	by	Peter	Nowell	 in	1976	(12).	The	theory	postulates	 that	cancers	arise	
from	a	single	cell	that	has	a	selective	advantage	over	its	neighbours	and	that	cancer	can	




in	 evolutionary	 biology	 (383,466);	 considering	 cancer	 as	 a	 disease	 of	 multicellular	
organisms	 in	 constant	 balance	 between	 Darwinian	 selection	 acting	 on	 the	 level	 of	 a	
single	 cell	 and	 the	 need	 for	 coordination	 between	multiple	 cells	 for	 the	 good	 of	 the	
organism	 (467,468).	 From	 this	 perspective,	 cancers	 occur	 when	 an	 individual	 cell	
behaves	 in	 an	 autonomous	 manner,	 escaping	 from	 the	 mechanisms	 in	 place	 to	
coordinate	cell	behaviour	(469).		
	
The	 classic	model	 of	 carcinogenesis	 describes	multiple,	 successive	 clonal	 expansions	





responsible	 for	 tamoxifen	 resistance	 in	 breast	 cancer	 (376)	 and	 chemotherapeutic	
resistance	in	CRC	PDX	models	(83,192).	More	broadly,	tumour	evolution	and	resultant	





























resistant	 sublines	 are	 characterised	 by	 several	 differentiating	 features:	 differences	 in	
proliferation	rates,	ERα-signalling	and	resistance	to	rapamycin	are	noted.	Future	work	
in	 this	 regarded	 should	 focus	 on	 an	 unbiased	 screen	 of	 the	 mechanisms	 by	 which	
resistant	cell	lines	differ.	An	RNA-seq	based	classification	of	resistant	lines	is	currently	
underway	 and	 should	 offer	 insight	 into	 regulatory	 pathways	 involved	 in	 the	 specific	
mechanism	of	tamoxifen	resistance	in	our	models.	Furthermore,	the	addition	of	further	
time	points	 in	our	NGS	analysis	would	afford	greater	 resolution	 in	 the	description	of	
clonal	phenotypes	in	our	control	clones.	For	example,	barcoded	clones	could	be	classified	








development	 of	 both	 tamoxifen	 and	 fulvestrant	 resistance.	 The	 authors	 found	 that	
resistance	to	each	drug	was	due	to	the	selection	of	a	rare,	pre-existing,	population	of	cells	
(483).	Utilising	a	mathematical	model	of	 stochastic	population	dynamics,	 the	authors	
were	able	 to	estimate	the	 fraction	of	pre-existing	barcodes	 in	each	scenario.	Using	an	
expected	mutational	frequency	of	10-5	per	division,	the	authors	demonstrated	resistant	





expression	 signatures	 were	 also	 present	 in	 metastatic	 sites	 of	 those	 relapsing	 on	
tamoxifen	 (483).	 Given	 the	 genomic	 instability	 of	 MCF7s,	 coupled	 with	 the	 near	
extinction	events	in	our	drug	treatment	arm,	it	would	be	interesting	to	model	whether	
any	 slight	 changes	 in	 VAF	 between	 naïve	 and	 resistant	 MCF7s	 would	 indeed	 be	
statistically	significant.		
	
Importantly,	 DNA	 hypomethylation	 at	 oestrogen-responsive	 enhancers	 has	 been	
associated	with	the	development	of	ERα+	breast	cancers,	and	the	reversal	of	this	process	
with	the	development	of	resistance	to	endocrine	therapy	(285).	Moreover,	heterogenity	
amougst	 tamoxifen	 resistant	models	 derived	 in	 parrallel	 processes	 has	 been	 studied	
previously	 (345)	 and	 the	 resistance	 process	 has	 been	 linked	 in	 the	 literature	 to	
pluriopotency	 factors	 such	 as	 SOX2	 (277)	 and	 OCT4	 (438,473).	 Taken	 together,	









In	Chapter	 4,	we	 study	 the	 role	 of	OCT4	 in	M-ICs	 and	 the	 development	 of	 tamoxifen	
resistance.	 Though	 resistance	 to	 4-OHT	 was	 the	 key	 phenotype	 under	 investigation,	
there	 is	 evidence	 that	our	 resistant	 lines	were	 oestrogen-independent	 and	may	 have	




same	population	 of	 cell	may	 be	 responsible	 for	 both	 phenotypes.	We	 also	 uncover	 a	
mechanism	by	which	tamoxifen	bound	ERα	may	directly	drive	the	expression	of	POU5F1.	
























addition	 to	 uncovering	 related	 signalling	 pathways	 (related	 to	 the	 p38MAPK-Skp2-
Nkx3-1	axis	or	otherwise),	4-OHT-ERα	or	OCT4	ChIP	experiments	would	shed	further	
light	on	regulatory	mechanisms.	Further,	applying	the	ClonTracer	labelling	methodology	
to	 POU5F1	 overexpressing	 cells	 as	 they	 develop	 tamoxifen	 resistance,	 could	 help	
determine	 whether	 OCT4	 is	 a	 true	 enabling	 factor	 in	 the	 resistance	 process.	
Furthermore,	 the	 mechanisms	 by	 which	 OCT4	 contribute	 to	 transcriptional	


























human	 breast	 cancer	 PDX	 models	 and	 adapted	 their	 use	 for	 high	 throughput	 drug	
screens	(198).	We	find	PDX	models	are	relatively	genomically	stable	over	multiple	in	vivo	














stable	on	passage	 (195,198),	 future	work	 in	 this	 regard	 should	apply	genomic	 clonal	
clustering	 techniques,	 such	 as	 PyClone	 (199),	 specifically	 to	 our	 barcoded	 STG282CT	
model.	Genomic	clonal	selection	 in	our	 identified	metastatic	sites	will	be	of	particular	
interest.	 Moreover,	 such	 analyses	 will	 help	 us	 understand	 any	 clonal	 (or	 cell-type)	
selection	artefacts	introduced	by	our	lentiviral	infection	protocols.	As	a	model	system	







Interestingly,	 a	 recently	 study	 from	 Echeverria	 et	 al.,	 (484)	 reported	 the	 use	 of	 the	
Cellecta	barcode	system	in	a	panel	of	TNBC	PDX	models	to	monitor	the	fate	of	individual	
tumour	cell	lineages	during	treatment	with	Adriamycin	combined	with	Cytoxan	(484).	
The	 authors	 found	 that	 PDXs	 initially	 exhibited	 partial	 sensitivity,	 followed	 by	
maintenance	 of	 residual	 tumours	 that	were	 resistant	 to	 chemotherapy	 and	 eventual	
relapse	of	 a	partially	 sensitive	 tumour.	 Interestingly,	 the	authors	report	 that	 residual	
tumours	 maintained	 the	 same	 clonal	 architecture	 as	 untreated	 tumours,	 but	 that	 a	
shared	 population	 of	 barcoded	 cells	 (representing	 ~20%	 of	 the	 total	 pool)	 were	
responsible	 for	 repopulation	 of	 the	 tumour	 following	 discontinuation	 of	 treatment.	
Further,	 exome	 sequencing	 revealed	 that	 mutant	 allele	 frequencies	 were	 largely	
conserved	during	the	same	process.	The	authors	go	on	to	suggest	that	residual	tumours	
exist	in	a	distinct	state	characterized	by	alterations	in	EMT,	metabolic,	and	cell	adhesion	
programs	 during	 treatment,	 but	 that	 these	 phenotypes	 reverted	 on	 continuation	 of	
tumour	 growth.	 In	 silico	 prediction	 of	 drug	 sensitivity,	 verified	 by	 pharmacological	





system	 across	 a	 comprehensive	 PDX	 biobank	 is	 ongoing.	 Aside	 from	 the	 case	 of	
tamoxifen	resistance,	studied	extensively	in	Chapter	3	and	Chapter	4,	the	ability	to	track	
the	 fate	 of	 individual	 cellular	 clones,	 perhaps	 in	 tandem	 with	 genomic	 clonal	
reconstruction,	 will	 be	 of	 great	 benefit	 in	 the	 study	 of	 multiple	 cases	 of	 treatment	
resistance	in	breast	cancer.	For	example,	RAD51	foci	has	recently	been	identified	as	a	
functional	 biomarker	 of	 homologous	 recombination	 repair	 and	 PARP	 inhibitor	
resistance	 in	 BRCA-mutated	 breast	 cancer	 (474).	 In	 one	 of	 our	 PDX	 models,	 PARP	

















































al.	 A	 Biobank	 of	 Breast	 Cancer	 Explants	 with	 Preserved	 Intra-tumor	
























































Maintaining Tumor Heterogeneity in
Patient-Derived Tumor Xenografts
John W. Cassidy, Carlos Caldas, and Alejandra Bruna
Abstract
Preclinical models often fail to capture the diverse hetero-
geneity of human malignancies and as such lack clinical pre-
dictive power. Patient-derived tumor xenografts (PDX) have
emerged as a powerful technology: capable of retaining the
molecular heterogeneity of their originating sample. However,
heterogeneity within a tumor is governed by both cell-auton-
omous (e.g., genetic and epigenetic heterogeneity) and non–
cell-autonomous (e.g., stromal heterogeneity) drivers.
Although PDXs can largely recapitulate the polygenomic archi-
tecture of human tumors, they do not fully account for het-
erogeneity in the tumor microenvironment. Hence, these mod-
els have substantial utility in basic and translational research in
cancer biology; however, study of stromal or immune drivers of
malignant progression may be limited. Similarly, PDX models
offer the ability to conduct patient-specific in vivo and ex vivo
drug screens, but stromal contributions to treatment responses
may be under-represented. This review discusses the sources
and consequences of intratumor heterogeneity and how these
are recapitulated in the PDX model. Limitations of the current
generation of PDXs are discussed and strategies to improve
several aspects of the model with respect to preserving hetero-
geneity are proposed. Cancer Res; 75(15); 2963 –8. !2015 AACR.
Introduction
Despite remarkable advances in our understanding of the pro-
gression of human malignancies and the molecular events that
underpin tumor survival, new therapies often fail to show signif-
icant efficacy in clinical trials. Projects such as The Cancer Genome
Atlas and METABRIC have demonstrated the remarkable hetero-
geneity across tumorspreviouslybelieved tobeof the samesubtype
(1). It could be argued that clinical trials fail to sufficiently stratify
patients based on relevant biomarkers of drug response: the
response rate of an unscreened population to a molecularly tar-
geted therapy typically lies between 10% and 20% (2). Patient
stratification based onmolecular determinants of drug efficacy and
tumor heterogeneity allows for significantly greater responses—
exemplified by the success of ALK kinase inhibitors in EML4-ALK–
positive non–small cell lung cancers (3). However, even with
patient stratification, clinical responses can be fleeting, often add-
ing only 6 to 12 months before disease progression (2). Thus,
understanding intertumor heterogeneity is the first step toward
improved drug efficacy and diminishing tumor relapse.
Intratumor heterogeneity is governed by both cell-autonomous
(e.g., genomic and epigenomic heterogeneity) and non–cell-
autonomous (e.g., stromal heterogeneity) factors. This heteroge-
neity has clinical implications in patient-specific responses to
therapy and the rapid emergence of resistance to targeted therapies
(4). By capturing intra and intertumor heterogeneity, patient-
derived tumor xenograft (PDX) models have a clear advantage
over traditional models, supporting their use in oncologic drug
discovery and preclinical development. PDX models largely reca-
pitulate cell-autonomousdriversofheterogeneity: exhibiting geno-
mic clonal dynamics reminiscent of their originating tumor sample
(5, 6). Moreover, phenotypically distinct isogenic cellular clones
have been shown to drive resistance to chemotherapy in colorectal
PDX models (7). The tumor microenvironment has long been
known to play an essential role in tumor progression and its role in
drug response is becoming apparent (8, 9). Although PDXs retain
the 3D architecture found in human tumors, stromal and immune
interactions may be altered by inter-species compatibility and
cellular component deficiencies in host models.
The poor performance of so many investigational drugs sug-
gests that preclinical tumor models lack clinical predictive power.
Indeed, one of the most often cited reasons for clinical failure is a
lack of preclinical models that recapitulate the complexity of
human cancers. It is with this in mind that many research and
pharmaceutical groups have turned to PDX models (10, 11).
The establishment and predictive power of PDXs have been
reviewed recently elsewhere (11). This review will focus on the
limitations of current PDX models and how these can be
addressed in the future, specifically in terms of maintaining the
heterogeneous nature of human cancers (summarized in Table 1).
PDXs are arguably the best models of tumor heterogeneity, and
therefore perhaps themost powerful tools for investigating tumor
biology. However, they may fail to fully account for many non–
cell-autonomous drivers of heterogeneity (Fig. 1A), and should be
adapted if they are to reach their full potential as predictors of
clinical efficacy in cancer drug development.
Clonal Dynamics and Tumor Heterogeneity
in PDX Models
Through the course of tumor initiation and progression,
cancerous cells undergo repeated mutational events that may
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or may not result in increased fitness relative to neighboring
cells. Dramatic increases in fitness are seen with the acquisition
of key driver mutations early in a tumor's evolution, for exam-
ple the loss of TP53 may lead to clonal dominance. However,
selection operates on phenotypes in response to stress-inducing
events, which may be stable or transient (12). A gain of fitness
in one clone relative to another does not necessarily imply the
loss of the latter in favor of the former. Rather, clonal popula-
tions within the tumor exist dynamically in space and time:
competing, and perhaps cooperating, to further increase fitness
of the tumor population as a whole (13). Clonal dynamics
derived from tumors' inherent heterogeneity are thus extremely
complex and can play key roles in tumor progression and
development.
This conceptual framework of clonal evolution in cancer pre-
dicts several clinically observable features (14). First, every muta-
tion or copy number aberration (CNA) present in the bulk tumor
need not be present in all cells; indeed, spatial variation exists in a
tumor's clonal composition. The existence of multiple subclones
explains variable response rates to therapy, even within a single
tumor mass, and the rapid emergence of drug resistance. For
instance, the presence of a minor KRAS-mutant clone can predict
colorectal cancer patients who will develop resistance to epider-
mal growth factor receptor (EGFR)–targeted therapy (4).
Our group has previously shown that breast cancer consists of
at least 10 distinct molecular subtypes with significant differences
in disease outcome and treatment responses (1). Furthermore, we
have helped delineate the diverse, variable clonal composition of
© 2015 American Association for Cancer Research
Genomic clonal
dynamics
Minor KRAS subclones predict
resistance to EGFR targeted
therapies in colorectal cancer.
Overall clonal diversity correlates
with drug resistance in ovarian
and oesophageal cancers.16, 17
Colorectal and breast PDX models
phenotypes.6, 7 ‘Type IV’ quiescent
clones were responsible for
resistance to chemotherapy in
colorectal cancer.7
Human stromal components are
replaced by murine equivalents
on PDX passage. It is unclear how
their human counterparts in
supporting tumor growth. Human
geneous in their ability to promote
treatment resistance.26, 27
Genomic clones reconstructed
in a panel of 15 breast cancer
PDX models revealed ongoing
clonal dynamics. Polyclonal
engraftment was possible, but





tumor and hence widen the
pool of cellular clones able
to contribute to treatment
resistance.20
on tumour progression is highly
complex. Checkpoint inhibitors
and other immunotherapeutics
are promising new treatment
strategies in oncology.
International collaborations such as
the EuroPDX Consortium should
facilitate sharing of expertise and
eventually lead to increased
engraftment with less pronounced
clonal selection.10
the native tumor microenvironment
should allow for more appropriate
epigenetic clonal diversity.
Patient matched stromal
components should be sourced
whenever possible. Although
in vitro, cell sorting may reduce
cells and this should be considered.
HuPDX immune models remain a
substantial technical challenge. But
the implications for study of tumor
biology are profound.
orthotopic models should be
considered where possible.
Synthetic human alternatives to
Matrigel should be investigated.
used for PDX implantation. The
NSG strain is characterised by a lack
of mature lymphocytes, the absence
of functional NK cells, defective
macrophages and defective
dendritic cells.33
Matrigel is currently used to increase
factors present in this murine base-
ment membrane extract could
support preferential engraftment of
ectopic implantation is commonly
used.23, 25
Regulated ECM maintains tissue
architecture and stem cell
compartments. Loss of structure
in cancer could contribute to
oscillation between distinct
transcriptional programs.21
Pro- and anti- tumor properties
populations of cancer associated
CAF or MSC populations could















































Implications for basic and
translational research Future prospects
Representation in
current PDX models
Table 1. Sources of tumor heterogeneity, their consequences in translational and basic cancer biology, and how they are currently represented in PDX models
NOTE: Strategies to improve themodel, by better representation of both cell-autonomous (genomic and epigenomic clones etc.) and non–cell-autonomous (stroma,
immune infiltrate etc.) drivers of heterogeneity are proposed.
Cassidy et al.
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triple-negative breast cancers (TNBC; ref. 15). By allelic frequency
measurements of 2,414 somatic mutations in 104 TNBCs, a
complete spectrum of molecular and clonal compositions was
characterized at diagnosis. Aside from the prognostic features of
specific rare subclones (4), there is an association between clonal
diversity and treatment resistance for at least some tumor types—
notably ovarian (16) and esophageal (17). Basal-like TNBCs have
previously been linked with shorter disease-free survival com-
pared with nonbasal-like TNBCs and tend to be associated with
higher clonal diversity (15). Furthermore, integration of genomic
and drug response data from breast cancer PDXmodels generated
in our laboratory shows that polygenomically engrafted tumors
are more resistant to therapy than monogenomically engrafted
tumors (Bruna and colleagues,manuscript in preparation). Clear-
ly more work is still to be done, but it seems likely that the clonal
composition of tumors will have future utility in predicting
disease outcome and informing treatment choice.
Multiple groups have attempted to define clonal dynamics
based on either lentiviral barcoding (cellular clones) or muta-
tional clustering (genomic clones) by population and single cell–
based computational approaches (5, 18). For example, Eirew and
colleagues (5) reconstructed the genomic clonal dynamics of a
panel of breast cancer PDX models using PyClone: a Bayesian
clustering method for grouping somatic mutations. In each of the
15 cases examined, clonal diversity was reduced by xenotrans-
plantation. This varied from extreme engraftment bias, selecting
minor clones present in the sample of origin, to only moderate
clonal selection. Remarkably, similar clonal dynamics were
observed in parallel xenografts established from the same sample.
In a separate study, Ding and colleagues (19) found that PDX
models established from a basal-like breast cancer were more
representative of the patient's metastatic lesion than the primary
tumor. These observations suggest that deterministicmechanisms
underline the clonal selection found on engraftment. Eirew and


























A, a primary breast tumor including some sources of heterogeneity found in the native microenvironment. Reciprocal signaling pathways between tumor
cells and TAMs and CAFs are highlighted. ECM is shown as collagen fibers with associated fibroblasts and macrophage/dendritic cells with T/B lymphocytes are
shown as part of the immune infiltrate, though other cell types (NK cells, myeloid-derived suppressors, etc.) have been omitted for simplicity. B, patient-matched
fibroblasts and immune cells as possible candidates for coengraftment in the next generation of PDX models. Current PDXs established in NSG mice lack an
adaptive immune system and may have impaired innate immune cell infiltrates and cytokine signaling due to defective IL2 receptor (33). CAFs are known to
contribute to treatment response; although murine fibroblasts are present in PDX models, it is unclear how faithfully these recapitulate their human counterparts
(26). C, a PDX tumor in its native microenvironment. Questions over whether pro- and antitumor CAF/TAM signaling pathways are present to the same extent
in PDX models as in the primary tumor are highlighted. Stromal and tissue architecture can have profound effects on transcriptional regulation but are often
overlooked in the establishment of PDX models (25). To highlight potential differences in ECM organization between the native microenvironment and that of the
PDX, here the ECM is shown as highly organized collagen fibers with closely associated myofibroblasts.
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colleagues (1, 5) further observed variable clonal dynamics
between PDXs established from different molecular subtypes,
underscoring the need for better representation of tumor molec-
ular subtypes. In summary, PDX models can, at least partially,
recapitulate the complex clonal dynamics of humanmalignancies
and engraftment biases may represent nonstochastic selection
events, which define a PDXmodel rather than limit its utility. The
variable tumor- and subtype-dependent engraftment rates (low
for some tumor types) and frequencies in the population mean
that PDX programs representative of intertumor heterogeneity
may require large multicenter collaborative efforts (such as the
EuroPDX consortium; ref. 10) and centralization of models.
Clonal evolution is a continuous process, and may be substan-
tially altered by the selective pressures applied during chemo- and
targeted therapy. Coupled with spatial heterogeneity within the
tumor, thismay result in the need formultiple-site repeat biopsies
to decipher the clonal composition and dynamics of a tumor and
inform treatment choice. Clearly these procedures will be highly
invasive and may not be technically possible; it is with this in
mind that many researchers have turned to liquid biopsies
(14, 20). If our hypotheses are correct, modeling of clonal evo-
lution in patient andmatched PDX by computational approaches
[such as PyClone (5) or CloneHD (18)] will allow unprecedented
basic and translational research into clonal drivers of tumor
progression and treatment response. Such studies will also be
necessary to determine the longevity of PDX models of each
cancer subtype, as it is unlikely that PDXs will remain patient-
relevant and genomically stable in perpetuity.
It has been proposed that aberrant DNA methylation patterns
in cancer can blur the lines between distinct phenotypic "attractor
states" (21). Thus, it may be important to consider cellular clones
as drivers of malignant progression, independent of their genetic
background. To track these isogenic cellular clones, lentiviral
tagging has been used tomark individual cells, and their progeny,
in breast and colorectal PDXmodels (6, 7). In an elegant study by
Kreso and colleagues (7), it was found that minor "type IV"
subclones in colorectal PDXs were able to repopulate the tumor
bulk after treatment with chemotherapy. These quiescent cell
populations were genetically similar to their highly proliferative
counterparts, and were later linked to the BMI1þ population
thought to act as reserve stem cells of the intestinal and colonic
crypts (22). As the cellular clones defined in this study were
isogenic, their phenotype may have been driven by microenvi-
ronmental cues capable ofmodulating cellular transition between
distinct gene expression patterns or epigenetic attractor states
(23). Hence, the microenvironment's composition could pro-
foundly alter both a cells propensity to malignancy and the
heterogeneity we hope to preserve in PDX models. Regardless,
we should not underestimate the significance of even a partial
translation of vastly heterogeneous human diseases into experi-
mental model systems.
Limitations of the PDX Model: Tumor-
Extrinsic Sources of Heterogeneity
Aside from clonal dynamics driven by intrinsic differences in a
cell's genetic or epigenetic background, intratumor heterogeneity
can be influenced by tumor-extrinsic factors in the non–cell-
autonomous compartment (Fig. 1A and Table 1; ref. 23). Cellular
interactions with the extracellular matrix (ECM) can alter gene
expression programs, drive differentiation, and profoundly alter
cell behavior. As cancers develop, tight regulation of the ECM is
lost and tissue architecture begins to degrade (8). A recent study by
Wang and colleagues (24) provides direct evidence that ECM-
dependent signaling confers dynamic switching between TGFBR3
(transforming growth factor b receptor 3)- and JUND (jun D
proto-oncogene)–related expression signatures. ECM-drivenoscil-
lations between signaling pathways such as those described could
have profound effects on propensity to malignancy. Furthermore,
solid-state ECM interactions are necessary for cells to maintain
stem cell properties and regulated ECM helps maintain the stem
cell niche (25). As cancer is often associated with a blurring of the
boundariesbetweenstemanddifferentiated cells, it is possible that
a loss of structured ECM is essential for the stability of multiple
subdominant cellular clones within a tumor (21). In PDXmodels,
Matrigel is often used to increase the engraftment efficiency;
however, it is worth noting that this is a murine basement
membrane extract and suitable synthetic human alternatives are
available. The presence of growth factors inMatrigel may favor the
engraftmentofone cell typeover another. Finally, asECMstructure
is tissue specific (25), researchers should consider the use of
orthotopic transplantations where possible.
The tumor microenvironment is further characterized by an
influx of stromal cells. Infiltrating cancer-associated fibroblasts
(CAF) can often confer resistance to cytotoxic and targeted ther-
apies (9); however, recent studies confer on fibroblasts a degree of
plasticity, with antitumor properties observed in some popula-
tions (26). Because of the high levels of CAF infiltrates seen in
some tumor types, heterogeneity within their population would
undoubtedly confer differential properties to the tumor bulk.We,
and others, have found that human stromal cells are gradually
replaced by murine equivalents upon engraftment in the mouse,
suggesting that implanted human cancer cells retain the ability
to recruit murine accessory cells to their niche. However, it should
be noted that some differences exist between ligand repertoires
of human and murine fibroblasts (27). Clearly stromal archi-
tecture and activity is mimicked in the murine host; however, it is
currently unclear how this reflects human stroma with regards to
supporting tumor growth and development.
It is with this in mind that many have begun to investigate the
coengraftment of human mesenchymal stem cells (MSC) or CAF
cell lines in PDXs (Fig. 1B and C). Here, care must be taken; the
role of MSCs in tumor development is still controversial andmay
represent patient (or tissue)-specific differences (28). If non–
patient-matched sources of stromal cells are implanted, hetero-
geneity between tumors derived from different patients could be
lost. Moreover, fibroblast cell lines vary considerably in their
ability to confer resistance to cytotoxic therapies through hepa-
tocyte growth factor (HGF)/c-Met signaling (9, 27). Patient-
derived fibroblasts can be isolated from tumor samples and
expanded in vitro, thus, coengraftment of matched stromal com-
ponents should be considered wherever possible. This would
significantly increase the advantages these models already have
in retaining the complex heterogeneity found in patient samples.
Considering the crucial role of the immune system in tumor
progression, perhaps the most obvious disadvantage of PDX
models is the necessity for severely immunodeficient host ani-
mals. Tumor cells are broadly thought to be antigenic: point
mutations in coding exons in a developed tumor results in a
large repertoire of neoantigens. Targeting of these neoantigens can
lead to significant CD8þ cytotoxic T-cell infiltration and tumor
cell death. However, most tumors eventually progress and evade
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the immune system—often through the dominant inhibitory
effects of suppressive pathways (so-called "immune checkpoints"
such as CTLA-4/B7 and PD-1/PD-L1). This is supported by the
prognostic value of the CD8þ to FOXP3þ (cytotoxic to regulatory
T-cell, Treg) ratio inmany solid tumors, and the recently reported
clinical efficacy of a variety of checkpoint inhibitors (29, 30).
The proinflammatory microenvironment established by CD8þ
T cells, M1 polarized tumor-associated macrophages (TAM), NK
cells, and others can lead to the recruitment of numerous
immune-suppressive components. TAMs and myeloid-derived
suppressor cells have been implicated in resistance to antiangio-
genic therapy. In addition, macrophage and CD4þ T-cell recruit-
ment following intensive chemotherapy in breast cancer patients
is associated with significantly reduced recurrence-free survival
(30). Clearly, the coengraftment of immune components into
PDX models (Fig. 1B) would facilitate both the study of novel
therapies targeting tumor-immune interactions and allow for
basic research into patient-specific cross-talk between tumor
progression and immune surveillance. Clone or patient-specific
differences in tolerization of dendritic cells, macrophage, and
neutrophil polarity and Treg infiltration could provide multiple
novel insights into tumor biology.
The most robust reconstitution of the human immune system
in immunodeficient mice is seen when bone marrow–derived
stem cells are coengrafted along with liver and thymus fragments
(BMT model; ref. 31). However, the highly invasive multisite
biopsy required renders this model impractical for patient-
matched humanized PDX models (huPDXs). CD34 marks a
population of hematopoietic stem and progenitor cells (HSPC)
found in the blood and bone marrow. Mice implanted with
CD34þ cells fromumbilical cord blood show robustmultilineage
engraftment of human immune populations, though with
reduced functionality relative to BMT mice. During chemother-
apy, CD34þ cells leave the bonemarrow and enter the circulation.
If patients are given granulocyte-macrophage colony stimulating
factor (GM-CSF; Leukine) to aid recovery from chemotherapy,
numbers of CD34þ cells in the circulation have been known to
exceed the bone marrow itself. Hence, CD34þ cells could poten-
tially be harvested from patient's blood to reconstitute a func-
tional, patient-matched, immune system in mouse models
(huCD34 model). As such, an immune system would mature in
the mouse and human immune cells would undergo central
tolerance to mouse antigens during development. However, as
theywould not be exposed to patient antigens during this process,
it is likely that theywouldmount a rapidnon–self-response to any
subsequently engrafted human tissue. One possible solution
comes from a recent study by Cosgun and colleagues (32),
showing immunodeficient adult mice carrying a mutation in the
Kit receptor could support robust, uniform, and sustained engraft-
ment of CD34þ cells. If patient-matched CD34þ HSPCs were
engrafted in adult Kit mutant mice with an established PDX
tumor, it is possible that a functional immune system could
develop in the presence of both human and mouse antigens.
The alternative, to engraft fully mature human immune cells, is
used in the huPBMC model. Here, mononuclear cells from the
peripheral blood mononuclear cells (PBMC) are isolated and
implanted in immunodeficient mice. PBMCs comprise around
75%CD4/CD8þT cellswith the remainder primarily containingB
and NK cells. As such, these models are well suited to short-term
experiments where lymphocyte function is of primary concern.
Aside from the lifetime of circulating cells, themajor limitation of
the huPBMC model is the rapid onset of graft versus host
disease (GVHD) as engrafted cells mount an immune response
against host murine tissue. The onset of GVHD can be delayed
somewhat by the use of NOD scid gamma (NSG) strains lacking
MHC I (33).
Undoubtedly, the reconstitution of a patient-matched immune
system in PDX models would be extremely valuable in the
development of novel oncologic drugs and, in particular, immu-
notherapeutics. The extent towhichfindingswould be valid in the
context of immunehyperactivation (againstmouse inhuPBMCor
against tumor in huCD34) is unclear.
Conclusions and Future Prospects—
Toward a huPDX Model
The PDX is arguably the most faithful model of cell-autono-
mous drivers of malignant progression. Sharing of expertise and
resources through collaborative initiatives, such as the EuroPDX
consortium, will lead to improved engraftment efficiencies and
increase the breadth of tumor subtypes available in these model
systems, contributing to a better representation of cancer hetero-
geneity in the laboratory (10).
Cooperation and competition between genetically and pheno-
typically distinct subclonal populations are thought to drive
tumor growth, resistance to therapy, and recurrence. Although
cell-autonomous sources of heterogeneity are clearly recapitulat-
ed in PDXmodels, current techniques fail to properly account for
non–cell-autonomous factors. The microenvironment has long
been known to play a significant role in tumor progression, but an
incomplete understanding of stromal influencesmakes coengraft-
ment of non–patient-matched cell compartments a risky strategy.
In order to maintain PDXs as models of diversity of human
malignancies, we must take care to engraft only patient-matched
stromal components. CAFs have known roles in resistance to
targeted therapy. It should, therefore, be a priority to ensure
patient fibroblasts are maintained in the tumor xenograft.
Reconstituting a patient-matched immune system in PDX
models is a significant challenge. Standard methods of engrafting
either CD34þHSPCs ormature circulating PBMCswill likely lead
to inappropriate immune responses against human or murine
tissues, respectively. In order to study long-term tumor–immune
interactions, a reconstituted immune systemmust simultaneous-
lymaintain tolerance to its human donor and acquire tolerance to
its new host. A solution could come from engrafting both mature
and na€"ve cell types. Maturing cells in the thymus and bone
marrowwould acquire central tolerance tomurine tissues, where-
as mature cells in the periphery could act to suppress inappro-
priate responses against human antigens.
PDX models are capable of recapitulating the complexity of
human malignancy remarkably well. These models have extraor-
dinary utility in basic cancer research and beyond this have
demonstrated clinical predictive power, allowing multiplexed
screening of novel therapeutics in vivo. However, the aforemen-
tioned limitations of this model must be carefully considered
when interpreting data. Although a significant amount of research
is still needed, patient-matched huPDX models with coengrafted
stromal and immune components would offer unprecedented
opportunity to study tumor biology and would be invaluable
models in oncologic drug development. In the future, huPDX
models could allow researchers and clinicians to both predict and
explain tumor response to novel targeted therapies.
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